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ABSTRACT 
This thesis reviewed and investigated several aspects of the management of enterocutaneous 
fistula (ECF). 
The best management of ECF, particularly complex fistulas, is in specialist units where there 
is a multidisciplinary structured approach.  Surgical management of ECF at St. Mark’s 
National Intestinal Failure Unit is safe and improving over time. The highest incidence of 
ECF development occurs following abdominal surgery particularly in the presence of 
Crohn’s disease.  The audit confirmed this in our unit. 
A retrospective audit of our unit revealed the majority of patients underwent definitive 
surgery.  There were improved overall healing rates following both surgery and conservative 
management in the current cohort, with also improvement in the 30 day post fistula resection 
mortality compared with a previous series at our unit. 
Multivariate analysis revealed co-morbidity, source of referral and aetiology had significant 
associations with ECF healing.  
This thesis has included the first study and design of a scoring system for predicting ECF 
healing. The scoring systems devised were both validated. They can provide further 
information to aid clinical management and decision making for the multidisciplinary team 
and predict the possible long term outcome for patients at external institutions. 
Meta-analyses of randomised control trials has revealed somatostatin and octreotide increase 
the likelihood of fistula closure, reducing the time to fistula closure, and neither has an effect 
on mortality.  
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Immunological studies revealed an increased on-going production of cytokines, in particular 
TNF-α, in non-IBD ECF compared with control terminal ileum tissue.  The data may provide 
evidence for the potential use of anti-TNF-α agents in the treatment of non-IBD ECF.   
A future pilot study has been designed with the aim to identify a potential novel therapy for 
patients with persistent enterocutaneous fistula not associated with inflammatory bowel 
disease.  Any positive findings would equate to a major medical advance with a new use for 
anti-TNF-α agents. 
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CHAPTER 1 
GENERAL INTRODUCTION 
Enterocutaneous fistulas (ECF) are abnormal communications between the 
gastrointestinal tract and the skin. Although rare, they are associated with 
considerable morbidity and mortality. Death related to ECF remains 
disproportionately high when compared with other surgical conditions.  Mortality 
rates for ECF vary from 6 - 33% (1-6).  
The incidence and aetiology of fistula are highly dependent on the surgical experience 
and case load at particular institutions and on patient and disease related cofactors. 
Much of the published data relate to experience at specialised centres treating 
complex cases (7).  St. Mark's Hospital is a national and international referral centre 
for intestinal and colorectal disorders.  The Intestinal Failure Unit has a long standing 
interest in inflammatory bowel disease (IBD), and this is reflected in the high 
prevalence of IBD patients treated at this institution.   
It is estimated that 75–85 % of ECF that form after an operation occur as a result of 
bowel injury or anastomotic leakage (1, 8) .   Fistula formation is also associated with 
surgery in the presence of IBD, malignancy or with division of dense adhesions (1, 8).   
In the remaining 15–25 % of cases, ECF form spontaneously secondary to the 
underlying pathology, with the most occurring in those with Crohn’s disease (1, 8).   
Up to 75% of patients undergoing abdominal or pelvic radiation will suffer some 
degree of radiation enteritis. In most cases this manifests as either bleeding or 
stricture; however, a small percentage may develop fistulous complications. In this 
subset of patients who develop a radiation-related ECF, it may take six months or 
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more for the fistula to become apparent (9).  The study by Lynch et al revealed ECF 
caused by radiotherapy in 8% of patients (10). 
Fistula formation can result in a number of serious or debilitating complications, 
varying from disturbance of fluid and electrolyte balance to sepsis and even death. 
The patient will almost always suffer from severe discomfort and pain. They may also 
have psychological problems, including anxiety over the course of their disease, and a 
poor body image due to the malodorous drainage fluid. Post-operative fistula 
formation often results in prolonged hospitalisation, patient disability, and enormous 
cost. Therapy has improved over time with the introduction of parental nutrition, 
intensive post-operative care, and advanced surgical techniques, which has reduced 
mortality rates (11). 
Although ECF can close spontaneously, those that remain open after two months,  
will often require surgical intervention as spontaneous closure is unlikely after this 
interval (1, 12).   It should be noted that major abdominal surgery stimulates the 
formation of dense adhesions.  This reaction is most severe between three weeks and 
three months after an operation, and further surgery during this time is more likely to 
be complicated by fistula recurrence (1, 10, 13). 
The first stage in my research will be to review the management of enterocutaneous 
fistulas and describe the numerous challenges it can present. This includes the 
difficulties which can arise from a reduction in functional length of the bowel and 
Intestinal Failure (IF).  I will review the management undertaken by the 
multidisciplinary approach involving physicians, dietician, pharmacists, 
29 
 
microbiologists, interventional radiologists, wound / stoma care therapists, nursing 
staff and surgeons.   
I will examine the clinical practice in the management of ECF and factors associated 
with fistula healing at our institution, which is a National Intestinal Failure centre in 
England.  Retrospective data will be collected and a univariate and multivariate 
analysis will be performed on variables deemed to affect the outcome of ECF healing.  
If relationships are found to exist between variables and ECF healing then a scoring 
system to predict spontaneous fistula healing prior to surgery will be devised.  This 
would be an additional source for the clinician in the decision making process. 
Several pharmacological treatments have been described in the management of ECF, 
and in particular there is varied opinion as to the use of somatostatin and octreotide.  
The potential benefits include reducing patient’s discomfort, shortening the length of 
hospital stay and reducing the cost of overall treatment.  Some authors argue that high 
cost, equivocal therapeutic effect on underlying diseases, painful injections and 
potential for long-term side-effects make the use of somatostatin and its analogues 
controversial.   
My research will include reviewing the literature comparing somatostatin and 
somatostatin analogues with standard medical therapy or a placebo in patients with 
ECF and conduct a meta-analysis. 
The biological agent Infliximab inhibits a range of biological activities of TNF-α. It 
has been approved for treating Crohn's disease and fistulising Crohn's disease.   My 
research will aim to study and assess the inflammatory activity, with a particular 
emphasis on TNF-α in non-IBD ECF when compared with control small bowel tissue.   
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The immunological studies will include assessing dendritic cells, which are antigen 
presenting cells that orchestrate the immune responses and regulate the production of 
cytokines by immune cells including T cells.  No study to date has assessed the level 
of TNF-α in non-IBD ECF.  The study will assess if there is evidence for the potential 
use of anti-TNF-α agents in the treatment of non-IBD ECF which would be an 
alternative option to benefit an already surgically challenging group of patients.   
1.1 Hypothesis: 
 Multiple factors which contribute to enterocutaneous fistula healing including 
patient factors, the choice and type of medical and surgical treatment options 
selected, and the immunological status of the ECF. 
 
1.2 Aims of Thesis:  
 Evaluate current management, practice and outcome of ECF at St. Mark’s 
Hospital and Academic Institute.  
 Examine and analyse factors associated with ECF healing. 
 Devise a scoring system to predict outcome of ECF healing and assess its 
validity.  
 Perform a meta-analysis of the use of somatostatin and somatostatin analogues 
in the treatment of ECF.  
 Assess the inflammatory activity, with a particular emphasis on TNF-α in non-
Inflammatory Bowel Disease ECF.  
 Explore the association between TNF-α and dendritic cells (DC) in non-
Inflammatory Bowel Disease ECF.  
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CHAPTER 2 
OVERVIEW OF THE LITERATURE:  
MANAGEMENT OF ENTEROCUTANEOUS FISTULA 
2.1 ABSTRACT 
Background 
Enterocutaneous fistulas (ECF) can present many challenges. They may result in 
reduction of functional length of the bowel and Intestinal Failure (IF).  Management is 
best undertaken by a multidisciplinary unit involving physicians, interventional 
radiologists, dieticians, pharmacists, microbiologists, wound / stoma care therapists, 
nursing staff and surgeons.  Optimal surgical treatment has not been well documented 
in these patients.  
Methods 
An overview of the literature has been conducted of the English language literature in 
the Pub Med, Medline, EMBASE, CINAHL and Cochrane databases using the search 
terms: Enterocutaneous Fistula, Short Bowel Syndrome, Intestinal Failure and 
Intestinal Transplantation. 
Results 
Operative intervention should be delayed until sepsis has been controlled, nutrition 
optimised, and adhesions matured. Full radiological bowel mapping should be 
obtained prior to surgery.  
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If the surgery results in short bowel syndrome (SBS) techniques to slow intestinal 
transit or increase functional bowel length currently have a limited role in the adult 
population. Intestinal transplantation has improved the outcome in selected patients 
with SBS. 
Conclusions 
Units are required to offer a multidisciplinary structured approach to the management 
of patients with ECF and intestinal failure from high output fistula or short bowel 
syndrome.   
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2.2 INTRODUCTION 
By definition, a fistula is an abnormal, epithelialised connection between two body 
structures.  The word ‘fistula’ is of Latin origin, and can mean a pipe or tube.  An 
enterocutaneous fistula is an epithelialised connection between the gastrointestinal 
tract and the skin.  This can be a devastating condition usually associated with 
abdominal surgery.  ECF have been described dating back many centuries.  The 18th 
century surgeon, Lorenz Heister, eloquently described his observations on the 
development of fistula after abdominal trauma in which he described “the lips of the 
intestines so wounded, would sometimes quite unexpectedly adhere to the wound of 
the abdomen (14).” 
We conducted an overview of the English language literature in the Pub Med, 
Medline, EMBASE, CINAHL and Cochrane databases using the search terms: 
Enterocutaneous Fistula, Short Bowel Syndrome, Intestinal Failure and Intestinal 
Transplantation. 
2.3 Aetiology 
The incidence of ECF is highly dependent on the surgical experience and case load at 
particular institutions and on patient and disease related co-factors.  Moreover, much 
of the published data relate to experience at specialised centres treating complex cases 
in particularly unstable patients (7) .   
The incidence of ECF after surgery for Crohn’s disease is approximately 13% with 
lower rates for other forms of abdominal surgery (15).  Hollington et al performed an 
11-year retrospective review of ECF managed at St. Mark’s Hospital between January 
1992 and December 2002.  This study included 277 patients with a median age of 48 
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years.  Most ECF occurred secondary to abdominal surgery (235 patients, 84.8%).  Of 
these, 111 (47.2%) had inflammatory bowel disease (76 Crohn’s disease and 35 
ulcerative colitis) and 6% had been treated with radiotherapy.   Of all patients, more 
than half (146, 57.7%) had inflammatory bowel disease (111 Crohn’s, 35 ulcerative 
colitis) (4). 
A low spontaneous healing rate was observed in 55 patients (19.9%).  Healing rate 
after definitive fistula surgery was 82.0%.  Definitive fistula resection resulted in a 
mortality rate of 3.0%.  The overall fistula-related mortality rate was 10.8%.  The 
spontaneous closure rate was lower than in many other reported series, perhaps 
reflecting the complex group of patients, many of whom were referred from other 
centres after failure of fistula healing.  In addition, the St. Mark’s Intestinal Failure 
Unit has had a long standing interest in inflammatory bowel disease, reflected in the 
relatively high prevalence of Crohn’s disease in this cohort (4). 
It is estimated that 75–85 per cent of ECF form after surgery as a result of bowel 
injury (inadvertent enterotomy) and / or anastomotic leakage (8, 16).  Fistula 
formation is more commonly associated with surgery in the presence of malignancy 
or inflammatory bowel disease, and with attempted division of dense adhesions (8, 
16).   
In the remaining 15–25% of instances, ECF form spontaneously secondary to 
underlying pathology.  Inflammatory bowel disease, in particular Crohn’s disease, is 
the commonest cause of spontaneous enterocutaneous fistulation in the developed 
world (8, 16), other causes include radiation enteritis, diverticular disease, 
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malignancy,  intra-abdominal sepsis and trauma (8, 16-19).  The study by Lynch et al 
revealed ECF caused by radiotherapy in 8% of patients (10). 
Decompressive surgery for abdominal compartment syndrome or laparostomy 
represents an additional risk for the development of ECF.  Having the underlying 
gastrointestinal tract exposed to the atmosphere, has additional risk of ECF 
development as a result of bowel wall oedema, serosal injury and frequent 
manipulation during temporary abdominal closure dressing changes (20).   
Symptoms can range from a minimal discharge from a low output fistula or recurrent 
abscess to multiple high output bowel loop fistulas with associated short bowel 
syndrome (SBS), sepsis and dehydration.  Biochemical complications can arise in 
patients with high output ECF including severe hypokalaemia, hypocalcaemia, 
hypomagnesaemia and hyponatremia requiring urgent correction and resuscitation. 
For critically ill septic patients early goal directed management should be commenced 
(21).  
The patient will almost always suffer from severe discomfort and pain. They may also 
have psychological problems, including anxiety over the course of their disease, and a 
poor body image due to the malodorous drainage fluid. Though not commonly 
addressed, persistent odour from the ECF can be a tremendous source of anxiety and 
social concern for these patients (22). Post-operative ECF formation often results in 
prolonged hospitalisation, patient disability, and enormous cost (20).  In a critically ill 
patient with an ECF, costs can average approximately $10,000 per day(22). 
Health-related quality of life (HRQL) is lower in patients treated for enterocutaneous 
fistula than in matched controls, particularly in those with concurrent medical 
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illnesses.  Patients treated successfully have normal independence in daily functioning 
(23). 
Therapy has improved over time with the introduction of parenteral nutrition, 
interventional radiology,  intensive care, and advanced surgical techniques and this 
has reduced mortality rates (4, 24).  However, the number of patients suffering from 
gastrointestinal ECF has not declined substantially.  This can be explained by the fact 
that with improved care, more complex surgery is being performed on patients with 
more advanced or complicated disease that are generally at higher risk. Therefore 
ECF remain an important complication following gastrointestinal surgery (11). 
Death related to ECF remains disproportionately high compared with that associated 
with other surgical conditions, as ECF are often associated with sepsis.  Studies 
reported over the past 30 years have shown mortality rates of 6–33 per cent in the 
most recent case series (2, 4, 5, 16, 25).  Many of the patients who survive can go on 
to develop SBS resulting in significant overlap between the two conditions. Given 
their complex nature, severe cases should be managed in specialist units.  
2.4.2 Management 
The management of ECF can present a paradigm of multidisciplinary care.  In those 
patients who fail to heal spontaneously surgical treatment is generally one of the last 
of many steps in the treatment of this condition (26).  A structured approach to the 
management of ECF has been shown to improve outcomes. Owing to the 
heterogeneity of this condition, randomised placebo controlled trials have not been 
performed and most recommendations are based on expert opinions (27).  This 
section will concentrate on the management of the most severe cases.  
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2.4.3 Medical management 
The medical management of persistent ECF falls into four main categories - 
specialised nutritional support, control of sepsis, judicious use of pharmacological 
agents and wound / stoma care.   
2.4.3.1 Specialised nutritional support 
Laparotomy should be deferred until there is re-epithelisation of the abdominal wall 
and attainment of adequate nutrition and good general medical status (4).  This 
process can take six months or more.  There is no consistent evidence to support the 
concept that oral nutrition needs to be withdrawn in the acute phase of an 
enterocutaneous fistula.  Healing is not enhanced and nutrition and patient moral may 
suffer.  Encouraging enteral feeding may also decrease parenteral requirements and 
the risk of associated liver disease (28).   
It has been suggested that total parenteral nutrition (TPN) has influenced fistula 
closure rates and mortality positively, although this has not been borne out by 
historical studies (16). The concept of ‘bowel rest’ in this setting is based on the 
observation that gastrointestinal secretions drop by 30–50 per cent in patients 
receiving PN and that this might aid fistula closure.  However, although this may 
improve fluid and electrolyte balance, published data to suggest an improvement in 
spontaneous fistula closure does not exist, as randomised trials investigating outcomes 
in patients kept ‘nil by mouth’ versus PN have not been performed (16).  
PN also has the additional risks of complications associated with central venous line 
placement.  These include pneumothorax, vascular injury and venous thrombosis.  PN 
may result in re-feeding syndrome characterised by electrolyte disturbance from the 
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rapid repletion of elements into depleted cells. This can result in hypokalaemia, 
hypophosphatemia and hypomagnesia as a result of glucose and amino acids rapidly 
moving into cells in exchange for potassium, phosphate and magnesium moving out. 
There is considerable data in the literature highlighting the benefit of enteral feeding 
maintaining gastrointestinal mucosal immunity, as well as decreasing fistula output. 
Reductions in intravenous fluid requirements can be aided by steps to reduce fistula 
output such as restricting hypo-osmolar fluids, encouraging electrolyte mixes and 
using anti-secretory agents and anti-motility agents (29). 
During prolonged fasting the body aims to conserve muscle and protein breakdown by 
switching to ketone bodies derived from fatty acids as the main energy source.  Many 
intracellular minerals become severely depleted during this period, although serum 
levels remain normal. Importantly, insulin secretion is suppressed in this fasted state 
and glucagon secretion is increased (30). 
During refeeding, insulin secretion resumes in response to increased blood sugar, 
resulting in increased glycogen, fat and protein synthesis. This process requires 
phosphates, magnesium and potassium which are already depleted and the stores 
rapidly become used up.  Formation of phosphorylated carbohydrate compounds in 
the liver and skeletal muscle depletes intracellular ATP and 2, 3 – diphosphoglycerate 
in red blood cells, leading to cellular dysfunction and inadequate oxygen delivery to 
the body's organs. Refeeding increases the basal metabolic rate. Intracellular 
movement of electrolytes occurs along with a fall in the serum electrolytes, including 
phosphate, potassium and magnesium. Glucose and levels of the vitamin B1 and 
thiamine may also fall.  Cardiac arrhythmias are the most common cause of death 
from refeeding syndrome, with other significant risks including confusion, coma and 
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convulsions and cardiac failure.  Biochemistry should be monitored regularly until it 
is stable (30). 
Patients who have been starved for some time often experience gastrointestinal 
disturbance during refeeding, in particular colicky abdominal pain, reflux symptoms, 
nausea and early satiety.  To help manage this, patients are often prescribed pro-
kinetic agents such as domperidone or metoclopramide, as well as acid suppressants 
such as omeprazole. 
The ability to discharge a patient pre-operatively on enteral or home parenteral 
nutrition (HPN)  can allow further wound healing and increase in muscle strength and 
general wellbeing prior to surgery (28).  
Parenteral nutrition may be avoided using enteral feeding administered into the distal 
bowel in a small minority of patients. It can be given either via a fistula or mucous 
fistula (fistuloclysis) (31).  Use of enteral nutrition via fistuloclysis, if used 
appropriately, avoids the complications of long term PN and may provide faster 
fistula healing (32). 
Teubner et al attempted fistuloclysis in 12 patients with jejunocutaneous or 
ileocutaneous fistulas with mucocutaneous continuity (33).  Feeding was achieved by 
inserting a gastrostomy feeding tube into the intestine distal to the fistula. Infusion of 
enteral feed was increased in a stepwise manner until predicted nutritional 
requirements could be met by a combination of fistuloclysis and regular diet. 
Parenteral nutrition was replaced in 11 of the 12 patients. Nutritional status was 
maintained, without complication, for a median of 155 (range 19 - 422) days until 
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reconstructive surgery could be safely undertaken in nine patients. PN had to be 
recommenced in one patient (33).   
2.4.3.2 Control of sepsis 
Sepsis is mainly found in the acute phase of ECF and is the commonest cause of death 
(34). Initial measures to treat abdominal sepsis are associated with an improved 
outcome in patients with intestinal failure.  Reber et al have reported that the 
mortality rate was increased and the spontaneous closure rate of ECF reduced in 
patients with uncontrolled sepsis when compared with those who had their sepsis 
treated within one month of diagnosis (35).  
Antibiotic therapy should be complemented by identification of the site of sepsis by 
imaging modalities. Computed tomography (CT) should be used as the first line 
investigation (36).  The success of percutaneous drainage of abdominal abscesses has 
improved in recent years (36-38).  In a study by Benoist et al percutaneous drainage 
was successful in 81% of patients and predictors of failure were abscesses less than 
5cm in diameter and lack of concomitant antibiotic therapy (38). 
Resection of the fistulating segment with exteriorisation of the bowel ends as stomas 
(total gastrointestinal disconnection), proximal diversion, abscess drainage or 
formation of a laparostomy may occasionally be needed to control sepsis (15, 39).  
However, the increased morbidity and mortality associated with early re-operation 
may preclude such an approach and these measures should be only adopted as a last 
resort. 
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Gastrointestinal disconnection combined with tube decompression of the bowel 
proximal to any fistulating segments resulted in an overall 77% survival rate in 22 
patients with intra-abdominal sepsis from gastric or small bowel fistulae (40).   
Adkins et al found that patients managed with an open abdomen had a higher 
mortality and ECF formation rate when compared with historical case-matched 
controls with a closed abdomen (41). The patients with the open abdomen had a 
mortality rate of 25% and fistula formation rate of 14.8%. 
 
The incidence of anastomotic leak varies depending on the level of anastomosis.  
Small bowel and ileocolic anastomoses have the lowest reported leak rates (1-3%).  
The highest rates are after coloanal anastomoses (10-20%).  The risk of anastomotic 
leak after low anterior resection of the rectum is inversely related to the distance of 
the anastomosis from the anal verge (42).  
 
The management of an anastomotic leak depends on whether the leak is “free” or 
“contained”.  "Free" leaks or those in which faeculent fluid spreads throughout the 
abdominal cavity, leading to diffuse peritonitis and septic shock.  Patients with a free 
leak should undergo emergency laparotomy with control of the anastomotic leak 
(takedown and creation of an end stoma +/- mucous fistula, primary repair and 
proximal faecal diversion, wide drainage and proximal faecal diversion) along with 
abdominal washout.  “Contained” leaks are those in which extravasation of contrast 
material is limited to the peri - anastomotic space and often result in the development 
of an abscess.  These situations are usually managed by insertion of a radiologically-
guided percutaneous drainage catheter.  Contained leaks managed in this manner may 
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heal spontaneously or may result in the formation of a controlled enterocutaneous 
fistula often accompanied by an anastomotic stricture.  Reoperation to address an 
anastomotic fistula or stricture should be deferred for six months to allow for 
resolution of the intra-abdominal inflammatory state. 
2.4.3.3 Pharmacological agents 
Proton pump inhibitors including Omeprazole (Losec®) and Lanzoprazole (Zoton®) 
have been shown to increase water absorption.  Using omeprazole 40mg twice a day 
in functional short bowel patients reduces fistula output (43-47). 
Omeprazole is a selective and irreversible proton pump inhibitor. It suppresses 
stomach acid secretion by specific inhibition of the H +/K + ATPase system found at 
the secretory surface of gastric parietal cells.  Because this enzyme system is regarded 
as the acid (proton, or H+) pump within the gastric mucosa, omeprazole will inhibit 
the final step of acid production (48). 
The inhibitory effect of omeprazole occurs within one hour after oral administration. 
The maximum effect occurs within two hours.  The duration of inhibition lasts up to 
72 hours. When omeprazole is stopped, baseline stomach acid secretory activity 
returns after three to five days. The inhibitory effect of omeprazole on acid secretion 
will plateau after four days of repeated daily dosing.  The absorption of omeprazole 
takes place in the small intestine and is usually completed within three to six hours 
(48) 
Proton pump inhibitor administration might cause diarrhoea via several different 
mechanisms, including easier colonization of enter pathogenic bacteria, inadequate 
protein digestion in the stomach, and a possible influence on H, K-ATPase in the 
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colonic mucosa.  In the absence of gastric acid, several kinds of bacteria, including 
Clostridium difficile, Salmonella, and Campylobacter species, were reported to easily 
colonize in the gut, causing enter colitis accompanied by diarrhoea or loose bowels 
(49). 
The loss of intestinal fluid in patients with high intestinal output most likely reflects 
the loss of normal daily secretions produced in response to food intake.  Increased 
duodenal volume could flush and dilute nutrients and electrolytes, thereby impairing 
intraluminal food assimilation and fluid and electrolyte absorption.  The transient 
gastric hyper secretion, which occurs after massive small bowel resection, may affect 
the digestive and absorptive processes by inactivating pancreatic enzymes and 
precipitating bile salts. There are, however, no data to support the hypothesis that 
gastric acid hyper secretion continues for longer periods in patients with a short 
bowel.  Patients with functional short bowel syndrome and a high faecal output do 
benefit from H2 receptor antagonists and proton pump inhibitors when considering 
wet weight and sodium absorption (43). 
Loperamide and other anti-diarrhoeal agents such as codeine phosphate can also be 
used to reduce fistula output.  Loperamide should be administered half an hour before 
ingestion of food and results in slowing of intestinal transit time.  It slows down the 
usual gut activity that is stimulated by eating.  Most people find that the bowel is most 
active in the morning and so loperamide helps most if taken before breakfast.  It is 
effective for eight to 12 hours.  Higher doses of loperamide are needed in patients 
with SBS as it circulates through the entero-hepatic circulation. 
44 
 
St Mark’s Electrolyte Mix can be provided to those patients whom become 
dehydrated.  This drink contains a solution of salt, glucose, and sodium bicarbonate 
(baking soda).  A useful test to identify dehydrated patients is ‘random urinary 
sodium.’   
Treatment of a high output ECF is similar to that from a high output jejunostomy.  If 
there is marked sodium and water depletion and severe thirst, it is often necessary to 
establish equilibrium by giving intravenous normal saline (2–4 l/day), keeping the 
patient “nil by mouth”, which will also demonstrate that output is driven by their oral 
intake. Over two to three days intravenous saline is gradually withdrawn while food 
and restricted oral fluids are reintroduced.  Great care must be taken not to administer 
too much fluid, which will readily cause oedema (partly due to high circulating 
aldosterone levels).  The aims of treatment are to maintain hydration/body weight and 
a daily urine volume of at least 800 ml with a sodium concentration greater than 20 
mmol/l (50). 
It is a common mistake for patients to be encouraged to drink oral hypotonic solutions 
to quench their thirst but this causes large stoma sodium losses.   Treatment for high 
output from a jejunostomy (ileostomy or high fistula) begins with the patient 
restricting the total amount of oral hypotonic fluid (water, tea, coffee, fruit juices, 
alcohol, or dilute salt solutions) and also of hypertonic fluids (fruit juices, Coca cola, 
and most commercial sip feeds) to less than 500 ml daily.  To make up the rest of the 
fluid requirement, the patient is encouraged to drink a glucose‐saline replacement 
solution (90 mmol/l sodium or more).  Many patients at home with marginally high 
stoma outputs (1–1.5 litres) will be helped by a combination of oral fluid restriction 
(less than 1 litre per day) and addition of salt to their diet.  Patients with stoma losses 
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of less than 1200 ml daily can usually maintain sodium balance by adding extra salt to 
the limit of palatability at the table and when cooking. When stoma losses are in the 
range 1200–2000 ml, or sometimes more, it is possible for a patient to maintain 
sodium balance by taking a glucose‐saline solution or salt capsules (50).  
As the sodium content of jejunostomy (or ileostomy) effluent is relatively constant at 
approximately 90 mmol/l and as there is coupled absorption of sodium and glucose in 
the jejunum, patients are advised to sip a glucose‐saline solution with a sodium 
concentration of at least 90 mmol/l throughout the day. The World Health 
Organization (WHO) cholera solution has a sodium concentration of 90 mmol/l and is 
commonly used (without the potassium chloride). Sodium chloride capsules (500 mg 
each) are effective when taken in large amounts (14/24 h) but can cause some patients 
to feel sick and even vomit.  If an enteral feed is given, sodium chloride needs to be 
added to make the total sodium concentration of the feed 100 mmol/l while keeping 
osmolality near to 300 mosmol/kg.  Mineralocorticoids (for example, 2 mg oral 
fludrocortisone or 2 mg intravenous d‐aldosterone) or high dose hydrocortisone  may 
reduce stoma output in patients with a retained ileum (50). 
The use of somatostatin or its analogue octreotide in the treatment of intestinal fistula 
is controversial.  Conflicting evidence of the efficacy of these agents is usually the 
result of heterogeneous patient populations and small patient numbers (51, 52).  A 
review of all controlled studies evaluating the effects of somatostatin or octreotide 
showed that no study demonstrated a significant increase in the rate of fistula closure 
(53).   While most studies demonstrate a reduction in fistula output in the initial few 
days of therapy, the cost of the treatment may not warrant their use as there is no 
impact on morbidity or mortality (25, 54, 55).  
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Crohn’s patients can present with stricturing, inflammatory or fistulating disease.  The 
medical management of patients has improved with the use of biological and 
immunomodulatory therapy.  Tumour necrosis factor alpha (TNF-α) blocking agents 
such as Infliximab have been shown to be effective for the maintenance of remission 
and maintenance of ECF healing in patients (56). 
2.4.3.4 Wound care and stoma therapy 
Expert care is paramount in maintaining skin integrity in patients with ECF.  The 
corrosive nature of the intestinal effluent may lead to painful and irritable skin 
destruction.  The effects of continuous moisture from the ECF and small bowel 
effluent in direct contact with the skin results in breakdown of skin with possible 
resultant excoriation, erythema, severe pain and an unsightly wound with the risk of 
developing infection.   
A specialised wound / stoma care nurse can avoid these problems with the adequate 
size and placement of stoma bags, or with the use of specific appliances that are 
designed to manage large defects (34). Skin barrier protection creams, pastes, 
adhesives, dressings, pouches are all available and have further advanced wound care 
management.  
Devitalised or necrotic tissue within a wound or around the ECF should be debrided 
prior to dressing or pouch application; otherwise the necrotic tissue will prevent 
granulation tissue formation whilst also acting as a culture medium for bacteria to 
grow. 
When the wounds are small, a simple stoma bag may be all that is necessary. Where 
large defects are present with large fistula outputs specialised pouches connected to a 
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drainage bag or even to low pressure / negative pressure wall suction may be used 
(57).   However there is concern regarding the process of applying negative pressure 
in close proximity of the exposed viscera and bowel, as this may contribute to 
subsequent ECF formation.  VAC dressings have been used extensively in the 
management of complex wounds due to proven enhancement in wound granulation 
and wound contracture (22).  Concerns about negative pressure increasing fistula 
output seem to be overstated. Modifications to this technique have shown great 
promise where the VAC dressing is applied to the peri fistula wound while skin 
barrier wafers are used to isolate the fistula itself.  The fistula is then managed with 
the pouch applied on top of the VAC dressing, thereby isolating fistula drainage from 
the remainder of the wound while taking advantage of all the benefits of a negative 
pressure dressing. The role that the VAC plays in this algorithm for care of these 
wounds remains to be seen as larger series and further experience is gathered (22). 
If ECF output is high and dressings are being changed more frequently than every 
four hours, a pouching system should be used.  Frequent dressing changes are 
impractical, and can also be associated with damage to the skin and healing tissue. 
It is essentially important to have a multidisciplinary approach with the wound care / 
stoma therapist.  This can contribute to improved protection for the skin, control of 
effluent and odour and a better quality of life and psychological wellbeing for the 
patient. 
2.4.4 Radiology 
Understanding the anatomy of the ECF optimises its evaluation and management.  
Imaging can confirm the anatomical site of the ECF.  A proximal or distal location 
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will require different nutritional and fluid requirements.  Imaging the bowel is 
essential prior to elective surgery for patients with intestinal failure.  A clear picture 
of the status of the bowel distal to any fistulating segments is paramount in excluding 
distal obstruction. Anatomical details of the ECF include diameter, length and the 
presence of additional side branch’s / tracts or associated abscesses.   
Several, modes of imaging are available to obtain the necessary information.  Barium 
follow through in combination with fistulograms have been shown to be accurate in 
determining length of remaining bowel (58).  Fistulograms are the most rapid and 
direct method of detecting an ECF.  They often show distal obstruction and also have 
the benefit of providing real time images and do not require the ingestion of contrast 
or intravenous injections.  A drawback is that they can fail to define the presence of 
disease proximal to the ECF or distal if an associated abscess cavity is present. 
Small bowel follow through is useful in evaluation of the distal bowel and 
identification of intraluminal causes of ECF, but it may fail to identify the location of 
the ECF.  It also has the drawback of taking several hours to perform.  Small bowel 
enterography provides greater mucosal detail then a follow through, but requires the 
placement of a nasogastric tube.   
While these examinations are useful in determining the length of remaining bowel 
other examinations such as CT enteroclysis and Magnetic Resonance Imaging (MRI) 
enteroclysis are also very useful in examining pathological bowel and areas of on-
going pathology such as areas of on-going obstruction or septic collection (59-61).  
They can also provide valuable information such as safe sites of entry into the 
abdominal cavity and the size of the abdominal wall defect. 
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CT scans are used with intravenous contrast to demonstrate inflammation, and oral 
contrast to differentiate loops of bowel from extra luminal abscesses or collections. 
CT enteroclysis differs from traditional CT in the type of contrast agent used.  CT 
enteroclysis has better sensitivity and accuracy for intraluminal findings, but 
traditional CT is better for visualising abscesses.  CT provides the clinician with the 
option of percutaneous drainage of an abscess or collection under radiological 
guidance.   
MRI is useful for identifying extra intestinal complications.   MRI is better than CT to 
differentiate between inflammatory and fistula disease.  In the postoperative patient, 
oedema or inflammation may be highlighted on T1-weighted images. Enhancement 
on T1 gadolinium images appears to be highly specific for active disease (62). MR 
enteroclysis has also been heralded as a superior form of investigation in these 
situations as it has the advantage of superior tissue characterisation and detection of 
intra and extra mural lesions without the use of ionising radiation (61).   
Limitations of MRI include problems with motion artefact from bowel peristalsis 
which can degrade picture quality, the time required to obtain images, and patients 
experiencing claustrophobia. 
Other special investigations such as conduitograms and vaginograms can be used in 
selected patients. Anorectal physiology and endoanal ultrasound should also be 
considered where loose stool or faecal incontinence is predicted as a post-operative 
outcome. 
Endoscopy is the gold standard for detecting mucosal disease.  Difficulty arises with 
identifying the internal opening of the ECF.  Although not widely used, there are 
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examples in the literature of clinicians using interventions such as fibrin glue for ECF 
and self-expanding silicone stents as treatment options for managing colostomy 
related ECF (63, 64). 
2.4.5 Anaesthetic considerations 
Major insults such as intra-abdominal sepsis and multi organ failure, necessitating 
management in an intensive care unit, invariably result in a residual reduction in 
cardio-respiratory and renal functional reserve that could restrict the ability to recover 
uneventfully from further major surgery (65).  
Exercise tolerance and physical fitness can be assessed in metabolic equivalent levels 
(METS). This is a validated method for determining functional capacity from a 
patient’s history and will help determine the need for further specialised cardio-
respiratory investigations.  Peri-operative cardiac risk is increased in patients unable 
to achieve four ‘MET’ levels of exercise (66).  If optimisation of physiological 
reserve is not achieved these patients are highly likely to develop critical illness.  
Patients receiving parenteral nutrition require careful monitoring of clinical, 
laboratory and nutritional indices.  Sodium and water retention can be a problem if 
malnourished patients are provided regimens in which all the non-protein energy is 
supplied as carbohydrate.  Peripheral and central venous access can be difficult in 
patients with chronic intestinal failure due to thrombosis from repeated venous 
cannulation's and parenteral nutrition. Doppler ultrasound is useful for identifying 
thrombosed central veins prior to surgery (67).  
Surgery for ECF is often lengthy, technically demanding and associated with large 
fluid shifts and a profound physiological stress response.  Blood loss from collaterals 
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and generalised venous oozing can be significant.  Cross-matched blood should 
always be available prior to the commencement of surgery.  
Effective prophylactic prevention of deep venous thrombosis (DVT) must be 
employed for these patients particularly in those with a history of bowel infarction or 
inflammatory bowel disease.  
Chronic usage of opioid and non-opioid analgesics is not uncommon in many patients 
with chronic ECF.   It is worthwhile harnessing the skills of the hospital’s pain service 
in the pre-operative management of such patients (68).  Modern approaches to the 
management of pain after abdominal surgery rely on two analgesic techniques, patient 
controlled analgesia (PCA) using an opioid, self-administered in small doses, and 
epidural analgesia (69).  
The aims of pain management are to achieve a level of pain relief which will allow 
coughing, deep breathing, mobilisation and communication with carers and facilitate 
rest and normal sleep patterns.  Ideally analgesic regimes should take into account 
periods where pain intensity is increased due to therapeutic interventions for example 
during physiotherapy and dressing changes.  
In patients having colorectal surgery oesophageal Doppler guided fluid management 
has been shown to reduce gastrointestinal morbidity (70).  The study concluded that 
patients in the Doppler guided fluid group achieved significantly higher cardiac 
output and stroke volume measurements as well as higher oxygen delivery at the end 
of the operation than the control group. A better intra-operative splanchnic blood 
supply may have contributed to the quicker recovery of gut function and reduction in 
gastrointestinal complications in the Doppler guided fluid group. 
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Conversely, fluid overload may lead to oedema of the gut, possibly contributing to 
enteric nutritional intolerance and prolonged ileus. Abdominal compartment 
syndrome may result in respiratory and renal failure (71).  
Hypothermia is defined as a core temperature of less than 36oC.  If hypothermia is not 
managed intra-operatively, 70-80% of patients may be hypothermic on admission to 
the recovery ward (72). Heat loss under anaesthesia occurs as a result of impaired 
thermoregulatory responses, anaesthetic induced peripheral vasodilatation, infusion of 
cold intravenous solutions, exposure of large surface areas of the body and opening of 
large body cavities during surgery. The degree of heat loss is also influenced by 
ambient temperature and airflow in theatre and skin preparation methods. 
Antibiotic prophylaxis with a single dose of cephalosporin and metronidazole is 
associated with reduced septic complications and should be administered at the 
commencement of each case (73, 74), unless otherwise recommended by the local 
microbiologist.  In prolonged cases this should be repeated intra-operatively.  The 
2013 update of the World Society of Emergency Surgery (WSES) guidelines for the 
management of intra-abdominal infections contains evidence-based recommendations 
for management of patients with intra-abdominal infections (75). 
Hyoscine butylbromide (Buscopan) can also be useful in reducing the volume of 
intestinal effluent.  Although its use in enterocutaneous fistula surgery has not 
previously been described, Buscopan has been shown to cause intestinal paralysis in 
21 seconds and result in reduced small bowel effluent (76). 
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2.4.6 Surgical management 
Several techniques for the management of ECF have been used.  Simple suture 
closure techniques, wedge resection and resection of the diseased bowel segment have 
been described.  Materials which have been inserted into the fistula tract to aid 
healing include fibrin glue, pastes, vicryl mesh plugs and bovine small bowel tissue 
(63, 77). 
In patients with an open abdomen, preventative techniques for ECF development 
include coverage of underlying viscera with omentum or other non-adherent 
protective barrier, avoidance of excessive resuscitation leading to bowel wall oedema, 
avoidance of serosal injury during dressing changes, and expedited fascial and skin 
closure. 
2.4.6.1 Prevention of Fistula Formation 
Meticulous surgical technique is imperative with attention to detail during the 
laparotomy to ensure that inadvertent enterotomies are avoided or identified and 
repaired (34). Avoiding early re-laparotomy where possible is probably the most 
important factor in reducing fistula formation (78). Careful attention to suture 
placement in laparotomy closure will also reduce the risk of iatrogenic fistula 
formation. 
Several reports in the literature have advocated the use of vacuum assisted closure 
devices to aid healing of laparostomy wounds (79-84).  In these series, successful 
closure of laparostomy wounds and enterocutaneous fistulae has been achieved with 
vacuum suction.    
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The vacuum suction wound management system can be used to isolate the ECF 
within the open wound, and hence allow pouching of the fistula.  The vacuum sponge 
can also be applied directly to the ECF in an attempt to aid closure.   
However, in our referral practice there have been several cases of vacuum suction 
devices applied to adjacent bowel leading to the formation of ECF (85).  There have 
been several reports of ECF formation in association with the use of vacuum assisted 
therapy on open wounds and exposed bowel (62).    
In one study with 112 patients treated with a specially created device that protected 
the bowel during application of the vacuum device there was 4.5% rate of fistula 
formation and an overall mortality rate of 25.9% (79) .  The technique involved a 
polyethylene sheet perforated multiple times with a scalpel blade and placed over the 
peritoneal viscera and beneath the peritoneum of the abdominal wall.  Next a moist 
sterile surgical towel is folded to fit the abdominal wall defect and placed over the 
sheet.  Two 10-French drains are placed over the towel and connected to a suction 
device (86). Another study examined the clinical outcomes of 29 patients in whom  
vacuum assisted closure (VAC) was used to aid the closure of abdominal wounds 
(87).  A high incidence (20%) of patients developed leakage of small bowel contents 
into the abdominal cavity because of intestinal fistulation during the VAC therapy.  
We are not aware of any prospective trials assessing the use of vacuum assisted 
therapy in the management of patients with ECF.      
The use of non - absorbable mesh can also lead to fistula formation and is discussed 
under the section on abdominal wall closure 2.4.6.5 (88).  
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2.4.6.2 Prevention of short bowel syndrome 
In conditions such as Crohn’s disease where multiple laparotomies may be required it 
is important to tailor any resections to preserve as much intestinal length as possible.  
Where feasible, techniques such as stricturoplasty are useful in maintaining intestinal 
length while addressing the underlying pathology (89-92).   
When normal bowel is adherent to a diseased segment of bowel, every attempt should 
be made to preserve the normal bowel.  Use of medical therapy to control 
inflammation in Crohn’s disease and judicious use of endoscopy to dilate strictures 
can also delay the need for surgery (52, 91). 
Post-operative sepsis and its related complications can lead to intestinal loss and 
prevention of such complications is important.  Pre-operative low albumin, steroid use 
and the presence of an abscess or fistula at the time of surgery significantly increases 
the risk of post-operative sepsis (15). 
Colonic preservation where possible, can be an important determinant in the need for 
long term parenteral nutrition.  Nightingale et al showed that patients with greater 
than 50cm of jejunum with an intact colon did not usually require long term parenteral 
nutrition – this was not the case in those with longer segments of jejunum but no 
colon (93). 
2.4.6.3 Intestinal reconstruction 
During the period of the ‘frozen’ abdomen, delayed surgical intervention for 
persistent fistula is advisable allowing for the obliterative peritonitis to subside and 
allowing laparotomy and adhesioloysis to be performed safely.  Careful clinical 
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examination may indicate when the dense reaction of adhesion formation has 
subsided. The abdomen should be soft and non-tender.  Mobility of the peritoneal 
contents may be appreciated on palpation of the abdomen.  A good clinical indicator 
of the appropriate time to operate on ECF patients is the presence of non-oedematous 
prolapsing bowel in the fistulating segments (4, 94). 
Although many ECF close spontaneously, if the ECF remains open after two months 
surgical intervention is likely to be needed as spontaneous closure is unlikely after 
this interval (16, 35).  Major abdominal surgery stimulates the formation of dense 
adhesions, especially when complicated by intra-abdominal sepsis. This reaction is 
most severe between three weeks and four months after operation, and further surgery 
during this time is more likely to be complicated by ECF recurrence (13, 16, 95).  
Other authors have commented that operative repairs should be performed when 
spontaneous closure does not occur, but it should be delayed for at least three months 
(16). 
2.4.6.4 General principles of surgical reconstruction  
1) Plan the surgical procedure in advance, delaying reconstructive surgery until 
optimal nutrition status, general fitness and re-epithelialisation of the peritoneum have 
been achieved (95).  Noting the above, re-operation should be avoided for at least four 
to six months after the last abdominal procedure where possible (4, 34, 95). 
2)  Resection and anastomosis rather than suture alone is associated with a better 
outcomes in enterocutaneous fistula repairs (96).  
3) Any intestinal anastomosis should be clear of septic abdominal sites and fistula 
tracks.  
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4) Anastomosis should be avoided in the presence of ischaemia and in severely 
malnourished patients. 
5) Judicious use of a covering stoma should be considered. 
6) Where large volume diarrhoea is a predicted outcome or in those patients with a 
weak sphincter an end colonic stoma should be considered although this can be 
avoided in most cases. 
The main advantages of restoration of intestinal continuity are increasing absorptive 
surface area and enhancing intestinal adaptation by enhancing the surface area 
exposed to the nutrient micro-environment (97).  There is evidence that bringing the 
colon back in to circuit reduces the incidence of hepatic disease in patients on large 
volumes of parenteral nutrition (93).  
In situations where sepsis has prevailed the rate of anastomotic dehiscence can be 
higher than expected (98).  In patients with SBS meticulous attention to anastomotic 
technique is vital. It has been considered that intestinal anastomosis in the 
malnourished patient should not be carried out. Given that most patients with short 
bowel syndrome (SBS) are hypoproteinemic and one of the aims of management in 
these patients is to increase the surface of absorption this principle may not 
necessarily apply to this group.   
Other studies including experimental studies have shown that factors such as serum 
albumin less than 3.0 g/L, steroids use, presence of peritonitis, bowel obstruction, 
perioperative transfusion of more than two units of packed red blood cells and chronic 
obstructive pulmonary disease were all significant predictive factors of anastomotic 
leakage (99, 100).    
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Lynch et al,  in a retrospective review analysed the management of  205 patients with 
enterocutaneous fistula (95). The primary diagnosis was Crohn's disease in 95 
patients, ulcerative colitis in 18 patients, diverticular disease in 17 patients, carcinoma 
in 25 patients (16 cases after radiotherapy), and mesh ventral hernia repair in 21 
patients was performed. After initial management, including CT-guided drainage of 
an intra-abdominal abscess or defunctioning stoma in some patients, definitive 
intestinal reconstruction surgery was performed in 203 patients.  The median time 
between the diagnosis of enterocutaneous fistula and the onset of a surgical procedure 
in the specialised unit was 5.8 months. Most of the patients (159 patients) had 
resection and re-anastomosis of the involved small bowel segment or ileocolic 
anastomosis.  An average of 21% of patients developed fistula recurrence within three 
months and postoperative mortality was 3.5% (95).  Wedge repair or over sewing the 
fistulous track were associated with a significant risk of fistula recurrence when 
compared with intestinal resection and anastomosis (32.7%  vs. 18.4%, respectively) 
(95). 
Experimental studies have shown that in ischaemic anastomoses neo-vascularisation 
can occur via the omentum (101).  Omental wrapping has been shown to be effective 
in post radiotherapy injuries to the colon and the successful use of omentum has also 
been demonstrated in aortoenteric fistula repairs (102).  
Although its use in the repair of ECF has not been described, it may be beneficial in 
protecting anastomoses or as a layer between any mesh and the intestines where 
fascial closure of the abdomen is not possible. 
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The results of intestinal reconstruction vary according to the techniques employed and 
with the end points assessed.  Hollington et al reported an 11 year experience of 
surgery for ECF in 277 consecutive adult patients (4).  In all situations resection with 
anastomosis was the choice of surgery.  The fistula healing rate was 82% although in 
some patients more than one attempt at repair was necessary to achieve healing.  This 
comprehensive report of surgery for ECF in adult patients and it highlights the 
success of simple reconstructive surgery without the use of complex adjunctive 
procedures.   
More recently we have reported results from the same unit with an improved overall 
healing rate (24). 150 out of 177 patients underwent definitive surgery (84.7%) with 
an overall healing rate of 94.6% compared with 82% in the previous series. This is 
discussed in Chapter 3. 
2.4.6.5 Abdominal wall reconstruction 
ECF are often associated with abdominal wall dehiscence and large skin defects.  
In most patients contraction of the granulation tissue over time reduces the midline 
defect to such an extent that primary closure of at least the skin of the abdomen is 
possible. Releasing incisions in the abdominal flanks can be useful in reducing 
tension on the abdominal wall and allowing primary closure (94).  
The modified components separation technique which consists of mobilising the 
rectus sheath and external oblique fascia, followed by division of the internal oblique 
component of the anterior rectus sheath down to the arcuate line and finally suturing 
the medial border of the posterior sheath to the lateral border of the anterior sheath is 
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a well described technique of abdominal reconstruction but this can be associated with 
significant  morbidity (98, 103-105).  
Reinforcement of an abdominal wall closure can be achieved with a non-absorbable 
mesh.  However, in situations where there is direct contact with the bowel and the 
mesh other reconstructive techniques should be considered as there is a high rate of 
enterocutaneous fistula formation in this setting (106).  Non-absorbable meshes are 
also avoided because ECF surgery is often performed in contaminated or grossly 
infected wounds. There is the possibility secondary mesh infection leading to mesh 
removal, and hence this is avoided. 
There is difference of opinion as to whether there is anything better than placing an 
absorbable synthetic mesh like Vicryl (Ethicon, Somerville, NJ, USA) (107).   
The use of absorbable mesh such as the biologic porcine-dermis derived cross-linked 
Permacol™ (Tissue Science Laboratory, Covington, USA) or non-cross linked 
Strattice™ ( Lifecell Corporation, Branchburg, NJ , USA) is safe, but have recurrence 
rates of 0 to 15% (107).  
One study aimed to determine factors which influence the outcome of surgical 
technique to close ECF within the open abdomen (88).  Their results revealed that re-
fistulation was more common when the abdominal wall was constructed with a 
prosthetic mesh (7 of 29, 24.1%) than with sutures (0 of 34, 0%).  The use of porcine 
collagen mesh was associated with a particularly high rate of re-fistulation (5 of 12, 
41.7%).  The authors concluded that simultaneous reconstruction of the intestinal tract 
and abdominal wall was associated with a high complication rate and simultaneous 
reconstruction of the abdominal wall with prosthetic mesh was associated with a 
61 
 
particularly high incidence of recurrent postoperative fistulation and should be 
avoided if possible. 
2.5 Complications of ECF: Intestinal failure and short bowel syndrome  
In the United Kingdom the estimated incidence of intestinal failure (IF) requiring 
treatment at a specialised unit is 5.5 per million population (26).  A recent study 
showed an overall survival rate of 86% in patients undergoing autologous surgical 
reconstruction, at a median follow up period of two years, in one such specialised unit 
(108).  Similar results have been achieved in other specialist units (26, 109). 
IF has been sub-classified into three types depending upon duration and irreversibility 
(110).  Thus:  
Type 1 IF is usually considered to be of less than 28 days duration.  It is typified by 
conditions such as postoperative ileus or small intestinal obstruction, usually requiring 
short term parenteral nutrition and generally resolving within 28 days.   
Type 2 IF is usually considered to be of greater than 28 days duration. Typical 
patients might include those with complex Crohn’s disease, intestinal fistulas or 
abdominal sepsis. These patients require much more prolonged nutritional and 
metabolic support pending spontaneous resolution or surgical treatment.  Patients with 
both Type 1 and Type 2 IF would be expected to return to full enteral autonomy in 
time.   
Type 3 IF is generally irreversible and usually occurs as a consequence of massive 
small bowel resection, leading to short bowel syndrome, although there is increasing 
recognition that severe motility problems may account for a small proportion of cases.   
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Patients with type 3 IF will require HPN and, in some cases, referral for intestinal 
transplantation may be appropriate.   Significant data exist on the management of this 
condition in the paediatric population, but treatment options are not necessarily 
applicable to the adult population (111).   
SBS refers to IF associated with a loss of intestinal length or competence below the 
amount required to maintain adequate enteral nutrition (112).  Normal small bowel 
length ranges from approximately 300cm to 800cm and SBS usually occurs when the 
length of small bowel is less than 100cm with a stoma, less than 50cm with an intact 
colon or when the patient continues to be dependent on  parenteral nutrition  after 
three months (93, 112-114).  
2.5.1 Aetiology 
The causes of IF also vary widely between institutions depending on their referral 
patterns. Scott et al reviewed 300 consecutive patients admitted to a specialised unit 
and showed that 42% of patients had Crohn’s disease and the most common 
complication necessitating admission was formation of enterocutaneous fistulae (26). 
Peptic ulcer (9%), pancreatitis (8%), mesenteric vascular disease (7%), malignancy 
(6%) and other miscellaneous causes (28%) accounted for the remainder of 
admissions.  
Intestinal failure is rare, occurring in 2 – 6.8 per 1 000 000 children in developed 
countries. Each year in Australia, there is expected to be approximately 40 new 
patients with intestinal failure.  The individual health care burden of intestinal failure, 
in terms of both social and economic costs, is enormous. Children with intestinal 
failure usually spend the first six months to two years of life in hospital, and the 
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average cost per child with intestinal failure has been calculated as US $1 619 851 
over a 5-year period (115). 
The aetiology of SBS is related to a loss of functional intestinal length usually as a 
result of multiple intestinal resections or a massive intestinal resection (112, 116). 
Multiple intestinal resections are most commonly associated with Crohn’s disease 
whereas massive intestinal resections are associated with catastrophic vascular events 
such as those following venous or arterial infarction, trauma, resections following a 
volvulus, or desmoid disease.  
In a European multi-centre study, the indications for PN in a group of patients with 
SBS were cancer (39%), Crohn’s (19%), vascular diseases (15%), radiation enteritis 
(7%) and AIDS (2%) (117).  Post-operative causes such as adhesions, volvulus and 
ischemia accounted for 25% of all patients with SBS in an American institution (118).  
The United States Food and Drugs Administration approved recombinant Growth 
Hormone for patients with short bowel syndrome based on the recent results of a 
double-blind randomised clinical trial (119). Further studies have shown that low dose 
growth hormone has successfully reduced the PN requirements for those with SBS 
(119-121).  However, experience of its use remains limited and long term outcome 
evaluation is required prior to its recommendation. 
2.5.2 Concurrent Cholecystectomy 
The risk of gall stone formation in patients with SBS is estimated at 44% (122, 123).  
This rate is not reduced by the presence of an intact colon (123). An intestinal length 
of less than 120cm, Crohn’s disease, long term PN and the absence of an ileocaecal 
valve are significant risk factors for gall stone formation (124). The risk of 
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inflammatory complications of cholelithiasis is greater than 50% in patients with SBS 
(125). Given the potentially severe nature of these complications serious 
consideration should be given to performing prophylactic cholecystectomy at the time 
of any definitive surgery (126). 
2.5.3 Adjunctive surgery 
A variety of techniques have been described to optimise the function of the remaining 
intestine (104). However they are of limited efficacy as the overall surface area of the 
bowel cannot be increased. Their use has not been extensively evaluated in adults.  
Sudan et al (108) reported their experience in the management of 50 patients (20 
adults, mean age 42 years) in a multidisciplinary intestinal failure unit. The surgical 
procedures included intestinal reconstruction (n=5), repair of enterocutaneous fistulas 
(n=5), resection of bowel segments (n=7), stricturoplasty (n=2), Bianchi tapering and 
lengthening (n=20), and STEP procedure (n=8). Sixty five per cent of patients were 
completely weaned off PN at follow-up. 
2.5.4 Reversed small bowel segments  
A short segment of distal small bowel is prepared and disconnected from the 
remaining bowel. It is then reversed, and re-anastomosed, with its blood supply intact 
(127). The aim of this procedure is to increase transit times. The ideal length of the 
reversed intestinal segment is about 10 cm in the adult population (128).  While the 
short term results of this procedure may be promising the long term results are limited 
and the clinical indications restricted (34).  
Segmental reversal of the small bowel (SRSB) is proposed in patients with short-
bowel syndrome (SBS) as a rehabilitative therapy.  A retrospective studied all 
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consecutive patients who had an SRSB between 1985 and 2010.The authors 
concluded that SRSB allows a gain in macronutrient absorption, which is associated 
with a lower HPN dependence.  They also recommend that SRSB should be 
integrated in intestinal rehabilitative adult programs (129). 
2.5.5 Colonic interposition  
Several cases of colonic interposition have been reported with the use of segments of 
at least 20 cm in length (130). There is evidence that the adaptive histological changes 
in the interposed colon are not just an experimental finding (130, 131).   This 
technique has not been studied extensively in the adult population. 
2.5.6 Neo valves  
The creation of ileocaecal neovalves was described some time ago for the purpose of 
delaying intestinal transit time (104, 132). There are several types of neovalves 
described in the literature (132-134).  While some experimental models have shown a 
reduction in intestinal transit time, creation of  these valves requires the use of part of 
the length of small bowel, with possible resultant complications such as pseudo-
obstruction and secondary enterocolitis (135, 136). 
2.5.7 Bowel “lengthening” procedures  
Bianchi described a unique technique to lengthen small bowel in the paediatric 
population (137). The technique consists of dividing dilated bowel longitudinally in 
the midline along the anti-mesenteric edge and then the creation of two vascularized 
hemi loops anastomosed in tandem.  It has been suggested that its main effect is to 
increase the transit time rather than mucosal absorption. 
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Most reports of this technique are in paediatric series. In a recent analysis most 
studies had small numbers of patients with an overall survival rate ranging between 
30 and 100%. Between 28 and 100% of patients were able to come off PN (104). The 
morbidity is the main drawback of this technique.  Anastomotic leakage in the long 
sutures lines and the need for further surgery due to pseudo-obstruction are common 
problems. The heterogeneity of the patients and technique in the published series 
make it difficult to achieve further definite conclusions (96, 104, 108).  
The serial transverse enteroplasty (STEP) technique involves sequential linear 
stapling of the distal small bowel from alternating directions, perpendicular to the 
long axis of the intestine (108, 138).  The STEP creates a zigzag-shaped bowel that is 
greater in length without putting the mesenteric blood supply at risk. In a cohort of 
five infant patients there were no perioperative complications at 26 months follow up. 
Again this procedure has not been extensively investigated in adults (139).  
More recently a retrospective review of a single centre series of intestinal lengthening 
over 15-year period in patients ≥ 18 years old has been performed (140).   Overall of 
17 patients who underwent Bianchi or serial transverse enteroplasty (STEP), ten 
(59%) patients achieved enteral autonomy and were off PN.  Of seven patients who 
were on PN, three patients showed significant improvement in enteral caloric intake. 
All except one showed significant improvement in symptoms of bacterial overgrowth.  
The authors concluded that bowel lengthening is technically feasible and effectively 
leads to weaning from PN in more than half of the adult patients and that at present 
lengthening procedures may be an underutilized treatment for adults with short bowel 
syndrome. 
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2.5.8 Future techniques  
The use of electrical pacing, mechanical tissue expansion and stem cells, have been 
described and are still the subject of on-going research (141-143).   In one study, two 
patients with low-output enterocutaneous fistulas after surgery were treated with 
electrical nerve stimulation (ENS).  Fistula output diminished rapidly in both cases, 
and the closure of the track was achieved after several sessions of ENS. The authors 
suggest that the procedure is simple and safe and is suggested as an option for the 
treatment of low-output enterocutaneous fistulas (144). 
Volpe et al showed that mesenchymal stromal cells from adipose tissue attached to 
suture material enhance the closure of enterocutaneous fistulas in a rat model.  This is 
done through maintaining viability and proliferative capacity. The authors suggest this 
approach may be a new and effective tool for ECF treatment (145). 
2.5.9 Intestinal Transplantation 
Intestinal transplantation is an alternative to long term parenteral nutrition offering 
restoration of normal physiology and gut function.  The first small intestinal 
transplantation was undertaken in Minnesota in 1967. The first intestinal 
transplantation undertaken in the UK was performed at Addenbrooke's Hospital in 
Cambridge in 1991.  St James’s Hospital in Leeds also undertook several intestinal 
transplants in the mid 1990's.  The results of intestinal transplantation have greatly 
improved over the last 15 years.  The main area of improvement has been the first two 
years after the transplantation. This seems to be largely due to the use of better anti-
rejection drugs (146). 
68 
 
Transplantation of the intestine offers a special challenge as not only is the intestine 
highly immunogenic but it also presents a significant infective risk if acute rejection 
episodes do occur due to bacterial translocation occurring across the damaged 
mucosal barrier. This dual problem of immunogenicity and infective risk resulted in 
failure of early attempts at transplantation (147).  
Following the advent of calcineurin inhibitor based immunosuppression with 
cyclosporine, renewed interest in intestinal grafting was eventually rewarded with 
successful combined liver / intestine grafting (148, 149).  However successful 
widespread application of intestinal grafting was not really possible until the 
introduction of the more potent and easily administered agent tacrolimus (150).  
Acute rejection of the intestine is now quite uncommon and has been replaced by 
sepsis as the major post-operative complication and cause of death. Survival seems 
now to be more related to careful preoperative preparation and scrupulous post-
operative management of patients (146). 
Long term PN can be associated with fatal complications such as irreversible liver 
failure, multiple line infections and thrombosis of central veins.  These complications, 
along with the possible requirement for extensive evisceration to remove desmoid 
tumours, are the indications for intestinal transplantation in patients with SBS (151, 
152). 
It is important to consider the pros and cons of transplantation for each patient on an 
individual basis.  Patients who are doing well on PN have a very good life expectancy 
and can live with a very good quality of life.   
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Survival following intestinal transplantation is not as good, although patients are 
usually free from PN and for some this can improve their quality of life (QOL), those 
patients who are doing well on PN will not notice a great deal of improvement in 
QOL, they might swap PN for other problems associated with the transplantation 
procedure and their life expectancy is not nearly as good. Therefore, intestinal 
transplantation should only be used for patients who are not doing well on PN. 
On the other hand if put forward too late when they have multiple complications and 
are in poor condition they are less likely to survive the procedure. The timing of the 
transplantation is therefore critical and this needs to be considered along with a host 
of factors which can vary widely between patients. 
Therefore in general, intestinal transplantation is indicated in patients with intestinal 
failure who are failing on PN (146).  
The following list of indications has been approved by the American 
Gastroenterology Association (AGA): 
1. Impending or overt liver failure due to PN induced liver injury 
2. Thrombosis of two or more major central veins   
3. Frequent central venous catheter infection & sepsis  
4. Frequent severe dehydration despite IV fluid supplement in addition to PN 
5. Quality of life 
Transplantation does not put patients back to normal and does give them on-going 
problems to deal with including taking lifelong medication, being more prone to 
infections, the need for regular visits to hospital for check-ups, often a permanent 
stoma (ileostomy) is required and obtaining employment is usually much more 
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difficult after a transplantation.  Furthermore, patients on PN who have not had any 
major complications are likely to live a lot longer than if they had transplantation.  A 
general comparative survival would be 90% survival at 10 years on PN compared to 
45% 10 year survival after transplantation (146). 
There are three types of intestinal transplantation: (i) isolated small intestine 
transplantation, (ii) combined liver and small intestine transplantation, and (iii) 
multivisceral (stomach, duodenum, pancreas, intestine and liver) (153, 154).  The 
intestinal transplant registry (last updated in 2005) documents 65 centres worldwide 
performing 1292 intestinal transplants in 1210 patients with around 140 intestinal 
grafts of all kinds being performed annually (155).   
The ratio of children to adults is approximately 60:40 due to the incidence of 
intestinal failure in children following on from developmental disorders such as 
intestinal atresia,  Hirschprung’s, microvillus inclusion disease or bowel loss due to 
neonatal problems such as gastroschisis, volvulus or necrotizing enterocolitis. The 
difficulty of maintaining small children on parenteral nutrition is compounded by 
their apparent increased sensitivity to parenteral nutrition related liver disease 
resulting in 50.4% of paediatric grafts being combined small bowel liver grafts as 
compared with 19.4% in adults.   
Of the 1210 patients recorded in the registry there are 658 current survivors, the 
longest now 17 years post-transplant with a functioning graft. Analysis of the two 
centres performing adult intestinal transplantation in England and Wales showed that, 
of 36 patients assessed for transplantation, 14 had surgery (156).  Of these patients the 
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one year graft and patient survival was 50% while the 3 and 5 year survival was 36% 
and 21% respectively (156).  
Graft and patient survival has improved with increasing experience of transplant 
teams (156, 157) and increases with centre volume (>10 cases) and have reached 
approximately 50% at 5 years (155).  Patients with isolated small intestinal transplants 
tend to have a better overall graft survival than those with liver and small bowel 
transplants or multivisceral transplants in some adult series (151, 156-158) but overall 
survival in the registry is similar for all groups, perhaps reflecting the inclusion in the 
data of some exceptionally good results in combined liver/small bowel transplantation 
in children (159). 
Careful pre-operative, post-operative and long term management of intestinal 
transplant patients by an experienced team remains the mainstay of long term graft 
survival (160).   
Multiorgan donation itself does not compromise the outcome of individual organ 
transplants.  Dissection of abdominal organs for transplantation is best performed 
after cold perfusion. Abdominal organs should be removed rapidly, en bloc, and 
separated during back-table dissection in the cold, particularly if pancreas or intestine 
is included.   Perfusion itself should be carried out after single cannulation of the aorta 
with an increased pressure (146, 160). 
The surgery can be very challenging in the face of a contracted abdomen, following 
multiple previous abdominal operations. The challenge of finding adequate space to 
implant the new organ or organs has led to much surgical innovation with the use of 
72 
 
tissue expanders pre transplant and reduced size en bloc combined liver/small bowel 
grafts (161).  
The Miami group have included composite grafts of abdominal wall in the transplant 
procedure to allow abdominal closure following implantation of the grafted organs 
(162, 163).  Improvements in immunosuppression, particularly antibody induction 
protocols and the use of tacrolimus have led to an improvement in overall graft 
survival (153). Immunosuppression related Post Transplant Lymphoproliferative 
Disorders (PTLD) remains a major problem and a significant cause of death following 
intestinal transplantation but adopting a long term anti-viral regime to minimise 
cytomegalovirus and Epstein-Barr virus associated lymphoma has contributed to 
improved survival in these patients (153, 157).   
Early diagnosis and treatment of rejection is important in avoiding rejection related 
sepsis and this can be achieved by frequent endoscopies in the immediate post-
operative period through a temporary loop ileostomy (153).   
Nutrition after small bowel transplantation is aimed at early enteral feeding with the 
use of non-elementary formulae resulting in discontinuation of PN within 4-6 weeks 
of transplantation (153, 164).  
2.6 CONCLUSIONS 
With specialised medical, radiological and surgical management the prognosis of 
patients with enterocutaneous fistula has improved (165, 166).  There are significant 
psychological, physiological and financial consequences following the development 
of an ECF, and the most effective means of treatment is prevention with meticulous 
surgical technique. 
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Any definitive surgical interventions should be delayed until there is nutritional 
optimisation, eradication of sepsis, maturation of adhesions and until full bowel 
mapping has been performed.  A period of home leave prior to surgery may be both 
mentally and physically beneficial, rather than an extended period of inpatient stay. 
Techniques to slow intestinal transit or to increase functional bowel length have a 
very limited place in adult patients with short bowel syndrome.  They may only serve 
to increase the risks of already lengthy and technically challenging surgical 
procedures.  
The survival of patients on long term PN has been estimated at 88% and 78% at three 
and five years respectively (166).  The addition of intestinal transplantation to the 
armamentarium of treatment modalities has further enhanced the survival prospects of 
those with SBS.   
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CHAPTER 3 
EXPERIENCE OF ENTEROCUTANEOUS FISTULA WITH 
UNIVARIATE AND MULTIVARIATE ANALYSIS EXAMINING 
FACTORS ASSOCIATED WITH HEALING LEADING TO 
DEVELOPMENT OF A VALIDATED SCORING SYSTEM 
 
3.1 ABSTRACT 
Background 
The management of enterocutaneous fistulas is complex and challenging.  We have 
examined factors associated with fistula healing at a National Intestinal Failure (IF) 
centre in England, and have devised the first scoring system to predict spontaneous 
fistula healing prior to surgery. 
Methods 
A retrospective audit of 177 patients with mean age of 48.7 years (median 49) treated 
over seven years (January 2003 to December 2009) has been completed.  Results have 
been compared to a previously reported series from this unit.  Stata statistical 
programme was used.  ECF healing was measured on a binary scale. Logistic 
regression analysis was performed. 
To assess the relationship with ECF healing a univariate analysis was performed. 
Univariate analysis was performed on variables: age, co-morbidity, referral source, 
referral time, aetiology, fistula origin, fistula complexity, fistula output, presence of 
laparostomy on admission, albumin at first presentation, number of previous 
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operations, time of surgery and bowel defunctioning at ECF surgery.  Odds ratio was 
used to reflect the odds of healing.  Multivariate analysis of the variables upon the 
outcomes was examined.  
Results 
There were 149 patients who underwent definitive surgery (84.7%).  The overall 
healing rate following surgery in the current series was 94.6% compared with 82% in 
the previous series.  Median delay from previous surgery to current operation was one 
year compared with eight months.  The 30 day post fistula resection mortality was 0% 
compared with 3.5% in the previous series.  Twenty eight patients underwent medical 
management alone with an overall healing rate of 46.4% compared to 19.9% in the 
previous series.  
Multivariate analysis revealed co-morbidity (p = 0.02), source of referral (p = 0.01) 
and aetiology (p = 0.006) had significant associations with ECF healing.  Regression 
coefficients were used to devise a scoring system.  The predicted probability of 
healing was calculated and compared with those observed.  This revealed an 
extremely good agreement between the predicted and observed percentage of ECF 
that healed within each category at our centre.   
This scoring system and another devised to be used by an external centre were applied 
to a prospective cohort of patients (85 patients) managed at our centre (Jan 2010 to 
December 2011). The scoring systems were validated as both revealed good 
agreement between the predicted and observed percentage of ECF that healed within 
each category.  Almost all patients with a score of zero and one healed, whilst those 
with highest scores healed least. 
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Conclusion 
Surgical management of ECF is safe and improving.   The most common aetiology 
for ECF formation is surgery performed in patients with a background of 
inflammatory bowel disease.  Fistula healing is affected by aetiology, co-morbidity, 
and source of referral.  The scoring system has potential to predict ECF healing and 
can be a useful decision making tool.  Recommendation is for the scoring system to 
be used by other centres in this regard.  
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3.2 INTRODUCTION 
Enterocutaneous fistulas are abnormal communications between the gastrointestinal 
tract and the skin.  The treatment of ECF is complex and challenging. It is estimated 
that 75–85 per cent occur as a consequence of bowel injury during surgery 
(inadvertent enterotomy) or anastomotic leakage (8, 16).   Our study examines healing 
and mortality in ECF patients.  We have also evaluated the current management 
practice and outcome over a seven year period at a National Intestinal Failure (IF) 
centre in England.  Results have been compared to a previously reported series from 
this unit (4). 
3.3 AIMS  
The primary aim of this study was to examine factors associated with fistula healing.  
The secondary aim of the study was to devise a scoring system to predict spontaneous 
fistula healing prior to surgery. 
 
3.4 METHOD 
A structured approach to the management of ECF is used in our institution.  
Management of persistent ECF includes control of sepsis, specialised nutritional 
support, wound care, mobilisation and mapping of the bowel anatomy.   Judicious use 
of pharmacological agents including the use of loperamide, codeine phosphate and 
high dose proton pump inhibitors and St. Mark’s Electrolyte Mix.  This is a glucose-
electrolyte solution. 
Definitive surgery with ECF resection is deferred until there is re-epithelisation of the 
abdominal wall and attainment of an adequate nutritional and general medical status.  
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Adequate nutritional status is when the patient is in an anabolic state (evidenced by 
gaining weight, muscle mass and muscle strength).  General medical status relates to 
stability of the underlying conditions as well as correction of any electrolyte and 
metabolic derangements.  This process can take over six months.   
Vacuum assisted pumps are avoided in our unit.  The use of non-absorbable meshes is 
also avoided because ECF surgery is often performed in contaminated or grossly 
infected wounds.  When required an absorbable synthetic mesh such as Vicryl 
(Ethicon, Somerville, NJ, USA) or the biological non-cross linked Strattice™ 
(Lifecell Corporation, Branchburg, NJ, USA) are used.  A stapled and oversewn or 
hand sewn, interrupted anastomosis is performed with 4-0 Ethibond (Ethicon, USA). 
Various techniques have been described in reconstruction plastic surgery flaps for 
ECF.  Sakurabaa et al describes an enterocutaneous fistula which developed between 
the small intestine and the sacral skin. The fistula was resected, and the resulting 
defect was successfully reconstructed with a superior gluteal artery perforator flap 
(167). 
Reconstructive surgical options for ECF include primary closure, components 
separation and the use of local, regional or free flaps with or without prosthetic mesh.  
Ali et al report a case of an abdominal enterocutaneous fistula secondary to a locally 
invasive sigmoid carcinoma, which was reconstructed with a pedicled antero-lateral 
thigh perforator (ALT) flap (168). 
From January 2003 to December 2009, 235 patients were coded by medical records as 
having ECF at St. Mark’s Hospital and North West London Hospitals NHS Trust, 
UK.  Hospital notes and clinical details were obtained from medical records, the 
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intestinal failure database, and from the use of the hospital computer clinical 
information system.   
Thirty two patients were excluded as they had incorrectly been coded for ECF. These 
included entero enteric: eleven, entero vesical: four, entero vaginal: seven, perianal: 
six, or no fistula: four. 
Overall, 203 patients were managed with ECF at our hospital.  Case notes were not 
located for 26 patients and hence 177 patients (87.3%) were available for review.  
Results have been compared to a previously reported series from this unit of an 11 
year experience of 277 patients (4). 
Statistical analysis was undertaken using the Stata software programme.  There was 
one main outcome of the study, that being fistula healing, which was measured on a 
binary (yes/no) scale.  The secondary objectives of the analysis were to examine 
factors associated with fistula healing. As a result of the binary nature of the outcome, 
all analysis was performed using logistic regression. 
The separate effect of each explanatory variable upon the outcome was examined 
individually in a univariate analysis. Univariate analysis was performed on 
variables: age, co-morbidity, source of referral, time to referral, fistula aetiology, 
fistula origin, fistula complexity, fistula output, presence of laparostomy on 
admission, albumin at first presentation, number of previous operations, time of 
surgery and bowel defunctioning at fistula surgery. 
Subsequently the joint effect of the explanatory variables upon the outcomes was 
examined in a multivariate analysis.  Only factors which showed some evidence of an 
effect upon each outcome (p < 0.2) from the univariate analyses were considered for 
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the multivariate analysis.   A different p value could have been reasonably chosen, 
however this value captured all variables that may have had even a very slight effect 
on outcome.   
A backwards selection procedure was performed to retain only those variables that 
were found to significantly influence the outcome. This involved removing non-
significant variables, one at a time, until only significant variables were left. 
BMI and weight were not included in any of the analyses, as data were only available 
for a subset of the total number of patients. 
The next stage in the analysis used a multivariate analysis results to generate a scoring 
system for predicting fistula healing.  This was done using the final logistic regression 
model from the multivariate analysis.  The score attributed to each variable was based 
on the size of the regression coefficients.  Once the scoring system was set up, the 
performance of the scoring system was evaluated by comparing the predicted healing 
rate with that observed from the data. 
This internal scoring system and another devised to be used by an external centres 
were applied to a prospective cohort of patients (85 patients) managed at our centre 
(Jan 2010 to December 2011), to validate the scoring system. 
3.5 RESULTS  
3.5.1 Aetiology of ECF  
Of the 177 patients, 87 (49.1%) were male and 90 (50.9%) female.  The 177 patients 
had a median age of 49 (range 9-84) years, with mean of 48.7 years. 
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There were 65 (36.7%) patients who had no co-morbidity.  Twenty eight (15.8%) had 
minor co-morbidity and 84 (47.5%) had a major co-morbidity.  Minor co-morbidities 
category included patients with mild systemic disease (ASA 2) and major co-
morbidity included patients with severe systemic disease or worse (ASA ≥ 3). 
Forty seven (26.9%) ECF occurred at our Trust. This was a reduction from 36.8% 
from the previous study (4).   
External referrals accounted for 130 patients (73.1%).   
The time elapsed between initial fistulation and referral to St. Mark’s Hospital was a 
median of four months, with mean of 9.1 months (range 0.25 – 96 months). 
Fistula resulted from surgery in 165 (93.2%) of the 177 patients (Table 1).  Of these, 
75 (45.4%) had inflammatory bowel disease (59 Crohn’s disease and 16 ulcerative 
colitis).  One patient had previous radiotherapy.  Twenty two patients (13.3%) 
developed fistula following prior surgery for intra-abdominal malignancy. 
Diverticular disease contributed to 12 patients (7.2%) developing fistula.   Fifty five 
patients (33.3%) developed a fistula due to a range of other causes following surgery 
including trauma, self-harm injuries, gynaecological surgery, ischaemic bowel 
surgery and iatrogenic injuries. 
Of the 177 patients, 12 (6.8%) developed a fistula in the absence of prior surgery.  
None of these patients had a prior ultrasound (US) or computer tomography (CT) 
guided radiological drainage procedure which could have contributed to fistulation. 
Ten of these patients who fistulated had Crohn’s disease. One patient had advanced 
rectal sigmoid cancer invading the bladder and with metastatic spread to the groin. 
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The groin initially drained as an abscess and then an ECF was identified.  One patient 
developed spontaneous fistulation with a background of diverticular disease. 
Eighty five (48.6%) of all 177 patients who developed a fistula had inflammatory 
bowel disease.  Of these 69 (39.0%) had Crohn’s disease and 16 (9.0%) had ulcerative 
colitis.   
 
Table 3.1:  Aetiology of ECF 
 Post-operative Spontaneous Total 
Crohn’s disease 59 10 69 
Ulcerative colitis 16 0 16 
Radiotherapy 1 0 1 
Intra-abdominal 
malignancy 
(including FAP) 
22 1 23 
Diverticular disease 12 1 13 
Other* 55 0 55 
Total 165 (93.2%) 12 (6.8%) 177 
 
* Includes ECF secondary to trauma, self-harm, iatrogenic injuries, ischaemic bowel surgery, 
gynaecological surgery or no associated condition. 
FAP – Familial Adenomatous Polyposis 
3.5.2 Fistula characteristics 
The ileum was the most common anatomical site of fistulation.  The stomach was 
involved in five patients, duodenum in three, jejunum in 23, ileum 124 and colon in 
42.  No site was recorded in three patients.  Patients with oesophageal, biliary, 
pancreatic, and perianal fistulas were excluded from this study. 
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The majority of patients (149/177) had only one anatomical site of fistulation 
involved.  Twenty two patients had two sites of fistulation and three patients had three 
sites.  Data were not available for three cases. 
ECF were classified as simple or complex.  Simple ECF involved a single tract from 
skin to bowel.  Complex fistula involved multiple loops of bowel or had the presence 
of an internal abscess cavity.  Complex fistulas were identified radiologically or 
intraoperatively.   Forty one patients had a simple fistula.  The majority, 134 patients, 
had complex fistula.  Complexity was not known in two patients. 
Fistula output was classified as high if the average output at presentation was greater 
than 500 ml in a 24 hour period.  High fistula output was present in 77 patients.  The 
majority presented with a low fistula output; 99 patients.  The fistula output was not 
recorded in one instance. 
Nineteen patients had a laparostomy associated with the ECF at the time of 
presentation to St. Mark’s Hospital.  
3.5.3 Radiological / Endoscopic Investigations 
Radiological or endoscopic investigations were performed to map the bowel anatomy 
in 170 patients (Table 2).  Seven patients had investigations performed at the referring 
hospital and did not require further investigations at St. Mark’s Hospital.  More than 
one investigation was undertaken in 88 patients to adequately assess and identify the 
bowel anatomy. As the bowel was discontinuous in most situations more than one 
radiological procedure needs to be carried out to map the entire bowel prior to 
definitive surgery. In situations where there was intra-abdominal sepsis multiple 
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investigations were sometimes required to assess the progress of measures to control 
or alleviate the sepsis. 
Small bowel follow through was the most common investigation (63 patients), 
followed by CT (61 patients) and fistulography (36 patients).  Retrograde studies of 
the distal bowel using a gastrograffin or barium enema were performed in 30 patients 
to ascertain whether any distal obstruction was present.  Twenty one patients had 
magnetic resonance imaging scan (MRI) to aid characterisation of the fistula tract 
especially in relation to the abdominal wall.  US were performed in 17 patients.  
During the course of their illness two patients had a positron emission tomography 
(PET) scan to determine the presence and severity of malignancy.  Interventional 
radiologically guided drainage procedures were performed in four patients; two with 
CT and two with US.  None of these four patients went on to develop spontaneous 
fistulation.    
Thirty patients underwent lower gastrointestinal tract endoscopic procedures 
(colonoscopy; 21, flexible sigmoidoscopy; 9).  Examination under anaesthesia (EUA), 
anorectal physiology (ARP) and endo anal ultrasound (EAUS) were performed in ten 
patients prior to surgery to ascertain bowel continence. 
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Table 3.2: Radiological / Endoscopic investigations performed at St. Mark’s  
Radiological / Endoscopic Investigation Number 
Small bowel follow through 63 
CT 61 
Fistulogram 36 
Retrograde study of the distal bowel 30 
MRI 21 
US 17 
Pouchogram 2 
PET 2 
Colonoscopy 21 
Flexible sigmoidoscopy 9 
Ileoscopy 2 
Upper Gastrointestinal endoscopy 2 
EUA 8 
ARP 1 
EAUS 1 
 
3.5.4 Nutritional support 
Fifty nine patients (33.3%) were either receiving parenteral nutrition (PN) or 
commenced on PN at first presentation.  Following either definitive surgery or 
conservative management at St. Mark’s Hospital this was reduced to 21 patients 
(11.9% requiring PN at discharge or last follow up including patients requiring home 
parenteral nutrition). 
All but one patient had blood tests taken for albumin level at first presentation as part 
of their initial assessment.  Of the 176 patients, the median was 32 with a mean level 
of 31.9 (range 17-49).  Both of these were slightly lower than the normal laboratory 
range at St. Mark’s Hospital of 35-50 g/l. 
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Body mass index (BMI) was calculated and recorded at the first consultation in 47 
patients (26.6%) whilst only the weight was recorded in 53 of the remaining patients.  
The median BMI was 20.3 with a mean of 22.4 with (range 14.6 – 47.6).  The median 
weight was 60 Kg with a mean 63.3 Kg (range 20 – 118Kg). 
3.5.5 Surgical and Conservative Management   
One hundred and forty nine patients (84.2%) required definitive fistula surgery and 28 
patients (15.8%) were managed conservatively.    
The median number of surgical operations performed at the referring hospital was 3 
with a mean of 3.1 (range 0-13).  The median number of operations performed at St. 
Mark’s Hospital prior to definitive fistula surgery was 2 with a mean of 2.4 (range 0-
9).   
Conservative treatment was indicated if a patient was deemed to be not fit to undergo 
major ECF resective surgery or due to bowel anatomy.  Those patients who declined 
surgery or who were referred for nutritional management were also managed 
conservatively.  
Of the 28 patients treated conservatively seven underwent minor surgery to control 
sepsis or close a wound.   Eleven patients were not suitable for surgical intervention 
and five patients declined to have surgery. 
The median time to definitive fistula surgery at St. Mark’s Hospital after a previous 
major surgery was 12 months with a mean of 25.9 months (range 1-170).  There was 
an increased median time from that described in the previous study (4). 
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The bowel was defunctioned in 49 (32.9%) patients who underwent definitive fistula 
surgery by formation of a stoma brought out proximal to the anastomosis. This was an 
increase from 38 (22.7%) patients in the previous study (4).  
Thirty six patients (20.3%) had the presence of an abdominal wall hernia as well as 
the co-existing fistula.  At the time of definitive fistula surgery the abdominal wall 
closure and hernia repair was aided with the use of a mesh in 26 patients (17.4%).  A 
Vicryl mesh (Ethicon) was used in the majority of patients; 24.  A prolene mesh 
(Ethicon, Somerville, New Jersey, USA) and Gore-Tex Dual mesh (WL Gore and 
Associates, Flagstaff, AZ, USA) were used in the other cases. 
3.5.6 Follow up 
Patients were followed up for a median of 22.8 months (range 1-88 months).   
3.5.7 Fistula Healing  
Of the 149 patients who underwent definitive surgery, re-fistulation occurred in 21 
patients (14.1%).  Figure 1 displays the ECF healing outcomes of all patients.   
Nine patients were managed conservatively after re-fistulation and of these four 
fistulas healed with the remaining five staying unhealed.  Two patients who re-
fistulated were treated conservatively with the use of Infliximab.  Of these one 
patient’s fistula healed whilst the others still persisted.  Ten patients underwent repeat 
definitive surgery, and following resection a further eight fistula healed.  Two 
continued to discharge effluent.  Overall of the patients who underwent definitive 
fistula surgery eight fistulae did not heal.  The final fistula healing rate after definitive 
surgery was 94.6% (141 of 149) compared with 82% in the previous series (4). 
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Of the 28 patients managed initially with conservative treatment 11 ECF healed 
(39.2%).  From this group of 11 fistulas there were two patients with re-fistulation. 
One patient was managed with further conservative treatment and the other with 
addition of Infliximab. Both of these ECF healed. 
Seventeen out of the twenty eight managed conservatively did not heal (60.7%).  
Fifteen patients of this group underwent further conservative treatment with only one 
fistula healing.  Two patients underwent further conservative treatment with the 
addition of Infliximab in one case.  Of these, one patient’s fistula healed.  Overall 
following conservative management 13 fistula healed of the 28 (46.4%) in 
comparison to 19.9% in the previous study (4). 
From those managed conservatively (28 patients), 10 out of 17 (58.8%) patients with 
low fistula output  had spontaneous closure in comparison with only two out of 11 
(18.2%) with high fistula output.  The Fisher's exact test gives a borderline statistical 
significance (p = 0.05) difference in healing between the two ECF output groups. 
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Figure 3.1:  Fistula Healing 
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3.5.8 Deaths 
The 30 day post fistula resection mortality was 0% in this current series compared 
with 3.5% in the previous series (4). 
There were two late deaths. The first patient was a 71 year old lady who was 
transferred to St. Mark’s Hospital with albumin at first consultation of 17. She had 
undergone six operations at the referring hospital.  Colonic biopsies revealed 
histology with a picture consistent with ischemic colitis.  She underwent a laparotomy 
and excision of an enterocutaneous fistula 17 months following initial presentation.  
At surgery she had multiple enterocutaneous fistula with abscesses noted in her 
peritoneal cavity and also a vesico-colonic fistula.  In addition to extensive 
adhesiolysis she had fistulating disease excised along with the excision of a sigmoid 
abscess.  She had a small bowel reconstruction of her abdominal wall with Vicryl 
onlay mesh.  Her subsequent recovery was marred by problems of mobility.  She was 
transferred to her local hospital where she continued to have abnormal liver function 
tests despite no biliary obstruction.  Parenteral nutrition was considered a possibility.  
Histology from the resected specimens revealed non-specific inflammatory changes 
with no diagnostic features of Crohn’s or Behcet’s disease.  Six months following 
return to the referring hospital she developed biliary sepsis and multi organ failure. 
The second patient was a 79 year old male with a history of high grade non-
Hodgkin’s lymphoma. Radiological imaging gave impression of a complex 
enterocutaneous fistula secondary to non-Hodgkin’s small bowel lymphoma.  Due to 
significant co-morbidities including cardiac impairment with a past history of 
coronary artery bypass graft, it was decided that the patient was not suitable for 
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surgical intervention. His enterocutaneous fistula was managed conservatively.  He 
underwent eight cycles of chemotherapy followed by a period of palliative care 
passing away at 15 months into follow up. 
3.5.9 Statistical Analysis 
The univariate analysis is shown in Table 3.3.  The first and second column highlights 
each of the variables analysed with their respective sub-categories. The third column 
provides details on the number and percentage of subjects that were healed in each 
group.   Also reported are odds ratios, which reflect the odds of fistula healing in each 
category relative to a baseline category. A value of greater than one implies that 
fistula healing is more common for that category than in the baseline category, whilst 
a value less than one implies that fistula healing is less common in that category than 
in the baseline category. 
The results indicated that only comorbidity was strongly associated with the 
occurrence of ECF healing. Patients with either a minor or major co-morbidity were 
less likely to heal relative to patients with no co-morbidity. The odds of healing were 
more than five times lower (or less than 20% as large) for patients with a co-
morbidity relative to patients with no co-morbidity. 
There was evidence of a difference between patients referred from internal and 
external sources, with this result of statistical significance (p = 0.05).  Patients from 
external sources were less likely to heal, with the odds of healing only around a 
quarter of the size of the odds for patients referred from an internal source. 
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Table 3.3: Univariate Analysis 
Variable Group Healed 
Number (%) 
Odds Ratio 
(95% CI) 
P-value 
Age  40 48/51 (94%) 1  
 40 - 60 75/86 (87%) 0.43 (0.11, 1.61)  
 > 60 31/40 (78%) 0.22 (0.05, 0.86) 0.08 
     
Co-morbidity None 63/65 (97%) 1  
 Minor 24/28 (86%) 0.19 (0.03, 1.10)  
 Major 67/84 (80%) 0.13 (0.03, 0.56) 0.02 
     
Source of referral Internal  46/47 (98%) 1  
 External  108/130 
(83%) 
0.22 (0.05, 0.99) 0.05 
     
1Time to referral ≤ 4 months 48/54 (89%) 1  
 > 4 months 43/50 (86%) 0.77 (0.24, 2.46) 0.66 (*) 
 Internal 
referral 
46/47 (98%) 2.88 (0.55, 15.0)  
     
Aetiology Post-op  - IBD 62/74 (84%) 1  
 Post-op - 
Other 
78 /84 (93%) 2.52 (0.89, 7.08)  
 Other(**) 14/19 (74%) 0.54 (0.16, 1.79) 0.06 
     
2Origin of 
fistula(***) 
Gastric - 
Jejunal 
24/25 (96%) 1  
 Ileal 112/129 
(87%) 
0.27 (0.03, 2.16)  
 Colonic 15/20 (75%) 0.13 (0.01, 1.18) 0.15 
     
3Fistula 
complexity  
Simple   36/41 (88%) 1  
 Complex 116/134 
(87%) 
0.90 (0.31, 2.58) 0.84 
     
4Fistula output Low 64/77 (83%) 1  
 High 89/99 (90%) 1.81 (0.75, 4.37) 0.19 
     
Laparostomy at  No 137/158 
(87%) 
1  
presentation Yes 17/19 (89%) 1.30 (0.28, 6.06) 0.74 
     
5Albumin at  25   43/46 (93%) 1  
presentation > 25 110/130 
(85%) 
0.38 (0.11, 1.36) 0.14 
     
6Number of  2 53/62 (85%) 1  
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previous 
operations 3 +   55/65 (85%) 0.93 (0.35, 2.48) 0.89 
     
7Time of 
definitive 
 12 months 70/72 (97%) 1  
surgery > 12 months   61/65 (94%) 0.44 (0.08, 2.46) 0.35 
     
8Bowel 
defunctioned 
No 95/100 (95%) 1  
 Yes 46/49 (94%) 0.77 (0.18, 3.35) 0.72 
 
(*) P-value for comparison of ≤ 4 months and > 4 months only. 
(**) Other category contains patients who developed spontaneous fistula. 
(***)  There were too few patient numbers in the gastric and duodenal group to have their own group.  
For the purpose of analysis these two groups were combined with the jejunal group.   
1Time to referral; data not available for 26 patients. 
2Origin of fistula; data not available for 3 patients. 
3Fistula complexity; data not available for 2 patients. 
4Fistula output; data not available for 1 patient. 
5Albumin; data not available for 1 patient. 
6Number of previous operations; data not available for 50 patients. 
7Time to definitive surgery; data only available in 137 out of the 149 patients. 
8Bowel defunctioned; in 49 of the 149 patients undergoing surgery. 
There was also evidence that aetiology affected healing, although this result was not 
statistically significant (p = 0.06). Patients in the ‘post-operative other (non – 
IBD)’category were the most likely to heal.  Those with an 'other' (patients who 
developed spontaneous fistula) aetiology were least likely to heal. There was also 
slight evidence that age was associated with healing, with older patients less likely to 
heal. 
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Univariate analysis from the prior study at our unit had identified a significant 
difference in fistula healing, between an albumin of   25 and > 25 (169).  However 
using this cut off for albumin, there was no evidence of an effect from our univariate 
analyses. After adjusting for the other variables, this variable was statistically 
significant in the multivariate analysis (p = 0.05). Patients with an albumin level 
above 25 were less likely to have healed. The odds of healing for this group were only 
a quarter of the size of that for patients with lower albumin levels. The results for 
albumin were clinically not justifiable.   
The effect of albumin was re-examined by changing the cut-off from all points 
ranging from 15 to 40.  This made little difference to the results, and it was still 
significant in the opposite direction to that which you might interpret in a 
multivariable analysis.  With these findings the analysis was repeated without 
incorporating albumin.   
The results indicated that after adjusting for the other explanatory variables, age, co-
morbidity, source of referral and aetiology all had some significant association with 
fistula healing. After adjusting for these four variables, there was no longer any 
significant effect of age upon fistula healing. 
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Table 3.4: Multivariate Analysis 
Variable Group Odds Ratio (95% CI) P-value 
Co-morbidity None 1  
 Minor 0.11 (0.02, 0.72)  
 Major 0.10 (0.02, 0.49) 0.02 
    
Source of referral Internal 1  
 External  0.14 (0.03, 0.67) 0.01 
    
Aetiology Post-op  - IBD 1  
 Post-op - Other 3.78 (1.26, 11.4)  
 Other 0.35 (0.08, 1.47) 0.006 
 
The final results of the multivariate analysis model is summarised in Table 3.4.  As in 
the univariate analyses, patients with co-morbidity (minor or major) had a much 
reduced chance of healing. Those referred from external sources were also less likely 
to heal.  Those ECF with 'other’ aetiology (spontaneous fistulation primarily in the 
presence of IBD) were least likely to heal. 
The next stage in the analysis used the multivariate analysis results to generate a 
scoring system for predicting fistula healing. This was done using the final logistic 
regression model from the multivariate analysis.  Instead of expressing the size of 
effects in the form of odds ratios, the size of effects was expressed in the form of 
regression coefficients.  The score attributed to each variable was based on the size of 
the regression coefficients.   
These are listed in Table 3.5, along with the points that have been attributed to each 
factor. The order of the categories for aetiology was moved, so that all regression 
coefficients were in the same direction. 
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Table 3.5: Regression coefficients applied 
Variable Group Regression 
Coefficient 
Points 
Constant - 6.3 - 
    
Co-morbidity None 0 0 
 Minor -2.2 2 
 Major -2.3 2 
    
Source of 
referral 
Internal 0 0 
 External -2.0 2 
    
Aetiology Post-op  - Other 0 0 
 Post-op - IBD -1.3 1 
 Other -2.4 2 
The points were attributed based on each point equated to a regression coefficient of 
approximately - 1.2.  This would indicate that two points equated to a coefficient of    
-2.4.  Based on this formula the predicted regression equation can be written as 
follows:  logit (p) = log (p/ (1-p)) = 6.3 - 1.2*Number of points, where p is the 
probability of fistula healing. 
From this equation, the predicted probability (or percentage) of fistula healing could 
be calculated. A summary of these predicted patients is shown in the Table 3.6. 
Table 3.6: Predicted probability of ECF healing 
Points % chance of healing 
0 99.8% 
1 99.4% 
2 98.0% 
3 93.7% 
4 81.8% 
5 57.4% 
6 28.9% 
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Once the scoring system was set up, the performance of the system was evaluated by 
comparing the predicted healing rate with that observed from our data of the seven 
year experience involving 177 patients. 
There were small numbers of patients with low and high scores. As a result, for an 
evaluation, these groups of patients were combined into a smaller number of groups. 
Table 3.7 shows the predicted percentage of subjects who would be expected to heal 
in each group based on the earlier equation, and also the observed number and 
percentage that were actually healed in each group. 
Table 3.7:  Predicted versus Observed ECF healing – Retrospective Cohort 
(Scoring System for St. Mark’s Hospital) 
 
Points Number patients Predicted healing 
(%) 
Observed healing 
Number (%) 
0 – 1 16 99% 16 (100%) 
2 36 98% 35 (97%) 
3 32 94% 31 (97%) 
4 57 82% 59 (88%) 
5 – 6 36 53% 13 (61%) 
    
 
Table 3.7 (Scoring System for St. Mark’s Hospital) suggests an extremely good 
agreement between the observed and predicted percentage of patients that are healed 
within each category.  Within each category the percentage numbers are very similar. 
This suggests that the model performs well for this dataset. 
It should be noted, that it is not surprising that the model performed well for this 
dataset.  This is because the model has been both developed and tested on the same 
set of data.  In such an instance, this sort of result might be expected.  The key test of 
the scoring system was to apply this model on an additional data source.  
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3.5.10 Scoring System devised for use by an ‘External Hospital’ - (Scoring 
System for External Centres) 
Further revision of the multivariate analysis and scoring system was performed. 
Source of referral was removed from the multivariate analysis to make the system 
suitable for use by any external institution (Table 3.8). The statistical methods used 
were equivalent to those described previously. 
Table 3.8: Multivariate analysis with source of referral removed 
Variable Group Odds Ratio (95% CI) P-value 
Co-morbidity None 1  
 Minor 0.14 (0.02, 0.85)  
 Major 0.10 (0.02, 0.49) 0.02 
    
Aetiology Post-op  - IBD 1  
 Post-op - Other 2.54 (0.88, 7.31)  
 Other 0.36 (0.09, 1.35) 0.03 
 
The results indicate that after adjusting for the other explanatory variables, co-
morbidity (p = 0.02) and aetiology (p = 0.03) both had a significant association with 
fistula healing. 
Points were again attributed based on each point equating to a regression coefficient 
of approximately -1.0.  So this would indicate that one point equated to a coefficient 
of -1.0, and two points equated to a coefficient of -2.0 (Table 3.9).   
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Table 3.9: Regression coefficients with source of referral removed 
Variable Group Regression 
Coefficient 
Points 
Constant - 4.4 - 
    
Co-morbidity None 0 0 
 Minor -2.0 2 
 Major -2.3 2 
    
Aetiology Post-op  - Other 0 0 
 Post-op - IBD -0.9 1 
 Other -2.0 2 
 
Based on this formula the predicted regression equation can be written as follows:  
logit (p) = log (p/ (1-p)) = 4.4 - 1.0*Number of points, where p is the probability of 
fistula healing. 
From this equation, the predicted probability (or percentage) of healing was 
calculated.  A summary of these predicted percentages is shown in Table 3.10. 
Table 3.10: Predicted probability of ECF healing 
Points % chance of healing 
0 98.8% 
1 96.8% 
2 91.7% 
3 80.2% 
4 59.9% 
 
Predicted occurrences of healing were compared with those observed from the data. 
There were only nine patients with a score of four.  This was a fairly small number to 
assess their performance. As a result, for an evaluation, patients with a score of four 
were combined with those with a score of three. 
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Table 3.11 (Scoring System for External Centres) shows the predicted percentage of 
subjects that would be expected to be healed in each group based on the earlier 
equation, and also the observed number and percentage that were actually healed in 
each group. 
Table 3.11: Predicted versus Observed ECF Healing – Retrospective Cohort 
(Scoring System for External Centres) 
Points Number patients Predicted healing 
(%) 
Observed healing 
Number (%) 
0 30 99% 29 (97%) 
1 25 97% 25 (100%) 
2 64 92% 58 (91%) 
3 or 4 58 77% 42 (72%) 
 
Table 3.11 also suggests a fairly good agreement between the observed and predicted 
percentage of patients that are healed within each category.  Almost all patients with a 
score of zero and one healed, whilst the observed healing of those with the highest 
points score (three or four) was the lowest.  Generally these results suggest that the 
model performs well for this dataset. 
3.5.11 Validation of scoring systems 
As describe above, the key test of both scoring systems Tables 3.7 and 3.11, was to 
apply the models on an additional data source.  The initial intention was to obtain data 
from an external source.   
Unfortunately this was not possible due to inadequate patient numbers at external 
hospitals, limited access to patient records and reluctance by some surgeons to 
contribute patients with poor outcomes. 
101 
 
I therefore collected data prospectively from January 2010 to December 2011 (two 
year period) at St. Mark’s Hospital to validate the scoring system.  Continuous data 
were collected from the endpoint of the previous seven year experience cohort.   
Overall, 85 patients were managed with ECF over the two year period.  Of the 85 
patients, 42 (49.4%) were male and 43 (50.6%) female.  The median age was 52 years 
(range 21-80), with a mean of 52.8 years. 
Nineteen (22.4%) had no co-morbidity.  Twelve (14.1%) had minor co-morbidity - 
mild systemic disease (ASA 2).  Fifty four (63.5%) had a major co-morbidity - severe 
systemic disease or worse (ASA ≥ 3). 
Nine (10.6%) of the ECF occurred within the Trust.  External referrals accounted for 
the majority of patients: 76 patients (89.4%). 
Fistula resulted from surgery in 81 (95.3%) of the 85 patients (Table 3.12).  Of these, 
24 had inflammatory bowel disease (18 Crohn’s disease and six ulcerative colitis).  
No patient had previous radiotherapy leading to ECF formation.  Fourteen patients 
developed a fistula following prior surgery for intra-abdominal malignancy.  
Diverticular disease contributed to ten patients developing a fistula.   Thirty three 
patients developed fistulas due to a range of other causes. 
Of the 85 patients, 69 ECF healed.  Seventy five patients underwent definitive 
surgery.  There were twelve re-fistulae following surgery and from these, a further 
two ECF healed following redo definitive surgery.  The overall ECF healing rate 
following surgery was 87% (65/75 patients).   
Of the ten patients who underwent conservative management, four ECF healed (40%).  
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Table 3.12: Aetiology of ECF Jan 2010 – Dec 2011 
 Post-operative Spontaneous Total 
Crohn’s disease 18 4 22 
Ulcerative colitis 6 0 6 
Radiotherapy 0 0 0 
Intra-abdominal 
malignancy  
14 0 14 
Diverticular disease 10 0 10 
Other 33 0 33 
Total 81(95.3%) 4 (4.7 %) 85 
 
The ‘Scoring System for St. Mark’s Hospital (Table 3.7) was applied to this new 85 
two year prospective cohort of patients.  The results are displayed in Table 3.13. 
The treatment protocol during both the seven year period and two year prospective 
cohort remained essentially the same.  Table 3.12 displays the aetiology of the ECF 
patients in the two year prospective group (January 2010 – December 2011). 
The increase in the number of patients was due to  a steady increase in the number of 
referrals to both the surgical and medical teams as well as to the appointment of a  
second Consultant General and Intestinal Failure Surgeon at the beginning of January 
2010. 
Table 3.13: Predicted versus Observed ECF healing (Jan 2010 – Dec 2011). 
Prospective Validation Cohort.  (Scoring System for St. Mark’s Hospital) 
Points Number patients Predicted healing 
(%) 
(As Table 3.7) 
Observed healing 
Number (%) 
0 – 1 1 99% 1 (100%) 
2 17 98% 16 (94%) 
3 6 94% 5 (83%) 
4 43 82% 35 (81%) 
5 – 6 18 53% 12 (67%) 
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This showed a good agreement between the predicted and observed percentage of 
patients that are healed within each category with a downward trend displayed for the 
highest scores. 
The final stage was to apply the ‘Scoring System for External Centres’ (Table 3.11) to 
this two year cohort of patients.  Although these patients attended St. Mark’s Hospital, 
we only scored the patients based on co-morbidity and aetiology and excluded the 
referral type (Internal / External).  Hence this could be used and appropriately applied 
by any external institution.  The results are shown in Table 3.14. 
Table 3.14: Predicted versus Observed ECF Healing.   
Prospective Validation Cohort.  (Scoring System for External Centres) 
 
Points Number patients Predicted healing 
(%) 
(As Table 3.11) 
Observed healing 
Number (%) 
0 14 99% 13 (93%) 
1 9 97% 8 (89%) 
2 39 92% 32 (82%) 
3 or 4 23 77% 16 (70%) 
 
Table 3.14 also suggests a fairly good agreement between the predicted and observed 
percentage of patients that are healed within each category, with trends in a similar 
direction. Almost all patients with a score of zero and one healed, whilst the observed 
healing of those with the highest points score (three or four) was the lowest. Generally 
these results suggest that the model performs well. 
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3.6 DISCUSSION 
This is the first study that has led to the development of a scoring system to predict 
ECF healing.  Predictive factors for mortality could not be meaningfully analysed as 
there were no mortalities. 
Univariate and multivariate analysis has identified that fistula healing is affected by 
co-morbidity, source of referral and aetiology.   
There was extremely good agreement between the predicted and observed percentages 
of patients who healed within each category. 
The time to definitive fistula surgery at St. Mark’s Hospital after previous major 
surgery was a median of 12 months.  This was an increased median time delay from 
eight months in the previous series (4).  Delaying surgery may be one factor which 
has led to the improved overall fistula healing rate after definitive surgery; 94.6% 
compared with 82%, and 30 day post fistula resection mortality; 0% compared with 
3.5% (4). 
Delayed surgical intervention for persistent fistula is advisable allowing for the 
obliterative peritonitis to subside and allowing laparotomy and adhesioloysis to be 
performed safely.  Operability of the peritoneal contents can usually be assessed on 
palpation of the abdomen. A further  clinical indicator for the appropriate time to 
operate on ECF patients is the presence of non-oedematous prolapsing bowel in the 
fistulating segments (4, 94). 
There was evidence of a difference between patients referred from internal and 
external sources (p = 0.05).  Patients from external sources were less likely to heal.  
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This may be due to a greater number of operations being performed at external 
institutions prior to the decision to refer to specialist care.  Our results did not show a 
large difference in the median number of surgical operations prior to definitive fistula 
surgery performed at the referring hospital compared to St. Mark’s Hospital (3 versus 
2).  However there was a notable difference in the range (range 0-13 versus 0-9).     
Most of the patients presented with a complex fistula, however only 33.3% received 
parenteral nutrition.  Patients with adequate nutritional requirements were investigated 
and followed up through the outpatient setting.  Identification of a complex fistula 
was at either following radiological investigation or during surgery.  
Previous studies have described factors which may contribute to ECF healing (16, 
170, 171).  Kuvshinoff et al. studied whether there were any laboratory or other 
features that would enable prediction of spontaneous closure in patients with 
gastrointestinal cutaneous fistulas (170).  Seventy nine patients with 116 fistulas were 
reviewed.  The presence of local sepsis, systemic sepsis, remote sepsis, the number of 
fistulas, fistula output, and the number of blood transfusions were not predictive of 
spontaneous closure, whereas serum transferrin was. Serum transferrin, retinol-
binding protein, and thyroxin-binding prealbumin were predictive of mortality.  These 
laboratory investigations are not carried out routinely in hospitals United Kingdom 
and would therefore not be of practical use in a scoring system.  They were hence not 
analysed. 
Somatostatin and its analogues are sometimes used in the management of ECF to aid 
a reduction in fistula output.  They are not licensed for use in the UK, although 
octreotide can be used at the physician’s discretion.   Recent meta-analysis has shown 
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that both somatostatin and its analogues increase the likelihood of ECF closure and 
both are beneficial in reducing the time to ECF closure. Neither had an effect on 
mortality.  Results of the meta-analysis suggest somatostatin is better than its 
analogues in relation to the number of ECF closed and time to closure (171).   
Lloyd et al. found there that is no evidence to suggest that restriction of enteral intake 
and ‘bowel rest’ results in increased rates of fistula closure and it may increase the 
incidence of complications.  Enteral nutrition should be used if possible, although 
high-output small bowel fistulas usually require supplemental parenteral nutrition 
(16).  The practice at St. Mark’s Hospital is to allow enteral nutrition for all patients if 
possible, with supplemental intravenous fluids or parenteral nutrition where 
necessary.     
Harvey et al. identified albumin as a factor that might predict sepsis and mortality in  
patients referred for metabolic and nutritional therapy (172).  More recently a 
multivariate analysis  by Lu et al. showed that serum albumin levels and the level of 
fistula output can be  used as important prognostic predictors of ECF healing in 
patients having PN following surgery for gastrointestinal malignancies (173).  Neither 
of these factors was found to be predictive in our unit. With the delay to definitive 
surgery, the albumin can be corrected and with optimisation of fluid management, 
high outputs can be managed.   
Datta et al. noted that factors which influence spontaneous closure of ECF include; 
long fistulous tract, intestinal continuity, absence of distal obstruction, no sepsis, low 
fistula output (< 500ml/24hr), no malnutrition, no anastomotic leakage and absence of 
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inflammatory bowel disease (174).  Our study revealed a statistically significant (p = 
0.05) difference in spontaneous healing between the two output groups.   
Infliximab is indicated for use to treat patients with ECF in Crohn’s disease, and its 
use has also shown benefit in patients without inflammatory bowel disease (175).  
Infliximab is now an established treatment for ECF in Crohn’s disease.  Three 
Crohn’s patients from our initial cohort were treated with Infliximab with healing in 
two.  There is one small study showing benefit in ECF patients without inflammatory 
bowel disease (175).   
Some studies have reviewed data and identified factors predictive of healing and 
mortality in patients managed medically alone or in those who required definitive 
surgical intervention. (2, 169, 176-178).   
Altimore et al. developed a prognostic index to classify post-operative ECF patients 
according to risk of death (176).  Following logistic regression analysis of risk factors 
the prognostic index comprised the Acute Physiology and Chronic Health Evaluation 
(APACHE II) and serum albumin concentration.   This severity score and mortality 
estimation tool comprises physiological measurements available within intensive care 
units.  The majority of our patients were transferred directly to the ward, and therefore 
this index was not assessed in this study. 
Campos et al. was the first to perform a multivariate analysis to determine the relative 
importance of factors associated with patients with gastrointestinal fistulas (2).  One 
hundred and eighty eight patients were prospectively analysed over a ten year period.  
Unlike our data, this sample of patients included both biliary and pancreatic fistulas.  
Variables significant for spontaneous closure were; cause of the fistula, fistula output, 
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institutional origin of the patient and occurrence of complications.  Variables 
significant for death were fistula output and the presence of complications. 
Mawdsley et al. analysed predictive factors for healing in patients with ECF in a 
cohort of 277 patients (169).  In patients who were treated operatively, successful 
ECF closure related to only one factor; the complexity of the ECF.  In patients 
managed conservatively, a decreased likelihood of ECF closure was associated with 
high fistula output, comorbidity and being referred from an external institution. 
Martinez et al. reviewed patients with post-operative ECF over a ten year period 
(178).  A similar number of patients, 174, were treated as at our institution.  Although 
the most frequent site of origin of the ECF was the small bowel, there were a greater 
number of patients with jejunal ECF as opposed to ileal ECF in our study.  This may 
be because in our unit, surgery primarily involved the ileum rather than the jejunum.  
ECF closure was achieved in 84 per cent of patients who underwent an operation in 
this study. Multivariate analysis showed that high outputs, jejunal fistulas, multiple 
fistulas, and sepsis were independent adverse factors related to non-spontaneous 
closure, need for operative treatment, and death. 
A more recent study by Martinez et al. assessed factors predictive of recurrence and 
mortality after surgical repair of ECF in 71 patients over a five year period (177). 
Univariate analysis revealed non-colonic ECF origin, high output, and non-resective 
surgical options as risk factors for recurrence, with the latter two remaining 
significant after multivariate analysis.  Univariate analysis revealed several significant 
risk factors for mortality, but after multivariate analysis there were two remaining 
significant factors; serum albumin < 3 g/dl and age ≥ 55 years. 
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Our study of 177 patients had a similar demographic profile as compared to the 
previous study at St. Mark’s Hospital (4).  There was a wide range (0.25 - 96 months) 
in time elapsed after initial fistulation before referral to St. Mark’ Hospital.  By far the 
greatest aetiology for ECF formation was surgery performed in patients with a 
background of inflammatory bowel disease, and more specifically Crohn’s disease.   
Spontaneous fistulation was also most commonly present in patients with a 
background of Crohn’s disease.  
The data included a wide variety of sites and number of ECF in relation to the 
gastrointestinal tract, but the most frequent site for fistulation occurred in the ileum.  
The majority of ECF were complex in nature. 
Fistula output has been classified differently by various authors but with our 
classification of 500ml in a 24 hour period, there was a slightly greater proportion of 
patients presenting with low output fistula (56%) than high output fistula. 
A wide range of radiological investigations were used to assess the bowel anatomy, 
with small bowel follow through and CT scan being the most frequently used.  We 
believe a greater number of interventional radiological procedures and conduitograms 
were performed than were identified.  This was due to lack of accessibility to early 
records of radiological procedures on the hospital computer records programme as 
well as poor documentation in hospital notes. 
The data obtained revealed a lack of recording of BMI with only 26.6% of patients 
having this documented.  After identifying and presenting these results, there has been 
a change in the hospitals practice in an attempt to improve recording of BMI and for it 
to make a positive impact on nutritional management of patients. 
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The results for albumin were clinically not justifiable.  This can be explained in that 
following the previous study at our unit which showed a better chance of fistula 
healing with an albumin of  > 25 (169), a change in practice was undertaken at St. 
Mark's Hospital, with a decision to operate on patients with an albumin as close to 
normal as possible.   This is evident as the vast majority of patients in our data set had 
albumin levels greater than 25.  This gave a greater opportunity of failed fistula 
healing in patients to be within the albumin > 25 group than  25, and this was borne 
out in the results shown. 
There was a greater range of number of operations performed at the referring hospital 
(0-13) than were performed at St. Mark’s Hospital (0-9) prior to decision for 
definitive surgery.   
Compared to the previous study at our institution (4), this study has revealed an 
improved fistula healing rate following both definitive surgery (94.6% versus 82%)  
and an improved fistula healing rate following conservative management (46.4% 
versus 19.9%).  There was also an improved 30 day fistula resection mortality rate 
(0% versus 3.5%).   
An important factor contributing to the improved outcome may be highlighted by the   
increase in median delay time to surgery to twelve months from eight months in the 
previous study (4). This is in keeping with the literature in that delaying 
reconstructive surgery until optimal nutrition status; general fitness and re-
epithelialisation of the peritoneum have been achieved.   Re-operation should be 
avoided for at least four to six months after the last abdominal procedure where ever 
possible (4, 34, 95). 
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Other factors leading to an improved outcome may include reduction in line infections 
and relate to an improved cohesion of our dedicated multidisciplinary team with 
increasing experience, insistence that the patient is discharged home prior to surgery 
wherever possible and improved medical management of Crohn’s disease with 
immunosuppressive and biological drugs. 
In cases showing no healing, strategies include optimising patients for surgery with 
treatment of sepsis, nutrition, mapping of the bowel anatomy and planned surgery 
after a period of at least six months after the last abdominal surgery. 
There is a wide variety of ECF patients attending St. Mark’s Hospital.  This can range 
from elective outpatient clinic attendance to admission to the Intestinal Failure Unit, 
with several months of inpatient stay whilst being managed conservatively or 
requiring surgical intervention after the prolonged period of time. 
Our analysis and scoring system had an aim of informing the patient on admission 
with a probability percentage chance of their ECF healing.  This would be without 
foretelling whether these patients ECF would require medical management to aid 
closure, or would require surgical intervention in the future.    With this in mind, our 
analysis of the 177 patients combined all data of patients treated both medically alone 
and those who underwent definitive surgery.   This technique was again used on the 
prospective cohort of 85 patients.  Predictive factors for mortality were not analysed 
as a result of the low mortality rate. 
Univariate and multivariate analysis has identified that fistula healing is affected by 
co-morbidity, source of referral and aetiology.   
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There was an extremely good agreement between the predicted and observed 
percentages of patients that healed within each category (Table 3.7). 
Both of the scoring systems devised to be used at either St. Mark’s Hospital (Table 
3.7) or external institutions (Table 3.11) have been validated on our prospective 
cohort of 85 patients (Tables 3.13 & 3.14). 
Table 3.9 can be used by external centres to apply points to patient at the time of first 
presentation with an ECF.  Table 3.11 can then be used to identify predicted healing 
rates for the patient.  
Adequate data was not available regarding time to closure and hence this could not be 
analysed.  This would be useful for any future study.   
The course of Crohn's fistulae and ECF associated with UC are different. To classify 
them in one group as has been done in this study is an over simplification. Thirteen 
variables were assessed in the univariate analysis.  Aetiology was sub divided into 
three further categories, and IBD was taken to include both Crohn’s and UC.   The 
total number of patients with UC related fistula was low in this series and it was 
difficult to independently assess this.  It can also be argued that the UC related fistula 
are more related to surgical misadventure or misdiagnosis of Crohn’s disease which 
may not always be apparent immediately.  Assessing their individual impact on 
clinical outcome would be useful for any future study as well as the potential impact 
on the scoring system. 
This study is the first to design a scoring system for ECF healing.  Future work 
intended is to contact units both nationally and internationally to apply the scoring 
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system.  This will allow assessment of its effectiveness and modifications to take 
place. 
3.7 CONCLUSION 
The scoring system is intended to be applied on all patients at their first presentation 
with an ECF.  This is prior to knowing if the patient will require medical treatment 
alone or progress to requiring surgery.   
The scoring systems can provide further information to aid clinical management and 
decision making for the multidisciplinary team and predict the possible long term 
outcome for patients at external institutions. 
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CHAPTER 4 
A META-ANALYSIS OF OUTCOMES FOLLOWING USE OF 
SOMATOSTATIN AND ITS ANALOGUES FOR THE 
MANAGEMENT OF ENTEROCUTANEOUS FISUTLAS  
4.1 ABSTRACT 
Background 
Several randomised control trials (RCT) have compared somatostatin and its 
analogues versus a control group in patients with enterocutaneous fistulas.  This study 
meta-analyses the literature and establishes whether they have a beneficial effect on 
ECF closure. 
Methods 
We searched MEDLINE, EMBASE, CINAHL, Cochrane and PubMed databases 
according to PRISMA guidelines.  79 articles were screened. Nine RCT met the 
inclusion criteria. Statistical analyses were performed using Review Manager 5.1.   
Results 
Somatostatin analogues versus control 
Number of fistula closed: A significant number of ECF closed in the somatostatin 
analogue group compared to control group, p = 0.002. 
Time to closure: ECF closed significantly faster with the use of somatostatin 
analogues compared to controls, p < 0.0001. 
115 
 
Mortality: No significant difference between somatostatin analogues and controls, p = 
0.68. 
Somatostatin versus control 
Number of fistula closed: A significant number of ECF closed with somatostatin as 
compared to control, p = 0.04. 
Time to closure: ECF closed significantly faster with somatostatin than controls, p < 
0.00001. 
Mortality: No significant difference between somatostatin and controls, p = 0.63. 
Conclusion 
Somatostatin and octreotide increase the likelihood of fistula closure.  Both are 
beneficial in reducing the time to fistula closure. Neither has an effect on mortality.  
The risk ratio for somatostatin was higher than the risk ratio for analogues. This may 
suggest that somatostatin could be better than analogues in relation to the number of 
fistulas closed and time to closure. Further studies are required to corroborate these 
apparent findings. 
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4.2 INTRODUCTION 
Somatostatin was discovered in 1972 (179) and is a naturally occurring peptide 
hormone. It has an inhibitory effect on gastrointestinal secretion (180).  Somatostatin 
has been found in the pancreas, stomach, intestinal mucosa and mesenteric neurones.  
It is used in the management of upper gastrointestinal haemorrhage, secretory 
diarrhoea, dumping syndrome and peptide-secreting neuro endocrine tumours because 
of its anti-secretory action (181).  
As the plasma half-life is 1–2 minutes it must be administered by continuous 
intravenous infusion.  Somatostatin reduces the secretion of a range of gastrointestinal 
hormones, including gastrin and cholecystokinin, which in turn reduce gastric and 
pancreatic secretions. In addition, somatostatin reduces splanchnic blood flow, 
reduces the rate of gastric emptying and inhibits gallbladder contraction.  
As a result of the short half-life, a number of synthetic analogues have been 
developed, and of these octreotide is used most commonly in the treatment of 
gastrointestinal fistula (16). 
Its significantly longer half-life allows it to be given by intermittent subcutaneous 
injection (usually three times daily). Despite the similarities, the receptor binding 
properties of somatostatin and octreotide are not identical and their actions may not be 
equivalent (16). 
Octreotide is licensed for use in the UK but not for use in the management of ECF.  If 
used in treating ECF, then the responsibility lies with the treating clinical physician.  
The cost of octreotide is £16.90p for 250 mcg (£33.80p for 500 mcg – maximum daily 
dose). 
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Somatostatin costs over three times that of octreotide at £56.60p for 250 mcg.  It is 
not licensed for use in the UK for any medical condition.  If required for use at the 
physician’s discretion, it is imported from the Netherlands.   
Enterocutaneous fistulas are abnormal communications between the gastrointestinal 
tract and the skin. Although rare, they are associated with considerable morbidity and 
mortality.  Death related to ECF remains disproportionately high when compared with 
other surgical conditions.  Mortality rates for ECF have been reported to range from 6 
- 33% (1-5). 
Fistula formation can result in a number of serious or debilitating complications, 
varying from disturbance of fluid and electrolyte balance to sepsis and even death. 
The patient will almost always suffer from severe discomfort and pain.  They may 
also have psychological problems which include; anxiety over the course of their 
disease, and a poor body image due to the malodorous drainage fluid (182).  Post-
operative fistula formation often results in prolonged hospitalisation, patient 
disability, and enormous cost. 
Both somatostatin and octreotide have been described as effective treatments for ECF 
in adults, with few short-term side effects (diarrhoea, flushing and abdominal pain).  
Accelerating spontaneous ECF closure reduces the period of parenteral nutrition 
requirement as well as the morbidity inherent to long-lasting conservative treatment. 
There is also the potential benefit of reducing patient’s discomfort, shortening the 
length of hospital stay and of cutting the cost of ECF treatment.  Some authors argue 
that high cost, equivocal therapeutic effect on underlying diseases, painful injections 
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and potential for long-term side-effects make the use of somatostatin and its 
analogues controversial (5).   
Although there are data suggesting reduced time to fistula closure, there is little 
evidence of the increased probability of spontaneous closure (1). 
There have been several randomised control trials (RCT) and studies (182-193) 
comparing somatostatin and somatostatin analogues versus standard medical therapy 
or a placebo (control group) in patients with ECF.  
4.3 AIM  
The objective of this study is to undertake a meta-analysis of the published literature 
to assess the efficacy of somatostatin and somatostatin analogues in the treatment of 
ECF. 
4.4 METHODS 
All comparative studies investigating the use of somatostatin and somatostatin 
analogues in the management of ECF were identified.  Articles dated between January 
1987 and March 2011. We searched the MEDLINE, EMBASE and CINAHL 
available through the National Library of Health website, the Cochrane library and 
PubMed databases available online.  
The text words “somatostatin”, “octreotide” and “analogues” were used in 
combination with the medical subject headings “enterocutaneous” and “fistula.” 
Irrelevant articles and reviews evident from the titles and abstracts were excluded. 
Relevant articles referenced in these publications were obtained and the "related 
119 
 
article" function was used to widen the results.  No language restriction was applied 
and trials on patients of any age or sex were included (Table 4.1).   
All abstracts, comparative studies, non-randomised trials and citations were searched 
comprehensively.  A flow chart of the literature search according to PRISMA 
guidelines (194) is shown in Figure 4.1. Seventy nine articles were screened for 
relevance.  Sixty one articles were not suitable for analysis as they were non -
comparative studies, reviews, unrelated articles or articles on other pathologies.  On 
further scrutiny nine randomised controlled trials were found to have useful data for 
this meta-analysis. 
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conflict resolved prior to final analysis. A third researcher confirmed the data 
extraction.  Outcome measures were chosen based upon whether they were common 
to the included articles. 
Statistical analyses were performed using Review Manager 5.1 (RevMan; Cochrane 
Collaboration, Copenhagen) (195). 
A value of p < 0.05 was chosen as the significance level for outcome measures. For 
continuous data (time to closure of fistula), the Inverse-Variance method was used for 
the combination of standardised mean differences (SMD).  Binary data (number of 
fistula closed and mortality) were summarised as risk ratios (RR) and combined using 
the Mantel-Haenszel method.  In each case a heterogeneity test was carried out to see 
whether the fixed effects model was appropriate.  In a sensitivity analysis, 1 was 
added to each cell frequency for trials in which no event occurred, according to the 
method recommended by Deeks et al (196). Where standard deviations were not 
reported these were estimated either from ranges or P-values.  Forest plots were used 
for the graphical display. 
Table 4.1 - Inclusion Criteria 
 
 
 
 
 
 All studies comparing somatostatin and 
somatostatin analogues with placebo or standard 
medical therapy 
 Trials on patients of any age or sex 
 Trials in all languages 
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4.5 RESULTS 
Thirteen full text articles were retrieved from the electronic databases and assessed for 
eligibility. Four trials (183, 188, 191, 197) were excluded and reasons are explained in 
Table 4.2.  
Table 4.2:  Excluded Trials 
Nine randomised controlled trials comparing somatostatin and somatostatin analogues 
for use in the management of ECF were included in our study according to our 
inclusion criteria.  
Trial Reason for exclusion 
Perez et al 1994 (183) Somatostatin used in 19 patients compared 
with 50 historical cases.   
Non-randomised clinical trial. 
Sitges-Serra et al 1993 (191) Series of 27 patients treated with 
octreotide after having received parenteral 
nutrition for a mean of 25 days.   
Non-randomised clinical trial. 
Kusuhara et al 1992 (197) Reduction of the effluent volume in high-
output ileostomy patients by a 
somatostatin analogue octreotide.   
Not related to enterocutaneous fistula. 
Nubiola-Calonge et al 1987 (188) Blind evaluation crossover trial.   Patients 
randomised to 2 days of octreotide 
followed by 2 days on placebo or vice 
versa, after which all patients were treated 
with octreotide.   
Inadequate length of study arms prior to 
randomisation. 
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Characteristics of trials comparing somatostatin analogues (octreotide and lanreotide) 
versus control or placebo are given in Table 4.3.   
Table 4.3:  Characteristics of trials: Somatostatin analogues (octreotide and 
lanreotide) versus control 
Trial Year Type N 
Type 
of RCT 
CON 
Protocol 
OCT 
protocol 
(LAN if 
stated) 
Population Characteristics 
Gayral 
et al 
2009 
CON 53 
P 
 
30mg 
placebo 
i.m at 
first visit 
30mg 
lanreotide 
i.m 
(prolonged 
release) at 
first visit.   
Subsequent 
treatment 
dependent 
on response 
of at least 
50% 
reduction in 
fistula vol. 
Male 32 (60.4%), female 21 
(39.6%).  Mean age (SD) 59 
(14.4). Pancreatic 35 (66%), 
duodenum 12 (22.6%), small 
bowel 6 (11.3%).  Mean 
fistula vol. (SD) / 24hr: 333.4 
(225.0) 
LAN 54 
Male 27 (50%), female 27 
(50%).  Mean age (SD): 54.8 
(15.6). Pancreatic 36 
(66.7%), duodenum 6 
(11.1%), small bowel 12 
(22.2%). Mean fistula vol. 
(SD) / 24hr: 340.4 (200.0) 
Leondros 
et al 
2004 
CON 15 
P 
 
Standard 
medical 
therapy 
100 µg s.c 
tds 
(Until 
fistula 
closure) 
Male/female 10/5.   Mean 
age (SD) 72 (13). Enteric 14, 
pancreatic 1.  Low output 10, 
high output (>500 ml / 24hr)  
5 
OCT 17 
Male/female 9/8.  Mean age 
70 (SD 11.1). Enteric 12, 
pancreatic 5. Low output 8, 
high output 9 
SMT 19 
Male/female 12/7.  Mean age 
61.5 (SD 16.9), p < 0.05. 
Enteric 12, pancreatic 7.  
Low output 9, high output 10 
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Jamil 
et al 
2004 
CON 17 
P 
Standard 
medical 
therapy 
Sandostatin 
(octreotide) 
100 µg s.c 
tds 
(Until 
fistula 
closure) 
 
55% male, age range 14-68, 
mean 39 yrs.  45% female, 
age range 19-56, mean 34 
yrs. ECF: 52% ileum, 18% 
jejunum, 12% colon, 9% 
biliary tree / pancreas, 6% 
duodenum, 3% appendix.  
Low output ECF (< 200ml / 
24 hr.) 24.24 % in control, 
18.18% octreotide group.  
Moderate output 15.15% & 
21.21% respectively. High 
output (> 500ml/24hr) 
12.12% & 9.10% 
respectively 
 
 
 
 
 
 
OCT 16 
Hernandez
-Aranda 
et al 
1996 
CON 45 
P 
Standard 
medical 
therapy 
100 µg s.c 
tds 
(Until 
fistula 
closure) 
ale/female 27/26 at start.  
Mean age 51 +/- 17 yrs. 
Oesophagus 9, gastric 7, 
duodenal 9, intestinal 28.  
ECF < 500 ml /24 hrs. = 6, > 
500ml / 24 hrs. = 47 
OCT 40 
Male/female 28/18 at start. 
Mean age 49   +/- 22 yrs.   
Oesophagus 2, gastric 3, 
duodenal 13, intestinal 28.  
ECF < 500 ml / 24hrs = 9, > 
500 ml / 24 hrs. = 37 
Sancho 
et al 
1995 
CON 17 
P 
Standard 
medical 
therapy +  
Placebo: 
saline 
100 µg tds 
s.c for 20 
days 
Male/female 8/9.  Age 65 
yrs. (58-73). Stomach 1, 
pancreas 2, duodenum 5, 
jejunum 4, ileum 5 
OCT 14 
Male/female 11/3. Age 64 
yrs. (58-70). Pancreas 3, 
duodenum 6, jejunum 1, 
ileum 4 
Scott 
et al 
1993 
CON 8 
P 
12 days 
placebo: 
acetate 
buffered 
saline s.c 
100 µg tds 
s.c for 12 
days 
Male/female 2/6. Mean age 
66.7 (range 33-78).  
Duodenal 4, small bowel 4 
OCT 11 
Male/female 5/6.  Mean age 
57.5 yrs. (range 22-67). 2 
gastric, 2 pancreatic, 7 small 
bowel 
SMT = Somatostatin, OCT = Octreotide, LAN = Lanreotide, CON = Control 
P = Prospective, R = Retrospective 
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Characteristics of trials comparing somatostatin versus control or placebo are given in 
Table 4.4.  
Table 4.4:   Characteristics of trials: Somatostatin versus control 
Trial Yr Type N 
Type 
of RCT 
CON 
Protocol 
SMT 
Protocol 
Population 
Characteristics 
Leondros 
et al 
2004 
CON 15 
P 
Standard 
medical 
therapy 
Continuous 
intravenous 
infusion  at 
6000 
IU/day 
(Until 
fistula 
closure) 
Male/Female 10/5.Mean 
age (SD) 72(13). Enteric 
14, pancreatic 1.  Low 
output 10, high output (> 
500 ml / 24 hr.)  5 
SMT 
19 
 
 
 
Male/female 12/7. Mean 
age (SD) 61.5 (16.9), 
p<0.05. Enteric 12, 
pancreatic 7.  Low output 9, 
high output 10 
Isenmann 
et al 
1994 
CON 20 
P 
Standard 
medical 
therapy 
Continuous 
intravenous 
infusion at 
250 µg/hr. 
(Until 
fistula 
closure) 
Mean age 59.9. Pancreas 9, 
duodenum 9, bile duct 2. 
Output average: 373.3 ml / 
24 hr. 
SMT 25 
Mean age 56. Pancreas 11, 
duodenum 12, bile duct 2.  
Output average: 303.8 ml / 
24 hr. 
Torres et 
al 
1992 
CON 20 
P 
 
Standard 
medical 
therapy 
TPN for 48-
72 hrs. 
followed by 
SMT 
continuous 
iv infusion 
at 250µg/hr. 
for 20 days.  
Infusion 
stopped if 
fistula un-
productive 
for 48 hrs. 
Male/female 10/10. Mean 
age 49.5 (37-78). Fistula 
output: 202.5 ml /24 hr. 
Pancreas 3, duodenum 2, 
jejunum 4, ileum 9, 
ileocolic 2 
SMT 
 
 
20 
Male/female 16/4. Mean 
age 61.9 (36-74) p < 0.05. 
Fistula output: 369.7 ml / 
24 hr., p < 0.05.  Pancreas 
4, duodenum 3, jejunum 3, 
ileum 9, ileocolic 1 
Spiliotis et 
al 
1990 CON 30 
P 
versus 
R 
group 
 
Standard 
medical 
therapy 
 
Continuous 
intravenous 
infusion at 
250µg/hr. 
Male/female 18/12. Mean 
age 63.5 (range 22-84 yrs.). 
Gastro duodenal 10, small 
bowel 9, biliary 4, 
pancreatic 7 
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SMT 18 
 (Until 
fistula 
closure) 
Male/female 10/8. Mean 
age 59.3 (range 26-74). 
Gastro duodenal 6, small 
bowel 6, biliary 2, 
pancreatic 4 
Leondros et al (187) compared three groups in the study; somatostatin, octreotide and 
control.  Characteristics and outcomes of this study were separated into both of the 
relevant tables accordingly.  
There were 141 patients in the somatostatin analogue group and 147 in the control or 
placebo group.  When comparing somatostatin with control or placebo, there were 82 
and 85 patients in each group respectively.   
The methodological quality of included trials is explained comprehensively in Table 
4.5 (198, 199) and Table 4.6 (200). 
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Table 4.5:   Modified Quality Score for Randomised Controlled Trials 
(Jaddad et al & Chalmers et al) 
 
Quality variables 
Gayral    
et al 
Leondros 
et al 
Jamil 
et al 
Hernandez-
Aranda  
et al 
Sancho 
et al 
Scott 
et al 
Isenmann 
et al 
Torres 
et al 
Was the study 
described as 
randomized such as 
using the words 
randomly, random, and 
randomization? [0,1] 
1 1 1 1 1 1 1 1 
Was randomization 
described and 
appropriate? [-1,0,1] 
1 1 1 1 1 1 1 1 
Was the study 
described as double 
blind? [0,1] 
1 0 0 0 1 1 0 0 
Was method of 
blinding appropriate?  
[-1,0,1] 
1 0 0 0 1 1 0 1 
Was there a description 
of withdrawals and 
dropouts? [0,1] 
1 1 1 1 1 1 1 1 
Inclusion Criteria 1 1 1 1 1 1 1 1 
Exclusion Criteria 1 0 1 1 1 1 1 1 
Study Period Given 1 1  1 1 1 1 1 
Appropriate statistical 
analysis 
1 1 1 1 1 1 1 1 
Hard End Points 1 1 1 1 1 1 1 1 
Sample size calculation 1 0 0 0 1 0 0 0 
Baseline comparable 1 1 1 1 1 1 1 1 
Any missing post op 
data 
1 1 1 1 1 1 1 1 
Allocation concealment 1 0 0 0 1 1 0 0 
Analysis by intention 
to treat 
1 1 1 1 1 1 0 0 
Score 15 10 10 11 15 14 10 11 
Score Max 15.              Poor = -1-5              Fair = 6-10              Good = 11-15 
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Table 4.6:  Methodological qualities of retrospective studies included in the trial.   
Adapted from the Scottish Intercollegiate Guidelines Network and Rangel et al. 
 
Quality variables Spiliotis et al 
Inclusion Criteria 1 
Exclusion Criteria 0 
Demographics comparable 1 
Can the number of participating centres be determined 1 
Can the number of clinicians who participated be 
determined 
0 
Can the reader determine where the authors are on the 
learning curve for the reported investigative procedure 
1 
Is the technique adequately described 1 
Is there any way that they have tried to standardise the 
technique 
1 
Is the age and range given for patients 1 
Do authors address whether there is any missing data 1 
Were patients in each group treated along similar timelines 1 
Dropout rates stated 1 
Outcomes clearly defined 1 
Blind Comparators 0 
Analysis by intention to treat 1 
Score 12 
Total 15 
Less than 6 – Poor quality. 
6-10 – Fair Quality. 
11 or more – Good quality 
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The outcome variables extracted are shown in Table 4.7 and 4.8.   
Table 4.7:  Outcomes:  Somatostatin analogues (octreotide and lanreotide) versus 
control 
Study Year Type N Closure n 
Time to closure 
(days) 
Mortality rate 
(%) 
Gayral et al 2009 
Control 53 20  Median 26 0 (0) 
Lanreotide 54 
35  
(p = 0.006) 
Median 17  
(assume p= 0.06) 
0 (0) 
Leondros et al 2004 
Control 15 4    
 Median 18  
(SD 5.3) 
2 (13.3)  
p > 0.05 
Octreotide 17 11  
Median 16.5  
(SD 16.6) 
0 (0) 
Jamil et al 2004 
Control 17 14  Mean 17.7 
2 (12)  
p > 0.05 
Octreotide 16 15  
Mean 14  
(assume p = 0.06) 
3 (19) 
Hernandez-Aranda  
et al 
1996 
Control 45 30  27 14 (31%) 
Octreotide 40 30  
18  
(p = 0.002) 
10 (25%)  
p > 0.05 
Sancho et al 1995 
Control 17 6  
Mean 12  
(SD 7) 
2 (12%) 
Octreotide 14 8  
Mean 7  
(SD 3)  
p=0.16 
2 (14%) 
Scott et al 1993 
Control 8 3   
Octreotide 11 1 (p > 0.05)   
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Table 4.8:  Outcomes:  Somatostatin versus control 
Study Year Type N Closure n 
Time to closure 
(days) 
Mortality rate 
(%) 
Leondros et al 2004 
Control 15 4    
Median 18  
(SD 5.3) 
2 (13.3)  
p > 0.05 
Somatostatin 19 
16  
(p = 0.007) 
Median 10.5  
(SD 7.5) 
0 (0) 
Isenmann et al 1994 
Control 20 3 / 16  19  
Somatostatin 25 14 / 18  13  
Torres et al 1992 
Control 20 3 / 16  19 0 (0) 
Somatostatin 20 17 / 20  
13   
(assume p = 0.06) 
0 (0) 
Spiliotis et al 1990 
Control 30 20 27.4 3 (10) 
Somatostatin 18 
14  
(p > 0.05) 
18.2  
(p < 0.01) 
1 (5.5) 
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4.5.1 Somatostatin analogues versus control 
4.5.1.1 Number of fistula closed 
Six studies (182, 184, 186, 187, 189, 190) contributed to a summative outcome.  
There was no significant heterogeneity among trials (Q = 9.38, df = 5 (p = 0.09); I2 = 
47%).    The number of ECF closed was significantly greater in the somatostatin 
analogue group (n = 100/152) compared to the control group (n = 77/155) [fixed 
effects model: RR = 1.36, 95% CI (1.12, 1.63), z = 3.17, p = 0.002; figure 4.2]. 
 
Figure 4.2: Forrest Plot of Somatostatin analogues versus control -Number of 
fistula closed 
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4.5.1.2 Time to closure 
Five trials (182, 184, 186, 187, 189) reported on time to closure.  There was no 
significant heterogeneity among the trials (Q= 3.52, df = 4 (p = 0.47); I2 = 0%).    
ECF were significantly more likely to close faster with somatostatin analogues (n = 
141) compared with the control (n = 147) group [fixed effects model: SMD = - 0.51, 
95% CI (-0.75, -0.28), z = 4.27, p < 0.0001; figure 4.3].  Of these, only one study 
(184)   showed a significant difference in a faster time to closure of fistula with the 
use of octreotide (p = 0.002).   
 
Figure 4.3:  Forrest Plot of Somatostatin analogues versus control - Time to 
closure 
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4.5.1.3 Mortality 
Five studies (182, 184, 186, 187, 189) reported on mortality.  There was no significant 
heterogeneity among the trials (Q = 1.03, df = 4 (p = 0.90); I2 = 0%).    No significant 
difference was highlighted between analogues (n = 17/141) and controls (n = 21/147) 
[fixed effects model: RR = 0.89, 95% CI (0.50, 1.56), z = 0.41, p = 0.68; figure 4.4]. 
Figure 4.4: Forrest Plot of Somatostatin analogues versus control - Mortality 
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4.5.2 Somatostatin versus control 
4.5.2.1 Number of fistula closed 
Four studies (185, 187, 192, 193) contributed to a summative outcome.  There was 
significant heterogeneity among trials (Tau2 = 0.84; Q = 19.07, df = 3 (p = 0.0003); I2 
= 84%); therefore the fixed effects model was inappropriate.  There was significant 
difference with greater number of ECF closed with the use of somatostatin (n = 
61/82) as compared to control group (n = 30/85) [random effects model: RR = 2.79, 
95% CI (1.03, 7.56), z = 2.02, p = 0.04; figure 4.5].   
Figure 4.5: Forrest Plot of Somatostatin versus control - Number of fistula closed 
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4.5.2.2 Time to closure 
Four trials (185, 187, 192, 193) reported on time to closure.  There was no significant 
heterogeneity among the trials (Q = 1.06, df = 3 (p = 0.79); I2 = 0%).    There was a 
significant difference, with ECF more likely to close faster with somatostatin (n = 82) 
than with controls (n = 85) [fixed effects model: SMD = - 0.79, 95% CI (-1.11, -0.47), 
z = 4.86, p < 0.00001; figure 4.6]. 
A significant benefit for the use of somatostatin was seen in one study (192) (p < 
0.01). 
Figure 4.6: Forrest Plot of Somatostatin versus control - Time to closure 
 
 
 
 
 
 
136 
 
4.5.2.3 Mortality 
Four studies (185, 187, 192, 193) reported on mortality.  There was no significant 
heterogeneity among the trials (Q = 0.12, df = 3 (p = 0.99); I2 = 0%).    No significant 
difference was highlighted between somatostatin (n = 4/82) and controls (n = 6/85) 
[fixed effects model: RR = 0.73, 95% CI (0.21, 2.59), z = 0.48, p = 0.63; figure 4.7]. 
 
Figure 4.7: Forrest Plot of Somatostatin versus control - Mortality 
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4.5.3 Fistula Output 
Of the nine randomised controlled trials, fistula output reduction was not recorded in 
three trials (184, 185, 187),   Torres et al (201) recorded a significant reduction in 
number of days (p < 0.05 and p < 0.01 respectively) in the somatostatin group when 
compared to the control group for a 50% or 75% reduction in fistula output volume 
respectively.  
Spiliotis et al (201) records that the somatostatin group had a 50% reduction in fistula 
volume in three days, in comparison to one week in the control group.  This is 
commented to be a significant difference.  There was also a significant difference to 
time to closure (p < 0.01), but no significant difference in number of fistula closed (p 
> 0.05). 
Jamil et al (186) recorded time for fistulous secretions to cease at 7, 14, 21 and 28 
days when comparing octreotide to control group.  No significant difference was 
noted in reduction of secretions and also there was no significant difference in time to 
fistula closure (p = 0.06). 
Sancho et al (189) recorded no significant difference in fistula output at 24, 48 or 72 
hours between octreotide and control group, and also there was no significant 
difference in time to fistula closure (p = 0.16).  
Scott et al (190) recorded fistula losses during 12 days of placebo and octreotide 
injections.  They noted no advantage in reduction in fistula losses or increased rate of 
spontaneous fistula closure in the patients that received octreotide.  There was also no 
significant difference in number of fistula closed (p > 0.05).   
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Gayral et al (182) showed a significant (p = 0.005) mean reduction in fistula output at 
72 hours of 45.1% in the lanreotide group versus 8.9% in the control group.  Time to 
closure did not have a significant difference (p = 0.06), however there was a 
significant difference in the number of fistula closed (p = 0.006). 
4.6 DISCUSSION 
Somatostatin receptors (ssts) comprise a family of  five heptahelical membrane 
proteins encoded by five related genes that map to separate chromosomes (6).  The 
clinically used somatostatin analogues, octreotide and lanreotide, act primarily by 
only binding to somatostatin receptor 2 (sst2) (202), and this may contribute to a 
comparatively less effective outcome.  
Octreotide has a much longer half-life (approximately 90 minutes, compared to 1-2 
minutes for somatostatin). Since it is absorbed poorly from the gut, it is administered 
parenterally (subcutaneously, intramuscularly, or intravenously). The 
pharmacokinetic and pharmacodynamics differences between somatostatin and its 
analogues require continuous infusion with somatostatin and the parenteral route for 
analogues. 
In this meta-analysis we have evaluated the effect of somatostatin and its analogues as 
an effective treatment for fistula closure.  Somatostatin was shown to be associated 
with an increased number of fistulas closed and a reduced time to closure when 
compared with analogues.  
All trials comparing somatostatin with control, favoured somatostatin.  All but one 
trial (190) comparing somatostatin analogues with control, favoured somatostatin   
analogues.   
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There was adequate data on three outcomes; fistula closure, time to closure and 
mortality.  Data of these are shown in Table 4.7 and 4.8.  Meta-analysis was 
performed on these outcomes. 
In comparing somatostatin analogues with control there was a significant difference in 
only one study (182) for fistula closure.  Gayral et al (182) recorded a significant 
difference (p = 0.006) with the use of the long acting analogue, lanreotide in fistula 
closure versus control.  
The meta-analysis reveals a significant difference (p = 0.002) in the number of fistula 
closed in the somatostatin analogue group compared to the control group; figure 4.2. 
Scott et al (190) was the only trial where the number of fistula closed was better in the 
control group rather than the somatostatin analogue group.  This is highlighted in the 
Forest Plot figure 4.2.  This anomalous result may be explained by the reduced 
duration of use of octreotide (12 days) when compared with other studies using 
somatostain analogues. 
This was the first prospective double blind trial of octreotide therapy in postoperative 
enterocutaneous fistula, and the authors would have only been aware of the previous 
mean therapy time to fistula closure rates reported to be 4.5 days (188). 
 Most of the studies use octreotide three times per day as a subcutaneous injection 
(184, 186, 187, 189, 190) but a continuous infusion may be more effective as 
demonstrated in the study using lanreotide (half-life: 2 hours) (182, 203) where a 
significant increased rate of  fistula closure was observed.   Further research with 
continuous infusion of somatostatin analogues may be useful to evaluate this.   
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There was also one study (187) which had a significant benefit (p = 0.007) in the 
number of fistula closed with the use of somatostatin as opposed to control. The meta-
analysis reveals a significant difference with a greater number of fistulas closed with 
the use of somatostatin as compared to the control group p = 0.04; figure 4.5.   
Somatostatin analogues are often thought to be effective at a clinical level as fistula 
output will often decrease as they are introduced.  This study has not been able to 
analyse the effect on fistula output due to the variation in reporting this between the 
studies. There was wide variability in the methodology to record fistula output. 
Pooling of data was not possible and hence a summative comparison was excluded 
from the meta-analysis.   
It can be noted from the trials where fistula output was recorded that both trials using 
somatostatin (192, 193) showed significant benefit in fistula output reduction.  
However we are unable to elucidate if this has an effect on closure rates. 
The three trials using octreotide (186, 189, 190) showed no significant benefit in 
fistula output reduction as well as closure rates. In contrast the long acting analogue, 
lanreotide, had both significant benefit in fistula output reduction and number of 
fistula closed. 
Some authors have reported that enteral elemental diets may reduce fistula output as 
much as parenteral nutrition (1, 204) without the associated complications of central 
line sepsis, thrombosis or pneumothorax and hence adherence to a short bowel regime 
is the most effective way of decreasing fistula output. This is also relevant when 
considering the use of somatostatin as it is believed to induce intestinal atrophy. 
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Common adverse effects of treatment with somatostatin analogues include nausea, 
abdominal cramps, loose stools, mild steatorrhea (presumably resulting from transient 
inhibition of pancreatic exocrine secretion and malabsorption of fat) and flatulence. 
These symptoms start within hours of the first subcutaneous injection, are dose-
dependent, and usually subside spontaneously within the first few weeks of treatment 
(205).    
In particular there is the risk of developing gallstones in patients undergoing therapy 
with somatostatin analogues.  Rates approaching 50 % have been reported when used 
in treating patients with metastatic gut neuro endocrine tumours (NETs) or malignant 
islet cell tumours (206). 
Data on complications including catheter, abdominal, urinary sepsis, pneumothorax, 
pneumonia, wound or skin problem were limited.   
Torres et al (193) reported a greater complication rate within the somatostatin study 
group (68.75 %, 11/16 patients) than the control group (35 %, 7/20 patients).  This 
was a significant difference.  Isenmann et al (185) and Leondros et al (187) noted no 
significant difference in complications between the study groups.  Jamil et al (186) 
had a 50 % less complication rate in the somatostatin group when compared to the 
control group. 
There was a wide variability in population characteristics in all the studies analysed.     
Torres et al (193) had a significant difference in the mean ages between the 
comparison groups as well as fistula output prior to the commencement of the trial.  
Leondros et al (187) showed a significant difference in mean age within the 
somatostatin group as opposed to the octreotide and control groups.   
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There was wide variability in the location of fistula as well as criteria used to define 
low or high output fistula in all studies (Table 4.3 and 4.4).  All studies except one 
(190)  stated time to closure.   
In five (184, 186, 187, 189, 190) out of the six randomised control trials which 
compared octreotide to standard medical therapy a dose of 100 micrograms 
subcutaneous injection three times per day was used, for a range of durations.  In 
comparing somatostatin with control, three of the four studies (185, 187, 192) used a 
continuous somatostatin intravenous infusion dose of 250 micrograms per hour, for 
varying durations.  Reviewing ‘time to closure’ for each of these studies, the current 
literature supports the use of either octreotide 100 micrograms subcutaneous injection 
three times daily or somatostatin intravenous infusion dose of 250 micrograms per 
hour for a minimum period of two weeks. 
Sancho et al (189) was the only trial to comment on when treatment should be 
commenced in relation to the duration of an enterocutaneous fistula.  Their inclusion 
criteria included all patients with postoperative enterocutaneous fistula of less than 
eight days duration with a daily output greater than 50ml. 
Our meta-analysis is limited due to several studies having small numbers of patients 
recruited.  There is further limitation due to the wide variability in study designs; 
which has been reflected in patient characteristics and study protocol. There is also a 
lack of clear definitions relating to recording of study outcomes: fistula closure, time 
of fistula closure, fistula output reduction, complication rate and mortality.   
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There was no significant heterogeneity except for when comparing somatostatin 
versus control for number of fistulas closed.  This may relate to Spiliotis et al (192) 
having higher number of patients in the control group then any of the other studies. 
The risk ratio for somatostatin was higher than the risk ratio for somatostatin 
analogues. This may suggest that somatostatin could be better than analogues in 
relation to the number of fistulas closed and time to closure.  This finding may be 
compounded by limitations such as different treatment protocols (Table 4.3 and 4.4), 
patient selection, population characteristics and methodology used to determine the 
actual time of closure of fistula for each trial. Further studies are warranted directly 
comparing both these agents to establish whether there is a significant difference 
between them. 
4.7 CONCLUSION 
Our meta-analysis suggests that somatostatin and octreotide increase the likelihood of 
fistula closure.  Both are beneficial in reducing the time to fistula closure. Neither has 
a significant effect on mortality when compared with standard medical treatment.  
The best results were following the use of somatostatin or long acting somatostatin 
analogue, lanreotide. 
The risk ratio for somatostatin was higher than the risk ratio for analogues. This may 
suggest that somatostatin is more effective than analogues in relation to the number of 
fistulas closed and time to closure. Further studies are required comparing these two 
agents to corroborate these findings. 
Recommendation is for a large randomised control trial with adequate patient 
numbers or a multi-centre trial with well-defined criteria and agreed parameters 
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between the participating centres.  If a clear option is identified this would benefit an 
already surgically challenging group of patients associated with a high morbidity and 
mortality where it is deemed standard medical treatment has failed. 
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CHAPTER 5 
PROSPECTIVE  STUDY OF IMMUNOLOGICAL FACTORS IN 
 NON-INFLAMMATORY BOWEL DISEASE 
ENTEROCUTANEOUS FISTULAS 
5.1 ABSTRACT 
Aim 
Tumour necrosis factor alpha (TNF-α) is a cytokine elevated in inflammatory bowel 
disease enterocutaneous fistula (IBD ECF).  Dendritic cells are antigen presenting 
cells that orchestrate the immune responses and regulate the production of cytokines 
by immune cells including T cells.  No study to date has assessed the level of TNF-α 
or the presence of dendritic cells in non-IBD ECF.  The aim of this study was to 
assess the inflammatory activity, with a particular emphasis on TNF-α in non-IBD 
ECF when compared with control small bowel tissue.  
Methods 
Tissue biopsies were obtained from ECF at operation from non-IBD patients and from 
terminal ileum in normal colonoscopy control patients. After overnight culture, 
accumulation of intracellular TNF-α was measured by flow cytometry in cells treated 
with monensin to assess the on-going cytokine production.  Data were acquired using 
FACS Canto II.  Unpaired Student’s t-test was used to compare variables between 
groups and p < 0.05 was regarded as significant. 
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Results  
The on-going production of TNF-α from dendritic cells (p = 0.0007), putative 
monocyte and B cell populations (p = 0.04) and CD3+ T cells (p = 0.04) was 
significantly higher in non-IBD ECF tissue than that from control tissue.  
Conclusions 
This study reveals results which may provide evidence for the potential use of anti-
TNF-α agents in the treatment of non-IBD ECF.  Recommendations are for a pilot 
study to assess whether this can be an alternative option to benefit an already 
surgically challenging group of patients.  Positive findings would equate to a major 
medical advance with a new use for anti-TNF-α agents. 
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5.2 INTRODUCTION 
The local production of tumour necrosis factor alpha (TNF-α) is thought to have a key 
role in the initiation and propagation of Crohn’s disease.  Production of TNF-α in the 
intestinal mucosa, serum and stool is increased in patients with Crohn’s disease (207).   
There are numerous biological activities that are attributed to TNF-activation. These 
activities include induction of the pro inflammatory cytokines such as IL1, IL6 and 
enhancement of leukocyte movement or migration from the blood vessels into the 
tissues by increasing the permeability of the endothelial layer of blood vessels.   
In animal models, antibodies to TNF-α prevent or reduce inflammation (208-212) , 
suggesting that therapy with such antibodies may be useful for chronic inflammatory 
disorders (213) . 
Infliximab is a genetically constructed IgG1 murine – human chimeric monoclonal 
anti TNF antibody that inhibits a broad range of biological activities of TNF-α, 
potentially by blocking the interaction of TNF-α with its receptors, or causing lysis of 
cells that produce TNF-α (207). 
Infliximab has been approved for treating ankylosing spondylitis, Crohn's disease, 
fistulising Crohn's disease, psoriatic arthritis, psoriasis, rheumatoid arthritis, and 
Ulcerative colitis.  It has also been used in the treatment of Behçet's disease (214) and 
sciatica due to slipped discs (215). 
Infliximab was first used for closure of fistula in Crohn's disease in 1999.  In a phase 
II clinical trial with 94 patients who had draining abdominal or perianal fistula, 
Infliximab was effective in closing fistula in 56-68% of patients (207) .  
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A Phase III clinical trial (ACCENT 2) showed that infliximab was additionally 
beneficial in maintaining closure of fistula, with almost two-thirds of all patients 
treated with the three initial doses of infliximab having a fistula response after 14 
weeks, and 36% of patients maintaining closure of fistula after a year, compared with 
19% who received placebo therapy (216). 
It is likely that persistent inflammation prevents adequate healing of these fistulas and 
that TNF-α and the subsequent stimulation of the pro-inflammatory cascade promotes 
their existence.  This may be along with the inhibition of growth factors which studies 
have demonstrated a beneficial effect of many e.g. platelet-derived growth factors, 
fibroblast growth factors, and granulocyte-macrophage colony stimulating factor on 
the healing process. 
Infliximab is currently not indicated for ECF caused by conditions other than IBD.   A 
small case series of three patients has reported healing of persistent ECF not 
associated with IBD following a single infusion of infliximab (175) .  There are no 
other studies to support this series in the use of infliximab for non-IBD ECF.  The 
inflammatory activity of non-IBD ECF has not been assessed in the past and the level 
of TNF- α activity in these cases is not known. 
There is also no study of association of TNF-α with dendritic cells (DC) in non-IBD 
ECF.  DC are potent antigen presenting cells that bridge the adaptive and innate 
immune systems to induce and regulate immune responses. They present as 
‘immature’ cells specialised for antigen uptake in most tissues of the body, 
particularly at sites of interface with the external environment such as the skin and 
mucosa and ECF.  A property that distinguishes DC from other types of antigen 
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presenting cell (macrophages and B-cells) is their potency in activating naïve T cells, 
which interaction generally occurs in secondary lymphoid tissue.   
DC are predominantly thought to originate from bone marrow derived precursor cells 
which are seeded into the circulation, although local renewal of DC subsets in the 
peripheral tissues has also been reported (217).  DC precursors become tissue resident 
immature cells at anatomical sites where they are likely to encounter antigenic stimuli 
such as the skin, GI tract or respiratory tract.  At these sites, DC display efficient 
endocytic activity, allowing them to sample environmental antigens for intracellular 
processing and subsequent presentation (218).   
DC sample an Ag by capturing it via various receptors such as Toll like or dendrites.  
They internalise the antigen and then fragments are uploaded on MHC Class II.  MHC 
Class I proteins are associated with internal antigens and disordered cells whereas 
MHC Class II protein molecules are associated with external antigens. 
DC go via lymphatic’s to the draining lymph nodes and stimulate naive T cells via the 
MHC Class II as well as imprinting homing markers such as b7 (gut homing marker) 
or skin homing marker cutaneous leukocyte antigen (CLA).    
This is described as providing a postcode, and hence directing the T cells where to go 
i.e. the gut or the skin.  The T cells will then go to where the antigen was encountered.  
When the T cells arrive at the skin or gut they produce and release the cytokines such 
as TNF-α 
DC are the major educators of the immune system.  They teach immune cells what to 
do.  They are essentially like a safety device because if we can inhibit the initial step 
of TNF-α on DC, then this will prevent the next step of TNF-α from T cells occurring. 
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Once DC get to the lymph nodes and have stimulated the naïve T cells, the DC then 
die.  They are cleared by macrophages.  The DC on skin are from the blood, and have 
come from the bone marrow.  The T cells go from the lymph node via blood to the 
e.g. skin. 
The DC already on the skin simply come from the bone marrow and then blood.  DC 
do not recirculate, although T cells do.  The DC on the skin will have CLA and b7.   
Areas with greater inflammation will have more DC present. 
DC which reside in the mucosa and cutaneous epithelium are ideally situated to 
perform their sentinel duties since they are both closely associated with sites of likely 
pathogen entry into the body and are capable of detecting antigens of both foreign and 
self-origin (219).  However, naïve T-cells are comparatively rare in the peripheral 
tissues and DC are unlikely to encounter antigen specific clones suitable for 
expansion at these sites.  DC therefore migrate to the draining lymph nodes via 
lymphatic vessels and interact with the re-circulating pool of naïve T-cells before 
exerting their effect (220).  Once situated in the tissue draining lymph nodes, DC 
present antigen peptides in the context of MHC and stimulate antigen specific T-cell 
clones to proliferate and differentiate.   The newly activated T-cell clones then re-
enter the circulation and home back to the target organ along gradients of specific 
chemokine’s that emanate from the destination tissues.  After infiltrating the 
peripheral tissues, the antigen specific T-helper cells then perform a variety of 
different functions that support the activities of effector leukocytes in eliciting the 
adaptive immune response.  
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5.3 HYPOTHESIS 
Immunological factors and their interaction are in operation within non-IBD ECF.  
The level of TNF-α activity is elevated in non-IBD ECF and IBD ECF when 
compared with control small bowel. 
5.4 AIM 
The aim of this study was to assess the inflammatory activity, with a particular 
emphasis on TNF-α of non-IBD ECF when compared with IBD ECF and control 
small bowel.   
5.5 METHODS 
Immunological factors involved in the pathogenesis in non-IBD ECF were assessed 
prospectively.  Immunological factors in three groups of patients were compared; 
• Group (i)  non-IBD ECF  
• Group (ii)  IBD ECF  
• Group (iii)  normal small bowel mucosa from terminal ileum (control group) 
5.5.1 Inclusion criteria 
For Group (i) non-IBD ECF:  
 Consent to the study 
 Male or female 
 18+ years 
 Single or multiple ECF for at least three months duration as a result of non-
IBD, and not responding to standard treatments 
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 ECF confirmed to be due to non-IBD by radiography, endoscopy or 
pathological examination 
For Group (ii) IBD ECF:  
 Consent to the study 
 Male or female 
 18+ years 
 Single or multiple ECF for at least three months duration as a result of IBD 
and not responding to standard treatments  
 ECF confirmed to be due to IBD by radiography, endoscopy or pathology 
 Patients with stable IBD 
For Group (iii) normal bowel mucosa (control group):  
 Consent to the study 
 Male or female 
 18+ years 
 Healthy volunteers with normal endoscopic examination of the bowel 
 No prior history of IBD or ECF 
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5.5.2 Exclusion criteria 
For Group (i) and Group (iii):  
 Current sepsis or abscess 
 Previous treatment with infliximab, investigational agents or any medication 
which reduces the concentration of TNF- α 
 History of Crohn’s disease or Ulcerative Colitis 
 Pregnancy 
For Group (ii):  
 Current sepsis or abscess  
 Previous treatment with infliximab, investigational agents or any medication 
which reduces the concentration of TNF- α 
 Patients taking steroids for IBD within one month prior to start of the study 
 Patients with acute flare up of IBD 
 Pregnancy 
5.5.3 Design  
All eligible patients were identified at referral, seen in the outpatient clinic or ward 
and offered participation in this study.  The study was explained, discussed and 
patients encouraged to ask questions for discussion.  A patient information sheet was 
provided.   After completing Good Clinical Practice (GCP) training, informed consent 
was obtained for the study.  Patients, who declined to enter the study, were treated 
with the normal standard of clinical care provided.  
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For patients who entered the study, the number and location of the ECF were noted.  
Drawings as well as photographs were used to document the sites of disease. 
5.5.4 Sample Collection 
5.5.4.1 Tissue 
Most patients with ECF were recruited prior to undergoing surgery on the ward or in 
outpatient’s clinic.  A few patients with ECF did not undergo surgery but were 
recruited on the intestinal failure ward.  Tissue was obtained in these patients using 
tissue biopsy with local anaesthetic.  Healthy control patients were recruited prior to 
undergoing screening colonoscopy. 
5.5.4.1.1 Surgery - Laparotomy with enterocutaneous fistula resection  
At the time of operation, biopsies where taken from the tissue within the ECF tracts of 
non-IBD and IBD patients: Groups (i) and (ii).   
Patients undergoing laparotomy with enterocutaneous fistula resection were placed in 
the supine position.  Following a general anaesthetic and antibacterial skin 
preparation, surgery was commenced.  Once the ECF specimen had been resected, 
this was placed in a sterile surgical bowl.  Forceps and scalpel were used to retrieve 
the ECF tract biopsies for immunology and placed in tissue medium.  Up to ten two 
mm samples were taken. 
Biopsies of the ECF tract were taken to assess for baseline pro and anti-inflammatory 
cytokine markers including TNF-α level. 
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5.5.4.1.2 Local anaesthetic ECF tissue biopsy 
 
A few patients with non - IBD ECF not undergoing surgery were recruited from the 
intestinal failure ward.  After cleaning the abdominal wall with antibacterial skin 
preparation, local anaesthetic was applied injected into the tissue around the ECF 
tract.  Using a sterile technique, biopsy forceps were used to take tissue samples under 
direct vision from within the fistula tract.   Up to ten two mm samples were taken. 
5.5.4.1.2.3 Colonoscopy 
Healthy patients undergoing screening colonoscopy with normal mucosa 
endoscopically and histologically were used as controls.  A maximum of ten biopsies 
were taken from the terminal ileum in addition to those required for clinical 
evaluation: Group (iii).  The terminal ileum was selected as the choice of biopsy, as in 
our experience the majority of ECF occurred with small bowel ileum tissue. 
5.5.4.2 Peripheral blood sample collection 
Peripheral blood (10-20 ml) was obtained from all three groups of patients. 
5.5.5 Primary outcome measure 
Cytokine profiles in the mucosa from all three groups was assessed using multiplex 
bead analysis.  Simultaneously analysis of the following cytokines, chemokine’s and 
growth factors was performed: IL2, IL4, IL6, IL10, TNF-α, IFNγ and IL17a. 
5.5.6 Secondary outcome measures 
Flow cytometer technique was used to identify whether the homing markers CLA and 
β7 were expressed on blood T cells and DC in the three groups.  In addition, the on-
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going production of the pro-inflammatory cytokines TNF- α, IL12, IL17A and IFN  
in T cells and DC from blood and tissue in these groups was determined.   
5.5.7 Sample size justification 
The study was powered to determine a 60% increase in TNF-α expression between 
non-IBD ECF and the control group.  With a 5% significance level and 90% power, 
14 patients are required in each group.  Statistical analyses was carried out using 
Sigma Stat software (SPSS Inc., Chicago, IL, USA).  The Student T-test for non-
paired data was used.  Error bars used represent standard error of the mean (SEM).  
Values of p < 0.05 were considered significant. 
5.5.8 Safety and Monitoring 
There was potential for increased pain and discomfort from the blood tests and 
biopsies of the fistula tract.  In both cases the patient was be informed during the 
initial explanation, consent stage, and prior to the procedure, that they may feel a very 
‘small pinch or prick’ sensation as the blood test or biopsy was being performed.  
There was minimal light bleeding following either test, and this was controlled as is in 
normal standard clinical practice with the application of gentle pressure until any 
bleeding subsided.  No untoward or adverse event took place. 
There was a small risk of an infection occurring at the site of blood taking and this 
was minimised by the use of standard hospital guidelines in relation to use of alcohol 
hand gel and sterile technique as is part of normal standard clinical care. No untoward 
or adverse event took place. 
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5.6 Ethics approval 
The research has received ethics approval from the National Research Ethics Service, 
North London REC 1.  REC reference: 08/H0717/24.  Protocol number cro1043.  
Date of approval: 26th July 2010. 
5.7 Funding 
Funding was secured from the Bowel Disease Research Foundation (BDRF).  BDRF 
is the only UK charity which funds research into all bowel diseases. An independent 
charity, BDRF functions as the research arm of the Association of Coloproctology of 
Great Britain and Ireland (ACPGBI). 
5.8 ACPGBI / BDRF website   
http://www.acpgbi.org.uk/BDRF/projects_funded/2011/rahbour 
 
5.9 IMMUNOLOGY METHODS 
Patients 
Patients with non-IBD ECF and IBD ECF were recruited as described above and 
underwent a planned operation, laparotomy with resection of ECF, or had tissue 
obtained using biopsy forceps under local anaesthetic.  Control patients in the 
experiments had no history or evidence of malignancy or inflammatory bowel disease 
on colonoscopy and had been referred with symptoms of per rectal bleeding or a 
change in bowel habit, or a screening follow up. 
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5.9.1 FACS sample processing 
5.9.1.1 Tissue collection and transport 
Biopsies were obtained from the surface of the enterocutaneous fistula tract at 
operation from non-IBD ECF patients, IBD ECF patients and from the terminal ileum 
in normal screening colonoscopy control patients.  Tissues were placed in complete 
medium (appendix), placed on ice and transported immediately for processing. 
5.9.1.2 ‘Walk out’  
Samples were removed from the transport medium using sterile forceps and processed 
within a Class-I safety cabinet.  The samples were washed in complete medium to 
remove blood.  One or two of these pieces were then placed in a test tube with 0.5ml 
of complete medium and incubated overnight at 37°C with 5% CO2 for subsequent 
freezing and multiplex analysis.   
The other samples were weighed and then separated out into two tubes with 1ml of 
complete medium in each and also incubated overnight at 37°C with 5% CO2.  These 
samples were used for intra cellular staining (ICS) and then FACS analysis. 
5.9.1.3 Intra cellular staining (ICS)  
After 24 hours incubation, the two test tube samples were removed.  The first tube 
was labelled ‘Control’ and to this an additional 100μl of complete medium was added.  
To the second test tube 100μl of Monensin was added.  Both test tubes were then 
returned to the incubator for an additional 4 hours.   
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The Monensin solution had been prepared the day before.  Vials containing 10μl of 
Monensin were stored at -80 °C.  One vial was taken out of the freezer and 990μl of 
RPMI added.  This was then stored in a 4°C refrigerator, ready to be used the 
following day. 
Monensin blocks the surface of the Golgi apparatus.  During the 4 hour incubation, 
any cytokines including TNF alpha which were produced from the Golgi apparatus 
could not escape and hence could not enter into the cytoplasm of the cell.  This 
technique is useful for assessing the intracellular on-going production of cytokines. 
Following 4 hours, both tubes were removed from the incubator.  The supernatant was 
removed from each tube and placed into a 50ml test tube labelled ‘Control’ or 
‘Monensin’ respectively.  A cell strainer was used to drain all excess supernatant from 
the tissue.  The tissue was then discarded.   
The 50 ml tubes were then centrifuged at 250g for 5 minutes and the supernatant was 
discarded.  The tubes were then washed with 2ml of FACS buffer and the cells were 
re-suspended by flicking the tube to obtain as many cells as possible.  The two test 
tubes were then centrifuged at 200g for 5 minutes and the fluid was discarded.  The 
cells were again re-suspended.  FACS buffer (200 μl) was then added to each of the 
50 ml tubes.   From the ‘Control’ tube 100μl was placed each into FACS tubes 
labelled 1-Control and 3-Control.  Similarly 100μl was removed from the ‘Monensin’ 
50ml test tube and placed into FACS tubes labelled 2-Monensin and 4-Monensin.   
Surface marker antibodies (highlighted red in Table 5.1) were added as shown in the 
Table 5.1, and left for 30 minutes.  These surface marker antibodies were: Lineage 
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cocktail (CD3, CD14, CD16, CD19 and CD34), CD3 and HLA-DR.  DC were 
identified as Lin negative and HLA-DR positive as explained below. 
Table 5.1:  ICS labelling grid with antibodies and isotype controls for surface 
markers and cytokines 
Tube FIT C PE PC5 APC 
1 - Control 2 - Monensin TNF-α 
10 µl 
IL12 
5 µl 
Lineage 
Cocktail 
10 µl 
HLA-DR 
5 µl 
3 - Control 4 - Monensin TNF-α 
10 µl 
IL17A   
5 µl 
CD3 
5 µl 
Interferon-  
5 µl 
Lineage cocktail (Lin) = CD3, CD14, CD16, CD19 and CD34 
After 30 minutes the cells were centrifuged in 2ml of FACS buffer (200g, 5 minutes).   
The fluid was discarded and the cells re-suspended.   
Cells were fixed in 1% paraformaldehyde for 15 minutes using 100μl of Leucoperm 
Reagent A (Serotec, UK).  The cells were then centrifuged in 2ml of FACS buffer 
(200g, 5 minutes).   The supernatant was then discarded and the cells re-suspended.   
The cells were made permeable using 50μl Leucoperm Reagent B (Serotec, UK). This 
was added along with cytokines antibodies as in Table 5.1 (shown in black).  These 
cytokines antibodies were: TNF-α, IL12, IL17A and Interferon-    
This procedure allows access of the antibodies for labelling cytokines intracellularly.  
After 15 minutes the cells were centrifuged in 2ml of FACS buffer (200g, 5 minutes).   
The fluid was discarded and the cells resuspended in 300µl of 1% paraformaldehyde. 
The samples were stored at 4 C in the refrigerator until acquisition on the flow 
cytometer within 48 hours.  
162 
 
As described above, Monensin has the ability to trap the cytokine within the Golgi 
apparatus.  We add a fixative (Reagent A) which makes the cells rigid and hence not 
‘collapse.’ Following this, Reagent B is added which makes the cells more permeable.  
Reagent B acts as a detergent soap.  If only Reagent B was added the cell would 
simply ‘collapse.’  An analogy is to think of a cell as a balloon.  If we inflate a 
balloon and then make holes in it, it would just collapse.  Therefore we need to make 
the surface ‘rigid’ by ‘freezing’ it and then make the holes.  We then wash the cells 
after four hours.  This washes away the non-specific binding of the Ab’s to TNF-α.  
We can then subtract the non-specific binding of the Ab to the TNF-α from the 
specific binding. 
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Fig 5.2:  Intra cellular staining of cells from tissue 
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5.9.1.4 Blood collection and transport 
Five to ten millilitres of human whole blood was obtained by venepuncture from non-
IBD ECF patients, IBD ECF patients and from normal healthy control volunteers.  
Blood was placed into sodium-heparin Vacutainers (Beckton-Dickinson), placed on 
ice and transported immediately for processing in the laboratory. 
5.9.1.5 Blood processing 
The whole blood was then diluted with an equal volume (1:1 ratio) of enrichment 
agent RPMI-1640 Dutch modification.  The solution was gently mixed and slowly 
added to an equal volume of Ficoll-paque density gradient.  This was centrifuged at 
250g for 30 minutes at room temperature.  Brakes were positioned to off during this 
centrifugation to prevent the sudden stop after 30 minutes, and rather to allow a 
gradual slowing down. 
Peripheral blood mononuclear cells (PBMC’s) were collected from the interface that 
resulted.  PMBC’s include lymphocytes (T cells, B cells, natural killer cells), 
monocytes, macrophages and dendritic cells.  An equal volume (1:1 ratio) of complete 
medium was added to the PBMC’s (Figure 5.3). 
The tube was then centrifuged at 250g for 5 minutes and the supernatant was 
discarded.  The cells were re-suspended and complete medium was added to the cells 
to make a 5 ml solution. 
Trypan blue (50μl of 0.4%) was added to a single well of a 96 well plate with 150μl 
of complete medium and 50μl of the cells solution was added to this well and mixed.  
A sample from this well was placed on a slide and microscopy used to count the 
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number of dye excluding cells present, followed by calculation of the number of cells 
present in the 5ml solution of cells. 
The cells were then divided for use in cell surface marking, intra cellular staining and 
multiplex analysis as explained below.  
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5.9.1.6 Blood cell surface markers 
FACS buffer (8mls) was added to PBMC’s.  They were then centrifuged at 200g for 5 
minutes and the supernatant was discarded and the cells were re-suspended 
1600μl of FACS buffer was then added.  400μl was then placed into each of four 
FACS tubes. Surface marker antibodies and isotype controls were added as shown in 
Table 5.2, and left for 20 minutes on ice.  
After 20 minutes the cells were centrifuged in 2ml of FACS buffer (200g, 5 minutes).   
The fluid was discarded and the cells aware re-suspended in 300µl of 1% 
paraformaldehyde. The samples were stored at 4 C in the refrigerator until acquisition 
on the flow cytometer within 48 hours.  
Table 5.2:  Cell surface marking labelling grid and isotype controls 
Tube FIT C PE PC5 APC 
1 CLA   
10µl 
β7   
5 µl 
Lineage cocktail  
10 µl 
HLA-DR 
5 µl 
2 r1ɣm   
2 µl 
rɣ2A   
2 µl 
Lineage cocktail 
10 µl 
HLA-DR 
5 µl 
3 CLA   
10 µl 
β7   
5 µl 
CD3   
5 µl 
- 
4 r1ɣm   
2 µl 
rɣ2A   
2 µl 
ɣ1   
5 µl 
- 
See Appendix V for definitions of antibodies 
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5.9.1.7 Blood Intra cellular staining 
Cells (500μl) were placed into each of four FACS tubes.  500μl of complete medium 
was then added into FACS tubes labelled 1-Control and 3-Control.  Monensin (100μl) 
was added into FACS tubes labelled 2-Monensin and 4-Monensin.  Into both of these 
FACS tubes, 400μl of complete medium was added. 
All four FACS tubes were then placed in the incubator for 4 hours.   
Following 4 hours, all four FACS tubes were removed from the incubator and 2ml of 
FACS buffer added to each.   
The tubes were then centrifuged at 200g for 5 minutes and the fluid was discarded.  
The cells were re-suspended by flicking the tube to obtain as many cells as possible.    
FACS buffer (100 μl) was then added to each of the four FACS tubes.    
Surface marker antibodies (highlighted red in Table 5.3) were added as shown in the 
Table 5.3, and left for 15 minutes.  These surface marker antibodies were: Lineage 
cocktail (CD3, CD14, CD16, CD19 and CD34), CD3 and HLA-DR. 
Table 5.3:  ICS labelling grid with antibodies and isotype controls for surface 
markers and cytokines  
Tube FIT C PE PC5 APC 
1 - Control 2 - Monensin TNF-α 
10 µl 
IL12 
5 µl 
Lineage 
Cocktail 
10 µl 
HLA-DR 
5 µl 
3 - Control 4 - Monensin TNF-α 
10 µl 
IL17A   
5 µl 
CD3 
5 µl 
Interferon-  
5 µl 
Lineage cocktail (Lin) = CD3, CD14, CD16, CD19 and CD34 
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After 15 minutes the cells were again centrifuged in 2ml of FACS buffer (200g, 5 
minutes).   The fluid was discarded and the cells re-suspended by flicking the tube to 
obtain as many cells as possible.   
Cells where fixed in 1% paraformaldehyde for 15 minutes using 100μl Leucoperm 
Reagent A (Serotec, UK).  The cells were then centrifuged in 2ml of FACS buffer 
(200g, 5 minutes).   The supernatant was then discarded and the cells re-suspended by 
flicking the tube to obtain as many cells as possible.   
The cells were made permeable using 50μl Leucoperm Reagent B (Serotec, UK). This 
was added along with cytokines antibodies as in the above table (shown in black).  
These cytokines antibodies were: TNF-α, IL12, IL17A and Interferon-    
After 15 minutes the cells were centrifuged in 2ml of FACS buffer (200g, 5 minutes).   
The fluid was discarded and the cells agitated by flicking the bottom of the test tubes 
to obtain as many cells as possible. The cells were suspended in 300µl of 1% 
paraformaldehyde. The samples were stored at 4 C in the refrigerator until acquisition 
on the flow cytometer within 48 hours.  
5.9.1.8 Beads for compensation in flow cytometry 
Two drops each of positive and negative antibody compensation beads were added to 
each of four FACS tubes.  Each bead has a set number of arbitrary binding sites which 
allows counting of how much antibody binds, and how much was positive or 
negative. Flurochrome (10μl) antibodies FitC, PE, PC5 and APC were added 
respectively to FACS tubes labelled 1, 2, 3 and 4.  Each FACS tube was then vortexed 
for a few seconds to mix the solution in each tube, and then left for 20-30 minutes.  
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Following this, 500μl of PBS was added to each of the four FACS tubes.  20μl of 
counting beads were added to each of the experiment tubes. 
5.9.1.9 Calibration / performance check 
PBS (350μl) was added to a single FACS tube.  2 drops of cytometer setup and 
tracking beads (CST beads) were added.  Using the CST beads a performance check 
was then performed on the FACS machine. CST beads are used for setting up the 
machine to the same settings every day. 
The purpose of calibration is because we want to have the same settings always in 
every experiment.  We want to have the same settings mechanically and for the lasers, 
and have standardised results.  Hence any difference found will be due to biological 
findings or reagent differences. 
5.9.1.10 Flow cytometry 
Multi-colour flow cytometry allows characterisation of individual cells in suspension 
by measuring size and granularity as well as identifying the wavelength of light given 
off by a flourophore (FitC, PE, PC5 or APC) attached to cells as they pass through 
one or more focused laser beams. 
Twenty microliters of flow-count fluorospheres (Beckham Coulter, High Wycombe, 
UK) at a known concentration was added to each tube to enable absolute cell number 
assessment. Samples were acquired for approximately 5 minutes at high flow rate 
until all cells had been analysed.  Compensation samples were acquired until between 
20000 and 50000 events had occurred. All data were then saved as list-mode data 
files, stored and transferred to a computer for subsequent analysis. 
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5.9.1.11 FACS analysis 
Data were acquired using FACS Canto II (Becton Dickinson, England). Further 
compensation and analysis of list-mode data were carried out subsequently using Win 
List software (Verity Software House, Maine).  To enable compensation, a region was 
made around lymphocytes, identified by their size and granularity on the side scatter 
(SSC) versus forward scatter (FSC) plot and, in each channel, the CD3 for PC5 
marker was evaluated and compensation applied with the compensation tool on Win 
List. Live cells (again, based on size and granularity) were analysed on a plot of 
HLA-DR +ve versus lineage cocktail -ve staining which identifies DC (Figure 5.4 and 
5.5). Lineage cocktail comprised specific monoclonal antibody labels for T cells 
(CD3), monocytes (CD14), macrophages (CD16), B cells (CD19), and stem cells 
(CD34) (Table 5.1).  T cells, macrophages, B cells and others were also identified by 
gating on viable cells and then determining the proportion of cells within this region 
positive for the flourophore corresponding to the cell marker in that tube.  Both 
Region Gating and Enhanced Normalized Subtraction (ENS) were used to analyse the 
flow cytometry data (Figure 5.6).  Data was then plotted on multi graphs and saved. 
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Fig 5.4:  Identification of cells by their size and granularity – Side scatter (SSC) 
versus forward scatter (FSC):  Win List software (Verity Software House, Maine) 
was used to identify cells by their size and granularity on the side scatter (SSC) versus 
forward scatter (FSC) plot. 
 
 
 
 
 
 
 
 
 
 
Fig 5.5:  Region Gating:  Identification of DC.  Cells staining HLA-DR +ve and 
lineage cocktail -ve identify DC:   Live cells were analysed on a plot of HLA-DR 
+ve versus lineage cocktail -ve staining which identifies DC. Lineage cocktail 
comprised specific monoclonal antibody labels for T cells (CD3), monocytes (CD14), 
macrophages (CD16), B cells (CD19), and stem cells (CD34). 
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Region gating is performed by drawing a region that excludes isotype matched control 
antibody non-specific staining.  This region can then be applied to the labelling 
histogram.  All events that fall within this region exceed the isotype control staining 
intensity and can be regarded as positively labelled cells.    The proportion of positive 
cells as a percentage of the total population is then calculated.  Region gating reduces 
the impact of differences in flurochrome, antibody binding and variation between 
batches of antibody. 
In immunohistochemistry by looking at the cells we want to see if an Ab has specific 
binding to the markers on the cells.  For example we may have ten cells staining for a 
particular marker.  We then add an isotype control (which is an immunoglobulin) and 
it may for example bind to three random cells.  Therefore we can say that this has 
non-specific binding.  We can subtract:  10-3 = 7 cells.  Therefore 70% of the cells 
have specific binding.  The same principle is used for the FACS. 
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Compensation is done after the experiment and when we load the FACS tubes into the 
FACS machine.  We have different fluorochromes to the Ab’s; FitC, PE, PC5 and 
APC.  The compensation is to make sure that all the Ab’s with the fluorochromes are 
falling within the parameters of the histograms.  Hence we do this to all of the 
fluorochrome Ab’s.  This does not change any of the results, but simple makes the 
graphical results more visible.  We apply the same to all cells of all experiments in 
exactly the same way. 
 
5.9.2 Multiplex sample processing 
5.9.2.1 ‘Walk out’ 
The one to two tissue biopsy samples set aside for cytokine analysis were placed in a 
FACS tube with 0.5ml of complete medium and incubated overnight at 37°C with 5% 
CO2.   
After 24 hours the cells were centrifuged at 200g for 5 minutes.   The supernatant was 
removed into a 1.2ml cryovial, labelled and placed into a freezer at -80°C until 
multiplex analysis was undertaken on all samples examining for the presence of IL2, 
IL4, IL6, IL10, TNF-α, IL17A and Interferon-    
5.9.2.1.1 Blood Multiplex 
PBMC’s (500 µl) were placed in a FACS tube and incubated overnight at 37°C with 
5% CO2.   
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The following day the cells were centrifuged, labelled and stored, ready for multiplex 
analysis in exactly the same manner as described above for ‘Walk out’ 
5.9.2.1.2 Multiplex methods 
All cryovials containing supernatant were thawed at room temperature and then 
vortexed.  Supernatant (50µl) was placed into labelled sample tubes containing 50µl 
of vortexed human cytokine capture beads (BD Biosciences, UK). Human Detection 
Reagent (BD Biosciences, UK) (50µl) was added to each tube and incubation at room 
temperature occurred for three hours, with the tubes protected from light using silver 
foil sealed bags.  1ml of buffer wash (BD Biosciences, UK) was then added to each 
tube before five minutes of centrifugation at 200g.  The supernatant was discarded 
and 300µl of wash buffer was added to re-suspend the precipitate. 
All samples were then acquired using FACS Canto II flow cytometer (Becton 
Dickinson, England) as described above until all events had been captured.  The 
resultant data was analysed using FCAP Array software (BD Biosciences, UK). 
Multiplex experiments are all done on the same day to avoid variation.  Each sample 
contains cytokines which have moved out of the tissue and into the supernatant, and 
which has then been stored at -80°C.  Multiplex involves beads which are cells.  The 
beads already have a fixed coated amount of a particular Ab such as TNF-α.  We add 
these beads separately coated with TNF-α Ab, IL12 Ab  and as required, to a sample 
supernatant.  Each bead has 0.5 picco grams of Ab on its surface.  Therefore when 
this Ab beads are added to the sample supernatant, we can find out how much of a 
particular cytokine is present in the solution. 
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5.10 RESULTS  
5.10.1 Tissue Biopsy 
Results are available on tissue biopsy of ten patients with non-IBD ECF and ten 
control patients.  The percentage positive (% +ve) of cells which were labelled 
following ICS were recorded in Figures 5.7 and 5.9     
5.10.1.1 Comparison of TNF-  and IL12 production by non-IBD ECF and 
control cells 
Results of intracellular staining on biopsies taken from ten non-IBD ECF patients are 
shown in Table 5.4 and 5.5. Production of TNF  by DC from non-IBD ECF tissue 
was significantly higher than that by DC from control terminal ileum tissue (Figure 
5.7).  All viable cells from non-IBD ECF tissue also produced significantly higher 
level of TNF compared with all viable cells from control terminal ileum tissue 
(Figure 5.7). 
Production of IL12 by DC from non-IBD ECF tissue was significantly higher than 
that by DC from control terminal ileum tissue (Figure 5.7).   All viable cells from non-
IBD ECF tissue also produced significantly higher level of IL12 compared with all 
viable cells from control terminal ileum tissue (Figure 5.7). 
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Patient 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
TNF-α  
in DC 
% +ve 
 
84.35 
 
49.19 
 
0 
 
22.89 
 
67.04 
 
77.52 
 
61.11 
 
74.62 
 
54.14 
 
75.99 
IL12  
In DC 
% +ve 
 
74.66 
 
45.24 
 
0 
 
31.12 
 
62.83 
 
73.97 
 
76.2 
 
0 
 
56.26 
 
0 
TNF-α in 
ALL cells 
% +ve 
 
56.12 
 
72.84 
 
73.46 
 
29.15 
 
36.57 
 
55.92 
 
71.96 
 
80.24 
 
55.64 
 
55.83 
IL12 in 
ALL cells 
% +ve 
 
41.4 
 
82.08 
 
4.32 
 
67.16 
 
45.53 
 
73.83 
 
72.36 
 
3.85 
 
46.55 
 
64.9 
Table 5.4:  Non - IBD ECF Patients DC and all cells % +ve ICS:  Results of ICS 
on biopsies taken from ten non-IBD ECF patients.  TNF-α and IL12 antibodies were 
used for labelling cytokines intracellularly. 
 
 
  
Mean 
 
SD 
 
SEM 
TNF-α  in DC % +ve 56.69 26.75 8.45 
IL12  in DC % +ve 42.03 32.17 10.17 
TNF-α  in ALL cells % +ve 58.77 16.51 5.22 
IL12  in ALL cells % +ve 50.20 27.76 8.78 
Table 5.5:  Mean, SD & SEM of Table 5.4 data:  Summary of results for data in 
Table 5.4 with mean, SD and SEM applied. 
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Patient 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
TNF-α in 
DC 
% +ve 
 
0 
 
97.09 
 
0 
 
78.18 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
IL12 in 
DC 
% +ve 
 
78.06 
 
90.53 
 
0 
 
3.88 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
TNF-α in 
ALL cells 
% +ve 
0  
3.64 
 
4.05 
 
58.69 
 
94.58 
 
60.65 
 
0 
 
0 
 
74.94 
 
52.68 
IL12 in 
ALL cells 
% +ve 
 
0 
 
74.55 
 
0 
 
73.76 
 
62.34 
 
76.76 
 
0 
 
0 
 
63.22 
 
14.69 
Table 5.6:  Control Patients (Endoscopy Terminal Ileum Biopsy) DC and all cells 
% +ve ICS:  Results of ICS on biopsies taken from ten control patients.  TNF-α and 
IL12 antibodies were used for labelling cytokines intracellularly. 
 
 
 Mean SD SEM 
TNF-α  in DC % +ve 17.53 37.22 11.77 
IL12  in DC % +ve 17.25 35.48 11.22 
TNF-α  in ALL cells % +ve 34.92 36.96 11.69 
IL12  in ALL cells % +ve 36.53 35.97 11.37 
Table 5.7:  Mean, SD & SEM of Table 5.6 data:  Summary of results for data in 
Table 5.5 with mean, SD and SEM applied. 
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5.10.1.2 Comparison of Intensity Ratio (IR) of TNF- and IL12 intracellular 
production by non-IBD ECF and control patients DC and all cells  
Results of ten non-IBD patient’s intensity ratios are provided in Table 5.9 with 
summary results in Table 5.10.  Results of ten control patient’s intensity ratios are 
provided in Table 5.11 with summary results in Table 5.12.   Table 5.13 provides side 
by side comparison of the mean intensity ratios between the two groups. 
There was significant difference in the intensity ratios of IL12 in all viable cells from 
non-IBD ECF tissue compared with control terminal ileum tissue (Figure 5.8).  
TNF was increased in DC and all viable cells of non-IBD ECF tissue, though not 
significantly. 
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Patient 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
TNF-α  
in DC  
IR 
 
1.6 
 
1.45 
 
0 
 
1.36 
 
1.52 
 
1.65 
 
1.18 
 
1.1 
 
1.4 
 
1.48 
IL12  
in DC  
IR 
 
2.04 
 
2.64 
 
0 
 
0 
 
1.59 
 
2.35 
 
1.21 
 
0 
 
1.36 
 
0 
TNF-α in 
 ALL cells  
IR 
 
1.02 
 
2.78 
 
1.06 
 
1.94 
 
2.18 
 
1.85 
 
1.23 
 
1.11 
 
1.46 
 
1.22 
IL12 in  
ALL cells  
IR 
 
1.1 
 
3.89 
 
2.66 
 
1.82 
 
2.32 
 
2 
 
1.3 
 
2.82 
 
1.44 
 
1.3 
 
Table 5.9:  Non - IBD ECF Patients DC and all cells Intensity Ratio (IR) ICS:  
Results of ICS on biopsies taken from ten non-IBD ECF patients.  TNF-α and IL12 
antibodies were used for labelling cytokines intracellularly. 
 
 
 
 Mean SD SEM 
TNF-α in DC IR 1.27 0.48 0.15 
IL12 in DC IR 1.29 0 0 
TNF-α in ALL cells IR 1.59 0.58 0.18 
IL12 in ALL cells IR 2.07 0.87 0.28 
 
Table 5.10:  Mean, SD & SEM of Table 5.9 data:  Summary of results for data in 
Table 5.9 with mean, SD and SEM applied. 
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Patient 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
TNF-α  
in DC  
IR 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
IL12 in  
DC  
IR 
 
1.64 
 
1.92 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
TNF-α in  
ALL cells  
IR 
 
0 
 
2.72 
 
2.91 
 
1.6 
 
1.14 
 
1.09 
 
0 
 
0 
 
3.42 
 
1.28 
IL12 in  
ALL cells  
IR 
 
0 
 
1.38 
 
0 
 
1.32 
 
1.22 
 
1.12 
 
0 
 
0 
 
4.54 
 
0 
Table 5.11: Control Patients (Endoscopy Terminal Ileum Biopsy) DC and all 
cells ICS Intensity Ratio (IR):  Results of ICS on biopsies taken from ten control 
patients.  TNF-α and IL12 antibodies were used for labelling cytokines intracellularly. 
 
 
 
 Mean SD SEM 
TNF-α in DC IR 0 0 0 
IL12 in DC IR 0.35 0.75 0.23 
TNF-α in ALL cells IR 1.42 1.26 0.39 
IL12 in ALL cells IR 0.95 1.41 0.44 
 
Table 5.12:  Mean, SD & SEM of Table 5.11 data:  Summary of results for data in 
Table 5.11 with mean, SD and SEM applied. 
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5.10.1.3 TNF- IL17a, IFN production by non-IBD ECF T cells and all cells 
Results of ten non-IBD patient’s mean % +ve following intracellular staining are 
provided in Table 5.14 with summary results in Table 5.15.  Results of ten control 
patients are provided in Table 5.16 with summary results in Table 5.17.   Table 5.18 
provides side by side comparison of the mean % +ve’s between the two groups. 
There were significant differences in the production of TNF alpha by T cells and all 
viable cells in non-IBD ECF compared with control terminal ileum tissue (Figure 
5.9).  
There was no significant differences in the production of IL17a by T cells in non-IBD 
ECF compared with control terminal ileum tissue.  However the on-going production 
of IL17a in all viable cells from non-IBD ECF was significantly higher compared 
with all viable cells from control terminal ileum tissue (Figure 5.9). 
Also on-going production of IFN  was significantly different in non-IBD ECF T cells 
compared with control terminal ileum tissue.   However there was no significant 
difference in IFN in all viable cells from non-IBD ECF compared with all viable 
cells from control terminal ileum tissue (Figure 5.9). 
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Patient 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
TNF-α in 
T cells 
% +ve 
 
49.09 
 
9.48 
 
0 
 
73.08 
 
35.62 
 
24.6 
 
29.37 
 
54.38 
 
52.25 
 
55.37 
IL17a in 
T cells 
% +ve 
 
74.56 
 
54.38 
 
0 
 
70.96 
 
74.69 
 
69.47 
 
47.23 
 
63.98 
 
52.77 
 
46.31 
IFN  in 
T cells 
% +ve 
 
70.38 
 
58.47 
 
48.24 
 
68.5 
 
2.01 
 
0 
 
46.34 
 
63.3 
 
64.34 
 
0 
TNF-α in 
All cells 
% +ve 
 
56.12 
 
65.46 
 
6.77 
 
31.99 
 
49.26 
 
30.73 
 
16.32 
 
16.63 
 
58.05 
 
51.01 
IL17a in 
All cells 
% +ve 
 
10.57 
 
73.16 
 
29.17 
 
63.4 
 
79.86 
 
58.78 
 
38.67 
 
50.21 
 
68.87 
 
49.27 
IFN  in 
All cells 
% +ve 
 
51.27 
 
59.63 
 
47.11 
 
54.24 
 
0.1 
 
0 
 
41.16 
 
27.74 
 
57.26 
 
0 
Table 5.14:  Non - IBD ECF Patients T cells and all cells % + ve ICS:  Results of 
ICS on biopsies taken from ten non-IBD ECF patients.  TNF-α, IL17a and IFNγ 
antibodies were used for labelling cytokines intracellularly. 
 
 
 Mean SD SEM 
TNF-α in T cells % +ve 38.32 22.71 7.18 
IL17a in T cells % +ve 55.44 22.31 7.05 
IFN  in T cells % +ve 42.16 29.66 9.37 
TNF-α in All cells % +ve 36.57 20.47 6.47 
IL17a in All cells % +ve 47.18 21.37 6.76 
IFN  in All cells % +ve 31.08 25.01 7.91 
 
Table 5.15:  Mean, SD & SEM of Table 5.14 data:  Summary of results for data in 
Table 5.14 with mean, SD and SEM applied. 
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Patient 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
TNF-α in  
T cells  
% +ve 
 
0 
 
0 
 
24.51 
 
2 
 
0 
 
20.7 
 
71.22 
 
0 
 
37.74 
 
36.08 
IL17a in  
T cells  
% +ve 
 
0 
 
0 
 
38.69 
 
74.13 
 
0 
 
6.61 
 
96.99 
 
0 
 
71.29 
 
68.03 
IFN  in  
T cells  
% +ve 
 
0 
 
52.7 
 
34.4 
 
21.91 
 
0 
 
0.16 
 
0 
 
45.5 
 
0.05 
 
0.43 
TNF-α in  
All cells  
% +ve 
 
0 
 
0 
 
4.05 
 
71.32 
 
0 
 
45.9 
 
0 
 
0 
 
49.89 
 
18.8 
IL17a in  
All cells  
% +ve 
 
0 
 
0 
 
0 
 
59.94 
 
0 
 
39.36 
 
0 
 
0 
 
35.76 
 
55.08 
IFN  in  
All cells  
% +ve 
 
0 
 
7.24 
 
54.09 
 
33.52 
 
0 
 
0.16 
 
53.16 
 
0 
 
19.7 
 
28.96 
Table 5.16:  Control Patients (Endoscopy Terminal Ileum Biopsy) T cells and all 
cells % +ve ICS:  Results of ICS on biopsies taken from ten control patients.  TNF-α, 
IL17a and IFNγ antibodies were used for labelling cytokines intracellularly. 
 
 
 Mean SD SEM 
TNF-α in T cells % +ve 19.22 23.89 7.55 
IL17a in T cells % +ve 35.57 38.73 12.25 
IFN  in T cells % +ve 15.52 21.35 6.75 
TNF-α in All cells % +ve 18.99 26.76 8.46 
IL17a in All cells % +ve 19.01 25.47 8.05 
IFN  in All cells % +ve 19.68 21.81 6.89 
 
Table 5.17:  Mean, SD & SEM of Table 5.16 data:  Summary of results for data in 
Table 5.16 with mean, SD and SEM applied. 
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5.10.1.4  Comparison of Intensity Ratio (IR) of TNF- IL17a and IFNγ  
intracellular production by non-IBD ECF and control patients T cells and all 
cells  
Results of ten non-IBD patient’s intensity ratios are provided in Table 5.19 with 
summary results in Table 5.20.  Results of ten control patient’s intensity ratios are 
provided in Table 5.21 with summary results in Table 5.22.   Table 5.23 provides side 
by side comparison of the mean intensity ratios between the two groups. 
 
The mean intensity ratio for cytokine TNF-  was greater though not significantly 
non-IBD ECF T cells and all viable cells in comparison to control tissue (Figure 
5.10).   
IL17a was significantly increased in T cells of non-IBD ECF though not all viable 
cells (Figure 5.10).   
In contrast IFNγ was significantly increased in non-IBD ECF all viable cells but not 
in T cells alone (Figure 5.10). 
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Patient 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
TNF-α in  
T cells  
IR 
 
1.55 
 
1.43 
 
0 
 
2.1 
 
1.35 
 
2.02 
 
6.13 
 
2.45 
 
1.22 
 
1.24 
IL17a in  
T cells  
IR 
 
1.2 
 
1.46 
 
0 
 
1.91 
 
1.86 
 
1.48 
 
4.41 
 
2.48 
 
1.2 
 
1.37 
IFN  in  
T cells  
IR 
 
1.79 
 
1.84 
 
1.66 
 
4.1 
 
0.88 
 
0 
 
3.23 
 
4.33 
 
1.64 
 
0 
TNF-α in  
ALL cells  
IR 
 
2.19 
 
2.79 
 
1.35 
 
2.04 
 
1.42 
 
2.16 
 
4.91 
 
1.12 
 
1.32 
 
1.24 
IL17a in  
All cells  
IR 
 
1.09 
 
3.7 
 
1.58 
 
2.38 
 
2.04 
 
1.66 
 
3.37 
 
1.24 
 
1.32 
 
1.35 
IFN  in  
All cells  
IR 
 
3.16 
 
4.67 
 
1.74 
 
1.96 
 
0 
 
0 
 
2.29 
 
1.43 
 
2.08 
 
0 
Table 5.19:  Non - IBD ECF Patients T cells and all cells Intensity Ratio (IR) ICS:  
Results of ICS on biopsies taken from ten non-IBD ECF patients.  TNF-α, IL17a and 
IFNγ antibodies were used for labelling cytokines intracellularly. 
 
 
 Mean SD SEM 
TNF-α in T cells IR 1.70 1.61 0.50 
IL17a in T cells IR 1.48 1.13 0.35 
IFN  in T cells IR 1.51 1.52 0.48 
TNF-α in ALL cells IR 1.94 1.14 0.36 
IL17a in All cells IR 1.84 0.91 0.28 
IFN  in All cells IR 1.73 1.49 0.47 
Table 5.20:  Mean, SD & SEM of Table 5.19 data:  Summary of results for data in 
Table 5.19 with mean, SD and SEM applied. 
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Patient 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
TNF-α in  
T cells  
IR 
 
0 
 
0 
 
2.77 
 
0 
 
0 
 
3.68 
 
1.08 
 
0 
 
1.08 
 
1.08 
IL17a in  
T cells  
IR 
 
0 
 
0 
 
1.3 
 
1.23 
 
0 
 
0 
 
1.08 
 
0 
 
1.08 
 
1.08 
IFN  in  
T cells  
IR 
 
0 
 
1.03 
 
1.62 
 
1.17 
 
0 
 
0 
 
0 
 
1.62 
 
0 
 
4.22 
TNF-α in  
ALL cells  
IR 
 
0 
 
0 
 
2.91 
 
1.49 
 
0 
 
1.18 
 
0 
 
0 
 
1.93 
 
1.43 
IL17a in  
All cells  
IR 
 
0 
 
0 
 
0 
 
1.44 
 
0 
 
1.16 
 
0 
 
0 
 
4.43 
 
3.41 
IFN  in  
All cells  
IR 
 
0 
 
1.25 
 
1.45 
 
1.43 
 
0 
 
0 
 
1.26 
 
0 
 
0.99 
 
1.25 
Table 5.21:  Control Patients (Endoscopy Terminal Ileum Biopsy) T cells and all 
cells ICS Intensity Ratio (IR):  Results of ICS on biopsies taken from ten control 
patients.  TNF-α, IL17a and IFNγ antibodies were used for labelling cytokines 
intracellularly. 
 
 Mean SD SEM 
TNF-α in T cells IR 0.97 1.30 0.41 
IL17a in T cells IR 0.57 0.61 0.19 
IFN  in T cells IR 0.97 1.34 0.42 
TNF-α in ALL cells IR 0.89 1.04 0.33 
IL17a in All cells IR 1.04 1.63 0.51 
IFN  in All cells IR 0.76 0.67 0.21 
Table 5.22:  Mean, SD & SEM of Table 5.21 data:  Summary of results for data in 
Table 5.21 with mean, SD and SEM applied. 
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5.10.2 Blood 
5.10.2.1 CLA and β7 homing markers on DC and all cells from blood of non-IBD 
ECF versus control patients 
Results of CLA and β7 homing markers on DC and all cells from blood of ten non-
IBD ECF patients are provided in Table 5.24 with summary results in Table 5.25.  
Results of ten control patients are provided in Table 5.26 with summary results in 
Table 5.27.   Table 5.28 provides side by side comparison of the mean intensity ratios 
between the two groups. 
There was a greater percentage of DC, though non-significant (p = 0.196), which had 
the presence of CLA surface marker in non - IBD ECF patient’s blood, then from 
control patient’s blood.   There was no significance difference for  surface marker 
between the two groups (p = 0.425) (Figure 5.11). 
CLA surface marker was significantly present on all viable cells from non - IBD ECF 
patient’s blood (p = 0.036).  We were unable to detect CLA surface marker on any of 
the ten control patient’s blood (Figure 5.11). 
The experiments have shown there to be a significance difference (p = 0.002) with 
greater percentage of cells having the β7 surface marker on all cells from the control 
group in comparison to the non-IBD ECF group.  This would suggest that control 
blood had a greater percentage of gut homing markers in comparison to non-IBD ECF 
blood, or we could say that there is a lack of gut homing cells in non-IBD ECF tissue 
(Figure 5.11). 
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Patient 1 2 3 4 5 6 7 8 9 10 
CLA  
on DC  
% +ve 
 
56.00 
 
37.54 
 
1.47 
 
31.67 
 
17.20 
 
0 
 
45.51 
 
0 
 
0 
 
93.12 
CLA  
on DC   
IR 
 
9.17 
 
2.71 
 
8.69 
 
6.85 
 
2.01 
 
0 
 
2.87 
 
0 
 
0 
 
6.09 
b7  
on DC  
% +ve 
 
88.32 
 
0 
 
88.45 
 
58.92 
 
33.62 
 
31.78 
 
16.06 
 
46.68 
 
18.77 
 
84.34 
b7  
on DC  
IR 
 
12.47 
 
0 
 
5.55 
 
6.00 
 
2.18 
 
3.41 
 
6.80 
 
3.52 
 
9.71 
 
15.67 
CLA on 
ALL cells  
% +ve 
 
1.15 
 
0 
 
0.59 
 
0.58 
 
23.27 
 
0 
 
0 
 
0 
 
9.13 
 
12.91 
CLA  on 
ALL cells 
IR 
 
1.26 
 
0 
 
12.76 
 
4.67 
 
1.49 
 
0 
 
0 
 
0 
 
4.20 
 
3.29 
b7 on  
ALL cells  
% +ve 
 
11.72 
 
0 
 
44.52 
 
18.74 
 
36.93 
 
52.06 
 
10.12 
 
64.22 
 
31.63 
 
25.66 
b7  on  
ALL cells 
IR 
 
1.09 
 
0 
 
3.72 
 
1.60 
 
1.87 
 
4.36 
 
9.75 
 
2.08 
 
5.38 
 
8.43 
Table 5.24:  Non - IBD ECF Patients DC and all cells % +ve Surface Markers:  
Results assessing the presence of CLA and β7 homing markers from blood of ten non-
IBD ECF patients. 
Table 5.25:  Mean, SD & SEM of Table 5.24 data:  Summary of results for data in 
Table 5.24 with mean, SD and SEM applied. 
 Mean SD SEM 
CLA on DC % +ve 28.25 30.92 9.77 
CLA on DC  IR 3.83 3.58 1.13 
b7 on DC % +ve 46.69 32.20 10.18 
b7 on DC IR 6.53 4.83 1.52 
CLA on ALL cells  % +ve 4.76 7.93 2.50 
CLA  on ALL cells IR 2.76 3.94 1.24 
b7 on ALL cells  % +ve 29.56 20.25 6.40 
b7  on ALL cells IR 3.82 3.21 1.01 
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Patient 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
CLA 
on DC 
% +ve 
 
68.36 
 
18.09 
 
0 
 
0 
 
0 
 
0 
 
76.32 
 
0 
 
0 
 
0 
CLA 
on DC 
IR 
 
2.33 
 
4.87 
 
0 
 
0 
 
0 
 
0 
 
1.45 
 
0 
 
0 
 
0 
b7 
on DC 
% +ve 
 
96.97 
 
59.35 
 
39.84 
 
47.36 
 
61.22 
 
51.29 
 
66.59 
 
70.94 
 
0 
 
0 
b7  
on DC  
IR 
 
31.81 
 
22.87 
 
6.43 
 
9.76 
 
24.87 
 
10.36 
 
19.81 
 
34.91 
 
0 
 
0 
CLA on 
ALL cells   
% +ve 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
CLA  on 
ALL cells  
IR 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
b7 on  
ALL cells   
% +ve 
 
52 
 
2.87 
 
55.92 
 
69.33 
 
60.82 
 
61 
 
63.07 
 
52.77 
 
21.82 
 
59.91 
b7  on  
ALL cells  
IR 
 
6.91 
 
10.10 
 
1.83 
 
4.81 
 
6.81 
 
4.1 
 
7.72 
 
3.89 
 
11.55 
 
7.3 
Table 5.26: Control Patients DC and all cells % +ve Surface Markers:  Assessing 
the presence of CLA and β7 homing markers from blood of ten control patients. 
 Mean SD SEM 
CLA on DC % +ve 16.27 30.13 9.53 
CLA on DC  IR 0.86 1.62 0.51 
b7 on DC % +ve 49.35 30.25 9.56 
b7 on DC IR 16.08 12.57 3.97 
CLA on ALL cells  % +ve 0 0 0 
CLA  on ALL cells IR 0 0 0 
b7 on ALL cells  % +ve 53.95 13.40 4.23 
b7  on ALL cells IR 6.50 2.94 0.93 
Table 5.27:  Mean, SD & SEM of Table 5.26 data:  Summary of results for data in 
Table 5.26 with mean, SD and SEM applied. 
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5.10.2.2 CLA and β7 homing markers on T cells and all cells from blood of non-
IBD ECF versus control patients 
Results of CLA and β7 homing markers on DC and all cells from blood of ten non-
IBD ECF patients are provided in Table 5.29 with summary results in Table 5.30.  
Results of ten control patients are provided in Table 5.31 with summary results in 
Table 5.32.   Table 5.33 provides side by side comparison of the mean intensity ratios 
between the two groups. 
There was a greater percentage of T cells and all cells, though non-significant (p = 
0.085) and (p = 0.089) respectively, which had the presence of CLA surface marker in 
non - IBD ECF patient’s blood, then from control patient’s blood (Figure 5.12). 
The experiments have shown there to be a greater percentage of cells having the β7 
surface marker on T cells (p = 0.012) and all cells (p = 0.310) from the control group 
blood in comparison to the non-IBD ECF group blood.  This would suggest that non-
IBD ECF blood has less gut homing markers then normal control patient’s blood or 
we could say that there is a lack of gut homing cells in non-IBD ECF blood (Figure 
5.12). 
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Patient 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
CD3  
% +ve 
 
78.88 
 
30.49 
 
50.02 
 
53.13 
 
56.29 
 
60.84 
 
38.03 
 
50.89 
 
54.98 
 
0 
CD3  
IR 
 
54.48 
 
5.65 
 
3.73 
 
21.28 
 
3.74 
 
4.98 
 
48.58 
 
39.47 
 
56.92 
 
0 
CLA on  
T cells  
% +ve 
 
26.79 
 
2.38 
 
0 
 
9.72 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
CLA on  
T cells   
IR 
 
1.66 
 
1.33 
 
0 
 
0.99 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
b7 on  
T cells  
% +ve 
 
47.13 
 
0 
 
49.38 
 
44.17 
 
36.13 
 
51.54 
 
38.85 
 
15.79 
 
44.1 
 
43.02 
b7 on  
T cells  
IR 
 
10.65 
 
0 
 
3.86 
 
4.83 
 
3.65 
 
4.92 
 
8.16 
 
9.4 
 
6.29 
 
7.95 
CLA on 
ALL cells  
% +ve 
 
15.68 
 
0 
 
0 
 
5.22 
 
1.22 
 
0 
 
0 
 
0 
 
0 
 
0 
CLA  on 
ALL cells 
IR 
 
1.18 
 
0 
 
0 
 
0.39 
 
1.73 
 
0 
 
0 
 
0 
 
0 
 
0 
b7 on  
ALL cells  
% +ve 
 
14.83 
 
0 
 
38.43 
 
45.87 
 
30.85 
 
43.07 
 
0 
 
53.85 
 
45.66 
 
34.09 
b7  on  
ALL cells 
IR 
 
1.17 
 
0 
 
3.41 
 
1.52 
 
2.78 
 
4.32 
 
0 
 
1.43 
 
4.1 
 
5.17 
Table 5.29:  Non - IBD ECF Patients T cells and all cells % +ve Surface 
Markers:  Results assessing the presence of CLA and β7 homing markers on T cells 
and all cells from blood of ten non-IBD ECF patients.  
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 Mean SD SEM 
CD3 % +ve 47.35 21.03 6.65 
CD3 IR 23.88 23.47 7.42 
CLA on T cells % +ve 3.88 8.60 2.72 
CLA on T cells  IR 0.39 0.66 0.20 
b7 on T cells % +ve 37.01 16.42 5.19 
b7 on T cells IR 5.97 3.16 1.00 
CLA on ALL cells  % +ve 2.21 5.00 1.58 
CLA  on ALL cells IR 0.33 0.61 0.19 
b7 on ALL cells  % +ve 30.66 19.29 6.10 
b7  on ALL cells IR 2.39 1.83 0.57 
Table 5.30:  Mean, SD & SEM of Table 5.29 data:  Summary of results for data in 
Table 5.29 with mean, SD and SEM applied. 
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Patients 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
CD3  
% +ve 
 
69.42 
 
65.02 
 
45.6 
 
63.99 
 
78.57 
 
84.66 
 
79.08 
 
70.33 
 
69.68 
 
76.46 
CD3  
IR 
 
27.41 
 
23.41 
 
19.54 
 
23.12 
 
58.37 
 
33.12 
 
30.02 
 
122.97 
 
166.73 
 
247.09 
CLA on  
T cells  
% +ve 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
CLA on  
T cells   
IR 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
b7 on  
T cells  
% +ve 
 
39.64 
 
42.94 
 
38.59 
 
75.43 
 
50.87 
 
42.65 
 
67.05 
 
63.83 
 
49.04 
 
62.00 
b7 on  
T cells  
IR 
 
8.53 
 
12.75 
 
6.36 
 
8.81 
 
11.45 
 
9.90 
 
12.22 
 
11.02 
 
8.18 
 
11.74 
CLA on 
ALL cells  
% +ve 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
CLA  on 
ALL cells 
IR 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
b7 on  
ALL cells  
% +ve 
 
42.66 
 
41.16 
 
14.78 
 
50.1 
 
36.92 
 
0 
 
56.71 
 
35.25 
 
31.45 
 
38.06 
b7  on  
ALL cells 
IR 
 
7.06 
 
10.03 
 
8.66 
 
7.44 
 
10.8 
 
0 
 
11.56 
 
10.66 
 
8.39 
 
11.37 
Table 5.31:  Control Patients T cells and all cells % +ve Surface Markers:  
Results assessing the presence of CLA and β7 homing markers on T cells and all cells 
from blood of ten control patients.  
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 Mean SD SEM 
CD3 % +ve 70.28 10.89 3.44 
CD3 IR 75.17 78.22 24.73 
CLA on T cells % +ve 0 0 0 
CLA on T cells  IR 0 0 0 
b7 on T cells % +ve 53.20 12.96 4.10 
b7 on T cells IR 10.09 2.07 0.65 
CLA on ALL cells  % +ve 0 0 0 
CLA  on ALL cells IR 0 0 0 
b7 on ALL cells  % +ve 34.70 16.51 5.22 
b7  on ALL cells IR 8.59 3.42 1.08 
Table 5.32:  Mean, SD & SEM of Table 5.31 data:  Summary of results for data in 
Table 5.31 with mean, SD and SEM applied. 
 
 
 Non- IBD ECF Patients 
(Mean of all patients) 
Control  Patients 
(Mean of all patients) 
CD3 % +ve 47.35 70.28 
CLA on T cells % +ve 3.88 0 
b7 on T cells % +ve 37.01 53.20 
CLA on ALL cells  % +ve 2.21 0 
b7 on ALL cells  % +ve 30.66 34.70 
Table 5.33:  Comparison of Non - IBD ECF Patients and Control T cells and all 
cells % +ve Surface Markers Means of all patients:  Side by side results of CLA 
and β7 homing markers from blood of non-IBD ECF versus control patients. 
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5.10.2.3 TNF- and IL12 production by non-IBD ECF blood cells 
Results of ten non-IBD patient’s blood mean % +ve following intracellular staining 
are provided in Table 5.34 with summary results in Table 5.35.  Results of ten control 
patients are provided in Table 5.36 with summary results in Table 5.37.   Table 5.38 
provides side by side comparison of the mean % +ve’s between the two groups. 
Production of TNF  by DC from non-IBD ECF blood cells was significantly higher 
(p = 0.0008) than that by DC from control blood patients.  All viable cells from non-
IBD ECF blood patients also produced significantly higher level of TNF compared 
with all viable cells from control blood patients (p = 0.001) (Figure 5.13). 
Production of IL12 by DC from non-IBD ECF blood patients was significantly (p = 
0.025) higher than that by DC from control blood patients.  All viable cells from non-
IBD ECF blood also produced higher level, though non-significant, of IL12 (p = 
0.088) compared with all viable cells from control blood patients (Figure 5.13). 
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Patient 
 
1 
 
2 
 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
TNF-α  
on DC  
% +ve 
 
16.28 
 
5.75 
 
68.33 
 
30.12 
 
64.87 
 
66.24 
 
73.65 
 
0 
 
51.57 
 
76.3 
TNF-α  
on  
IR 
 
1.19 
 
4.92 
 
1.12 
 
2.41 
 
1.5 
 
3 
 
1.09 
 
0 
 
2.90 
 
1.98 
IL12  
on DC  
% +ve 
 
0 
 
13.84 
 
73.46 
 
29.10 
 
67.86 
 
74.62 
 
0 
 
0 
 
48.23 
 
46.64 
IL12  
on DC  
IR 
 
0 
 
2.85 
 
1.18 
 
1.34 
 
1.28 
 
1.99 
 
0 
 
0 
 
1.53 
 
1.71 
TNF-α  
on ALL cells 
% +ve 
 
0 
 
52.94 
 
0 
 
17.64 
 
51.45 
 
60.59 
 
6.31 
 
0.69 
 
62.62 
 
58.37 
TNF-α  
on ALL cells 
IR 
 
0 
 
1.39 
 
0 
 
0.46 
 
1.28 
 
1.38 
 
3.09 
 
1.61 
 
1.43 
 
1.81 
IL12 on 
ALL cells  
% +ve 
 
0.78 
 
11.57 
 
23.23 
 
11.86 
 
0 
 
32.25 
 
10.91 
 
0 
 
68.51 
 
49.71 
IL12  
on ALL cells 
IR 
 
1.68 
 
1.63 
 
1.13 
 
1.48 
 
0 
 
1.21 
 
0.84 
 
0 
 
1.11 
 
1.36 
Table 5.34: Non - IBD ECF Patients DC and all cells % +ve ICS:  Results of ICS 
on blood taken from ten non-IBD ECF patients.  TNF-α and IL12 antibodies were 
used for labelling cytokines intracellularly. 
 
Experiment Number Mean SD SEM 
BLOOD    
TNF-α on DC % +ve 45.31 29.52 9.33 
TNF-α on IR 2.01 1.37 0.43 
IL12 on DC % +ve 35.37 30.90 9.77 
IL12 on DC IR 1.18 0.94 0.29 
TNF-α on ALL cells % +ve 31.06 28.19 8.91 
TNF-α on ALL cells IR 1.24 0.92 0.29 
IL12 on ALL cells % +ve 20.88 23.04 7.28 
IL12 on ALL cells IR 1.04 0.60 0.19 
Table 5.35:  Mean, SD & SEM of Table 5.34 data:  Summary of results for data in 
Table 5.34 with mean, SD and SEM applied 
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Patients 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
TNF-α  
on DC  
% +ve 
 
0 
 
0 
 
0 
 
0 
 
0 
 
54.40 
 
0 
 
0 
 
0 
 
0 
TNF-α  
on  
IR 
 
0 
 
0 
 
0 
 
0 
 
0 
 
1.99 
 
0 
 
0 
 
0 
 
0 
IL12  
on DC  
% +ve 
 
0 
 
0 
 
2.57 
 
82.72 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
IL12  
on DC  
IR 
 
0 
 
0 
 
3.83 
 
1.03 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
TNF-α on 
ALL cells  
% +ve 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
TNF-α on 
ALL cells  
IR 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
IL12 on  
ALL cells  
% +ve 
 
47.48 
 
0.85 
 
0.6 
 
29.08 
0.7  
0 
 
0 
 
4.1 
 
0 
 
0 
IL12 on  
ALL cells  
IR 
 
1.05 
 
0.84 
 
5.96 
 
1.05 
 
5.78 
 
0 
 
0 
 
5.75 
 
0 
 
0 
Table 5.36: Control Patients DC and all cells % +ve ICS:  Results of ICS on blood 
taken from ten control patients.  TNF-α and IL12 antibodies were used for labelling 
cytokines intracellularly. 
 
 Mean SD SEM 
TNF-α on DC % +ve 5.44 17.20 5.44 
TNF-α on IR 0.19 0.62 0.19 
IL12 on DC % +ve 8.52 26.08 8.24 
IL12 on DC IR 0.48 1.21 0.38 
TNF-α on ALL cells % +ve 0 0 0 
TNF-α on ALL cells IR 0 0 0 
IL12 on ALL cells % +ve 8.28 16.44 5.19 
IL12 on ALL cells IR 2.04 2.64 0.83 
Table 5.37:  Mean, SD & SEM of Table 5.36 data: Summary of results for data in 
Table 5.36 with mean, SD and SEM applied. 
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5.10.2.4  Comparison of production of TNF- IL17a, IFN from Non - IBD ECF 
and Control patient’s blood T cells and all cells  
 
Results of ten non-IBD patient’s blood mean % +ve following intracellular staining 
are provided in Table 5.39 with summary results in Table 5.40.  Results of ten control 
patient’s blood are provided in Table 5.41 with summary results in Table 5.42.   Table 
5.43 provides side by side comparison of the mean % +ve’s between the two groups. 
There were significant differences in the production of TNF-α  by T cells (p = 0.0005) 
and all viable cells (p = 0.0003) in non-IBD ECF blood compared with control blood 
patients (Figure 5.14).   
There were also significant differences in the production of IL17a by T cells (p = 
0.009) and all viable cells (p = 0.0001) in non-IBD ECF blood compared with control 
blood patients (Figure 5.14).   
Also the on-going production of IFN  was significantly different by T cells (p = 
0.015) and all viable cells (p = 0.0008) in non-IBD ECF blood compared with control 
blood patients (Figure 5.14).   
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Patient 1 2 3 4 5 6 7 8 9 10 
CD3 % +ve 0 44.16 32.66 0 0 0 45.71 0.43 0 31.73 
CD3  
IR 
 
0 
 
3.64 
 
3.66 
 
0 
 
0 
 
0 
 
2.03 
 
12.12 
 
0 
 
1.55 
TNF-α on  
T cells  
% +ve 
 
54.35 
 
90.89 
 
0 
 
48.41 
 
65.25 
 
42.71 
 
40.14 
 
0 
 
61.51 
 
61.77 
TNF-α on  
T cells 
 IR 
 
1.37 
 
5.29 
 
0 
 
2.22 
 
1.12 
 
1.25 
 
1.51 
 
0 
 
1.42 
 
1.49 
IL17a on  
T cells  
% +ve 
 
19.30 
 
91.99 
 
35.68 
 
48.99 
 
44.04 
 
27.96 
 
31.13 
 
0 
 
46.47 
 
14.77 
IL17a on  
T cells  
IR 
 
1.15 
 
5.53 
 
1.33 
 
2.67 
 
1.14 
 
1.14 
 
1.26 
 
0 
 
1.11 
 
12.84 
IFNg on  
T cells  
% +ve 
 
1.23 
 
48.7 
 
22.15 
 
24.02 
 
1.65 
 
66.4 
 
36.89 
 
40.36 
 
0 
 
41.73 
IFNg on  
T cells  
IR 
 
65.09 
 
2.63 
 
1.47 
 
23.06 
 
0.83 
 
4.43 
 
1.31 
 
3.21 
 
0 
 
2.02 
TNF-α on  
All cells  
% +ve 
 
0 
 
81.93 
 
0 
 
27.31 
 
49.26 
 
50.61 
 
51.82 
 
0 
 
63.73 
 
60.16 
TNF-α on  
ALL cells  
IR 
 
0 
 
3.99 
 
0 
 
1.33 
 
1.2 
 
1.26 
 
1.4 
 
0 
 
1.36 
 
1.67 
IL17a on  
All cells  
% +ve 
 
0 
 
83.28 
 
37.49 
 
40.25 
 
58.92 
 
48.51 
 
39.74 
 
0 
 
69.36 
 
51.06 
IL17a on 
 All cells  
IR 
 
0 
 
4.18 
 
1.18 
 
1.78 
 
1.23 
 
1.11 
 
1.2 
 
0.3 
 
1.1 
 
1.27 
IFNg on  
All cells  
% +ve 
 
38.64 
 
48.7 
 
40.43 
 
42.59 
 
4.32 
 
60.91 
 
0 
 
0 
 
25.87 
 
67.96 
IFNg on  
All cells  
IR 
 
1.25 
 
2.63 
 
1.28 
 
1.72 
 
1.12 
 
2.89 
 
0 
 
0 
 
1.05 
 
1.14 
Table 5.39: Non - IBD ECF Patients T cells and all cells % +ve ICS:  Results of 
ICS on blood taken from ten non-IBD ECF patients.  TNF-α, IL17a and IFNγ 
antibodies were used for labelling cytokines intracellularly. 
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 Mean SD SEM 
CD3 % +ve 30.93 18.21 5.76 
CD3 IR 4.6 4.30 1.36 
TNF-α on T cells % +ve 46.50 28.33 8.95 
TNF-α on T cells IR 1.56 1.47 0.46 
IL17a on T cells % +ve 36.03 24.92 7.88 
IL17a on T cells IR 2.81 3.82 1.20 
IFNg on T cells % +ve 28.31 22.52 7.12 
IFNg on T cells IR 10.40 20.36 6.43 
TNF-α on All cells % +ve 38.48 29.82 9.43 
TNF-α on ALL cells IR 1.22 1.17 0.37 
IL17a on All cells % +ve 42.86 26.69 8.44 
IL17a on All cells IR 1.33 1.12 0.35 
IFNg on All cells % +ve 32.94 24.67 7.80 
IFNg on All cells IR 1.30 0.94 0.29 
Table 5.40:  Mean, SD & SEM of Table 5.39 data:  Summary of results for data in 
Table 5.39 with mean, SD and SEM applied. 
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Patients 1 2 3 4 5 6 7 8 9 10 
CD3 % +ve 71.13 58.79 0 4.42 52.7 48.23 44.01 0 76.92 0 
CD3  
IR 
1.31 1.48 0 3.15 1.68 1.7 1.01 0 1.81 0 
TNF-α on  
T cells  
% +ve 
 
0 
 
0 
 
0 
 
0 
 
0 
 
39.75 
 
0 
 
30.78 
 
0 
 
0 
TNF-α on  
T cells  
IR 
 
0 
 
0 
 
0 
 
0 
 
0 
 
1.10 
 
0 
 
1.06 
 
0 
 
0 
IL17a on  
T cells  
% +ve 
 
0 
 
0 
 
23.76 
 
0 
 
0 
 
0 
 
0 
 
0 
 
26.30 
 
56.27 
IL17a on  
T cells  
IR 
 
0 
 
0 
 
3.50 
 
0 
 
0 
 
0 
 
0 
 
0 
 
1.14 
 
1.10 
IFNg on  
T cells  
% +ve 
 
35.61 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
33.98 
 
2.16 
 
13.03 
IFNg on  
T cells  
IR 
 
1.01 
 
0.33 
 
0 
 
0 
 
0 
 
0 
 
0 
 
1 
 
0.94 
 
1.07 
TNF-α on  
All cells  
% +ve 
 
0 
 
0 
 
0 
 
0 
 
0 
 
3.07 
 
0 
 
0 
 
0 
 
0 
TNF-α on  
ALL cells  
IR 
 
0 
 
0 
 
0 
 
0 
 
0 
 
4.17 
 
0 
 
0 
 
0 
 
0 
IL17a on  
All cells  
% +ve 
 
6.74 
 
0.63 
 
5.58 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
IL17a on  
All cells  
IR 
 
1.64 
 
43.38 
 
3.45 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
IFNg on  
All cells  
% +ve 
 
4.27 
 
6.26 
 
0 
 
0 
 
0 
 
4.9 
 
9.32 
 
4.13 
 
2.16 
 
8.27 
IFNg on  
All cells 
 IR 
 
0.94 
 
1.01 
 
0 
 
0 
 
0 
 
1.04 
 
1.2 
 
0.84 
 
0.94 
 
2.12 
Table 5.41: Control Patients T cells and all cells % +ve ICS:  Results of ICS on 
blood taken from ten control patients.  TNF-α, IL17a and IFNγ antibodies were used 
for labelling cytokines intracellularly. 
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 Mean SD SEM 
CD3 % +ve 35.62 31.27 9.89 
CD3 IR 1.21 1.00 0.31 
TNF-α on T cells % +ve 7.05 15.01 4.74 
TNF-α on T cells IR 0.21 0.45 0.14 
IL17a on T cells % +ve 10.63 19.12 6.04 
IL17a on T cells IR 0.57 1.12 0.35 
IFNg on T cells % +ve 8.47 14.44 4.56 
IFNg on T cells IR 0.43 0.50 0.15 
TNF-α on All cells % +ve 0.30 0.97 0.30 
TNF-α on ALL cells IR 0.41 1.31 0.41 
IL17a on All cells % +ve 1.29 2.58 0.81 
IL17a on All cells IR 4.84 13.58 4.29 
IFNg on All cells % +ve 3.93 3.39 1.07 
IFNg on All cells IR 0.80 0.66 0.20 
Table 5.42: Mean, SD & SEM of Table 5.41 data:  Summary of results for data in 
Table 5.41 with mean, SD and SEM applied. 
 
 Non- IBD ECF Patients 
(Mean of all patients) 
Control  Patients  
(Mean of all patients) 
CD3 % +ve 30.93 35.62 
TNF-α on T cells % +ve 46.50 7.05 
IL17a on T cells % +ve 36.03 10.63 
IFNg on T cells % +ve 28.31 8.47 
TNF-α on All cells % +ve 38.48 0.30 
IL17a on All cells % +ve 42.86 1.29 
IFNg on All cells % +ve 32.94 3.93 
Table 5.43: Comparison of Non - IBD ECF Patients and Control T cells and all 
cells % +ve ICS Means of all patients:  Side by side results of ICS with TNF-α, 
IL17a and IFNγ antibodies. 
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5.10.3  Results of ICS on tissue biopsy and blood from IBD ECF patient 
Only one patient was recruited with IBD ECF from whom tissue from the ECF tract 
and blood was taken.  The results are shown in Tables 5.44 and 5.45.    
TNF-α in DC % +ve 0 
TNF-α in DC IR 0 
IL12 in DC % +ve 0 
IL12 in DC IR 0 
TNF-α in ALL cells % +ve 0 
TNF-α in ALL cells IR 0 
IL12 in ALL cells % +ve 0 
IL12 in ALL cells IR 0 
  
CD3 % +ve  
CD3 IR  
TNF-α in T cells % +ve 81.08 
TNF-α in T cells IR 1.1 
IL17a in T cells % +ve 0 
IL17a in T cells IR 0 
IFNγ in T cells % +ve 75.27 
IFNγ in T cells IR 1.24 
TNF-α in All cells % +ve 73.62 
TNF-α in ALL cells IR 1.29 
IL17a in All cells % +ve 0 
IL17a in All cells IR 0 
IFNγ in All cells % +ve 68.42 
IFNγ in All cells IR 1.52 
Table 5.44: Tissue Biopsy: IBD ECF DC, T and all cells % +ve ICS: 1 patient:  
Results of intracellular staining on biopsy taken from one IBD ECF patients.  TNF-α 
and IL12 antibodies were used for labelling cytokines intracellularly on DC and all 
cells.  TNF-α, IL17a and IFNγ antibodies were used for labelling cytokines 
intracellularly on T cells and all cells. 
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CLA on DC % +ve 0 
CLA on DC  IR 0 
b7 on DC % +ve 67.65 
b7 on DC IR 7.74 
CLA on ALL cells  % +ve 0 
CLA  on ALL cells IR 0 
b7 on ALL cells  % +ve 53.36 
b7  on ALL cells IR 6.81 
  
CD3 % +ve 65.8 
CD3 IR 113.47 
CLA on T cells % +ve 0 
CLA on T cells  IR 0 
b7 on T cells % +ve 64.67 
b7 on T cells IR 7.66 
CLA on ALL cells  % +ve 0 
CLA  on ALL cells IR 0 
b7 on ALL cells  % +ve 52.98 
b7  on ALL cells IR 6.9 
  
TNF-α in DC % +ve 0 
TNF-α in DC IR 0 
IL12 in DC % +ve 0 
IL12 in DC IR 0 
TNF-α in ALL cells % +ve 0 
TNF-α in ALL cells IR 0 
IL12 in ALL cells % +ve 0 
IL12 in ALL cells IR 25.67 
  
TNF-α in T cells % +ve 0 
TNF-α in T cells IR 0 
IL17a in T cells % +ve 0 
IL17a in T cells IR 1339.67 
IFNγ in T cells % +ve 0 
IFNγ in T cells IR 1207.77 
TNF-α in All cells % +ve 0 
TNF-α in ALL cells IR 0 
IL17a in All cells % +ve 0.06 
IL17a in All cells IR 15.49 
IFNγ in All cells % +ve 0.08 
IFNγ in All cells IR 64.67 
Table 5.45: Blood: IBD ECF DC, T and all cells % +ve Surface Markers and ICS: 1 
patient:  CLA and on blood DC, T cells and all cells. TNF-α, IL12, IL17a and IFNγ 
antibodies were used for labelling cytokines intracellularly. 
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5.10.4 Multiplex 
5.10.4.1 Multiplex Tissue Results 
Multiplex analysis was performed on tissue obtained from each of six patients with 
non-IBD ECF (Table 5.47) and control patients (Table 5.48), as well as the one IBD 
ECF patient (Table 5.49). 
IL2, IL4, IL10, TNF-α, IFNγ and IL17a were all present in greater quantities, though 
not significantly, in non-IBD ECF tissue compared with normal control terminal 
ileum tissue (Figure 5.15). 
IL6 was significantly (p = 0.00009) present in greater quantity in in non-IBD ECF 
tissue patients compared with normal control terminal ileum tissue patients (Figure 
5.16). 
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PROT 
(pg/ml) 
      Mean SD SEM 
IL2 6.53 6.53 6.57 7.34 20.70 6.53 9.04 5.72 2.33 
IL4 11.97 10.65 11.81 12.99 27.97 9.41 14.13 6.88 2.81 
IL6 3353.25 2378.69 3725.24 3684.33 2173.01 1036.49 2725.17 1057.46 431.70 
IL10 8.42 8.75 79.74 11.92 10.40 7.37 21.10 28.77 11.74 
TNF-α 6.42 6.24 6.64 9.76 9.73 6.25 7.50 1.74 0.71 
IFNγ 9.97 9.97 9.78 13.58 16.26 10.05 11.60 2.70 1.10 
IL17a 2.27 2.27 13.62 3.75 2.46 2.18 4.43 4.54 1.85 
Table 5.46: Multiplex analysis showing tissue production of cytokines from Non-
IBD ECF Tissue:  Multiplex results in pg/ml of six patient’s non-IBD ECF tissue.  
Cytokines assessed (IL2, IL4, IL10, TNF-α, IFNγ and IL17a). 
 
 
PROT 
(pg/ml) 
      Mean SD SEM 
IL2 6.59 6.65 6.53 6.56 8.21 6.55 6.85 0.66 0.27 
IL4 9.76 10.35 9.89 10.09 13.30 9.69 10.51 1.38 0.56 
IL6 121.22 66.46 192.71 154.96 565.82 203.45 217.44 177.83 72.60 
IL10 10.88 8.71 8.43 9.76 16.35 10.79 10.82 2.89 1.18 
TNF-α 6.24 6.37 6.31 6.41 7.00 6.45 6.46 0.27 0.11 
IFNγ 11.64 10.47 9.98 10.79 12.56 10.07 10.92 1.00 0.40 
IL17a 2.48 2.20 2.18 2.25 2.19 2.19 2.25 0.11 0.04 
Table 5.47: Multiplex analysis showing tissue production of cytokines from  
Control Tissue: Multiplex results in pg/ml of six patients control tissue. Cytokines 
assessed (IL2, IL4, IL10, TNF-α, IFNγ and IL17a). 
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PROT (pg/ml)  
IL2 6.53 
IL4 9.41 
IL6 17.49 
IL10 9.83 
TNF-α 6.44 
IFNγ 10.17 
IL17a 2.26 
Table 5.48: Multiplex analysis showing tissue production of cytokines from IBD 
ECF Tissue:  Multiplex results in pg/ml of one patient IBD tissue. Cytokines 
assessed (IL2, IL4, IL10, TNF-α, IFNγ and IL17a). 
 
 
 Non-IBD ECF Tissue 
Mean PROT (pg/ml) 
Control Tissue Mean PROT 
(pg/ml) 
IL2 9.04 6.85 
IL4 14.13 10.51 
IL10 21.10 10.82 
TNF-α 7.50 6.46 
IFNγ 11.60 10.92 
IL17a 4.43 2.25 
Table 5.49: Comparison of Non-IBD ECF Tissue and Control Tissue Means:  
Side by side comparison of multiplex cytokine results for non-IBD versus control 
patient tissue. 
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5.10.4.2 Multiplex Blood Results 
Multiplex analysis was performed on blood obtained from seven patients with non-
IBD ECF (Table 5.51) and four control patients (Table 5.52), as well as the one IBD 
ECF patient (Table 5.53). 
IL2, IL10, TNF-α, IL17a and IL6 were all present in greater quantities, though not 
significantly, in non-IBD ECF blood compared with normal control blood patients 
(Figure 5.17 and 5.18). 
IL4 and IFNγ were not significantly but very mildly present, and in greater quantity in 
control blood then non-IBD ECF patients’ blood (Figure 5.17).   
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PROT 
(pg/ml) 
       Mean SD SEM 
IL2 7.600 6.538 6.538 7.811 7.031 6.538 6.538 6.942 0.555 0.209 
IL4 9.589 9.419 11.051 9.419 9.419 10.706 10.288 9.985 0.691 0.261 
IL6 44.716 48.379 3721.322 10.577 34.363 2492.788 3252.561 1372.101 1706.282 644.91 
IL10 10.024 10.439 151.373 9.599 14.378 15.753 66.965 39.790 53.341 20.161 
TNF-α 6.380 6.453 23.361 6.245 6.307 6.287 6.318 8.765 6.436 2.432 
IFNγ 11.489 9.870 10.124 14.580 10.242 9.616 10.174 10.871 1.739 0.657 
IL17A 2.296 2.176 2.745 3.711 2.254 2.171 2.188 2.506 0.568 0.214 
Table 5.51: Multiplex analysis showing blood production of cytokines from Non-
IBD Blood:  Multiplex results in pg/ml of non-IBD ECF patient’s blood. Cytokines 
assessed (IL2, IL4, IL10, TNFα, IFNγ and IL17a). 
 
PROT (pg/ml)     Mean SD SEM 
IL2 6.550 6.538 6.538 6.548 6.543 0.006 0.003 
IL4 10.125 10.476 9.419 10.763 10.196 0.579 0.289 
IL6 1681.084 2397.398 11.169 43.771 1033.356 1197.818 598.909 
IL10 16.287 46.814 8.693 10.734 20.632 17.747 8.873 
TNF-α 6.610 6.297 6.245 9.642 7.198 1.636 0.818 
IFNγ 10.124 9.785 9.836 16.434 11.545 3.262 1.631 
IL17A 2.217 2.214 2.166 6.860 3.364 2.330 1.165 
Table 5.52: Multiplex analysis showing blood production of cytokines from 
Control Blood:  Multiplex results in pg/ml of control patient’s blood. Cytokines 
assessed (IL2, IL4, IL10, TNF-α, IFNγ and IL17a). 
 
 
 
 
 
222 
 
 
PROT (pg/ml)  
IL2 6.538 
IL4 9.508 
IL6 790.017 
IL10 8.425 
TNF-α 6.703 
IFNγ 20.278 
IL17a 3.241 
Table 5.53: Multiplex analysis showing blood production of cytokines from IBD 
Blood:  Multiplex results in pg/ml of one patient IBD blood. Cytokines assessed (IL2, 
IL4, IL10, TNF-α, IFNγ and IL17a). 
 
 
 Non-IBD Blood Mean 
PROT (pg/ml) 
Control Blood Mean 
PROT (pg/ml) 
IL2 6.942 6.543 
IL4 9.985 10.196 
IL10 39.790 20.632 
TNF-α 8.765 7.198 
IFNγ 10.871 11.545 
IL17a 2.506 3.364 
Table 5.54: Comparison of Non-IBD Blood and Control Blood Mean PROT 
(pg/ml):  Side by side comparison of multiplex cytokine results for non-IBD versus 
control patient blood. 
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SUMMARY OF RESULTS 
 
TNF-α 
Tissue: On-going production of TNF-α by DC (p = 0.0007), all viable cells (p = 
0.001), and T cells (p = 0.04) was significantly higher in non-IBD ECF than that from 
control tissue.   
Blood: On-going production of TNF  by DC (p = 0.0008), all viable cells (p = 
0.001) and T cells (p = 0.0005) was significantly higher from non-IBD ECF blood 
compared with control. 
 
IL12 
Tissue: On-going production of IL12 by DC (p = 0.022) and all viable cells (p = 
0.008) was significantly higher in non-IBD ECF than from control tissue.   
Blood: On-going production of IL12 by DC (p = 0.025) from non-IBD ECF blood 
was significantly higher than from control.   
 
IFN  
Tissue: On-going production of IFN  by T cells (p = 0.016) from non-IBD ECF was 
significantly higher than control tissue.    
Blood: On-going production of IFN  by T cells (p = 0.015) and all viable cells (p = 
0.0008) was significantly higher in non-IBD ECF blood compared with control.   
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IL17a  
Tissue: On-going production of IL17a in all viable cells (p = 0.002) was significantly 
higher from non-IBD ECF compared with control tissue.   
Blood: On-going production of IL17a by T cells (p = 0.009) and all viable cells (p = 
0.0001) was significant higher in non-IBD ECF blood compared with control blood. 
 
CLA surface marker 
Blood: There was a greater percentage of DC, T cells, and significantly all viable 
cells (p = 0.036), which had the presence of CLA surface marker in non - IBD ECF 
patient’s blood, then from controls.    
 
Mutiplex 
Tissue: IL2, IL4, IL10, TNF-α, IFNγ, IL17A and IL6 were all present in greater 
quantities, in non-IBD ECF tissue compared with normal control terminal ileum 
tissue.   
Blood: IL2, IL10, TNF-α, IL17A and IL6 were all present in greater quantities, in 
non-IBD ECF blood compared with normal control blood patients.   
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5.11 DISCUSSION 
To the best of our knowledge, there are no studies in the literature regarding the 
assessment of immunological response in ECF of IBD or non-IBD ECF.   
This study has shown the on-going production of TNF-α from dendritic cells (DC) (p 
= 0.0007), putative monocyte and B cell populations (p = 0.04) and CD3+ T cells (p = 
0.04) was significantly higher in non-IBD ECF than that from control tissue.  Larger 
sample numbers will be required to confirm statistical validity. 
The production of TNF  by DC and all viable cells from non-IBD ECF patients was 
significantly higher (p = 0.0008 and p = 0.001 respectively) than that by from control 
blood patients.    
From blood ICS experiments, there were significant increased difference in the 
production of TNF-α by T cells (p = 0.0005) and all viable cells (p = 0.0003) in non-
IBD ECF blood compared with control blood patients.   
DC undergo maturation and migrate to draining lymph nodes in response to signals 
that indicate local “danger” or tissue damage.  This would be the case in non-IBD 
ECF.  These signals include cytokines such as TNF-α.  During maturation, DC up 
regulate their expression of MHC class II and costimulatory molecules and acquire 
the ability to stimulate naïve T cells. Communication between DC and T cells is a two 
way process with important interactions occurring particularly between members of 
the TNF and TNF receptor protein families.  These interactions serve to further 
activate the DC and regulate their survival (222). 
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The population of gut DC is a dynamic one, with cells constantly trafficking into and 
out of the gut compartment.  Migration of gut DC can be further increased by 
inflammatory stimuli, including TNF-α (222). 
IL12 production was also significantly higher from DC and all viable cells in non-
IBD ECF tissue.  On-going production of IL17a, not in T cells, but in all viable cells 
from non-IBD ECF was significantly higher compared with all viable cells from 
control terminal ileum tissue.   
Production of IL12 by DC from non-IBD ECF blood patients was significantly (p = 
0.025) higher than that by DC from control blood patients.  All viable cells from non-
IBD ECF blood also produced non-significantly higher level of IL12 (p = 
0.088) compared with all viable cells from control blood patients. 
Hart et al showed that in IBD, DC are activated, and more DC produce pathologically 
relevant cytokines (223).  The study also showed that in Crohn's disease, more colonic 
DCs produced IL12 and IL6.  As our study has revealed a higher level of IL12 
produced from DC in non-IBD ECF compared to control tissue, it would be useful to 
compare the level directly with IBD ECF in a future study.  Our study did not 
investigate the production of IL6 from DC tissue. 
IFN  was significantly higher in T cells, though not in all viable cells, from non-IBD 
ECF compared with control terminal ileum tissue.   Also the on-going production of 
IFN  was significantly higher by T cells (p = 0.015) and all viable cells (p = 0.0008) 
in non-IBD ECF blood compared with control blood patients.  Murine Peyer’s patch 
DC up regulate IL10 and generate T cells that produce high levels of IL4 and IL10 
and less IFNγ. In contrast, DC from the spleen generate T cells producing 
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predominately IFNγ (222).  Patients with IBD even in an inactive state of disease 
exert an increased capacity for IFNγ induction in T cells mediated by intestinal 
epithelial cells (224). 
From blood experiments, there was a greater percentage of DC, T cells, and 
significantly on all viable cells (p = 0.036), which had the presence of CLA surface 
marker in non - IBD ECF patient’s blood, then from control patient’s.   There was no 
significant difference in the gut homing marker.  Mann et all has shown that blood DC 
mostly express both gut and skin homing markers, indicating potential to migrate to 
both major immune surface organs, and induced multi-homing T cells (225). 
There were also significant differences with increased production of IL17a by T cells 
(p = 0.009) and all viable cells (p = 0.0001) in non-IBD ECF blood compared with 
control blood patients. 
The main function of IL17a appears to be the regulation of local tissue inflammation 
via the coordinated expression of pro-inflammatory and neutrophil-mobilizing 
cytokines and chemokine’s. High concentrations of IL17a are associated with 
inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. 
Therapeutic monoclonal antibodies against human IL17a have shown promise for the 
treatment of psoriasis and rheumatoid arthritis.  This is particularly useful as one-third 
of rheumatoid arthritis patients do not respond to current TNF inhibition treatments 
and to the patients that lose the initially good response to TNF inhibition treatment. 
Wedebye et al found that colitis development was associated with an increase in 
IL17a producing TH17 cells in spleen, mesenteric lymph nodes, and lamina propria. 
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The study suggests that  IL17a blockade as a potential strategy in inflammatory bowel 
disease therapy (226). 
There were limitations to the number of samples on which multiplex analysis could be 
performed. Samples from the non-IBD and control groups were selected 
consecutively to avoid any bias.   
IL2, IL4, IL10, TNF-α, IFNγ, IL17A and IL6 were all present in greater quantities, in 
non-IBD ECF tissue compared with normal control terminal ileum tissue.  IL2, IL10, 
TNF-α, IL17A and IL6 were all present in greater quantities, in non-IBD ECF blood 
compared with normal control blood patients.  Thus results of our multiplex analysis 
for both tissue and blood experiments have shown greater quantities of pro-
inflammatory cytokines to be present in the non-IBD ECF group as one would expect 
in response to inflammation. 
Although the production of TNF-α in the intestinal mucosa is increased in patients 
with Crohn’s disease, this study is the first to show the presence of TNF-α in a non-
IBD ECF.  Hence these date may explain the clinical results of Infliximab used in the 
small case series of three patients which reported healing of persistent ECF not 
associated with IBD to have healed following a single infusion of infliximab (227).   
The aim of this study was to assess and compare the immunological factors in three 
groups of patients.  Unfortunately as the study progressed it became evident that this 
would be difficult to do, and this was one of the limitations of the study.  Patients with 
inflammatory bowel disease ECF had at some stage used medications including 
steroids, immunosuppressive drugs such as Azathioprine, Mesalazine or 5-
aminosalicylic acid (5-ASA), or used anti-TNF-α agents such as Infliximab or 
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Humera (Adalimumab).  We decided to continue with the study to compare patients 
with non-IBD ECF with normal control patients.  Although an IBD-ECF group was 
not used, it is well known that TNF-α levels are higher in Crohn’s disease tissue 
compared to healthy controls and anti-TNF-α therapy has shown efficacy in the 
closure of fistula associated with IBD (228). 
We acknowledge that this study compared tissue from the ECF in the non-IBD group 
and tissue from small bowel and from normal control group.  Ideally tissue should be 
compared from similar sites, but in essence as control patients are ‘normal’ then no 
ECF is available in these cases.  For future work one could compare ECF tissue and 
small bowel tissue from the same patient. 
The study was limited to ten patients in each of non-IBD ECF and the control group.  
This was due in difficulty in co-ordinating times for when patients were undergoing a 
laparotomy and surgical resection of the ECF or colonoscopy and the availability of 
laboratory facilities.  For each patient, after specimens were taken laboratory facilities 
were required for three to four days continuously.   
Experiments were also only possible when all antibodies and FACS reagents were 
available, and this had to be identified prior to taking specimens from patients. 
5.12 CONCLUSION 
A trend has been found with a higher on-going production of cytokines in non-IBD 
ECF compared with control terminal ileum tissue.  The addition of a greater number 
of samples may show significant differences between the two groups of patients and 
provide validity to this trend.  
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Data from this study may provide evidence for the potential use of anti-TNF-α agents 
such as Infliximab in the treatment of non-IBD ECF patients.  Recommendations are 
for a pilot study to assess whether this can be an alternative option to benefit an 
already surgically challenging group of patients.  A research protocol will have to be 
developed for the safe administration of an anti-TNF-α agent.  This will have to be 
submitted and approved by the MHRA (Medicines and Healthcare Products 
Regulatory Agency) as the product though licensed for use, would have to be used out 
of its indication in patients with non-IBD ECF.  Any positive findings would equate 
to a major medical advance with a new use for anti-TNF-α agents. 
In conclusion, this data may provide evidence for the potential use of anti-TNF-  
agents in the treatment of non-IBD ECF. 
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CHAPTER 6 
DISCUSSION 
This thesis reviewed and investigated several aspects of the management of 
enterocutaneous fistula. 
This thesis has shown that the best management of ECF, particularly complex fistulas, 
is in specialist units where there is a multidisciplinary structured approach.  Surgical 
management of ECF at St. Mark’s National IF Unit is safe and improving.   
The highest incidence of ECF development occurs following abdominal surgery 
particularly in the presence of Crohn’s disease. The audit confirmed this in our unit, 
with the most common aetiology for ECF formation being in surgery performed in 
patients with a background of inflammatory bowel disease.   
Management of persistent ECF has been divided into five main categories; specialised 
nutritional support, control of sepsis, judicious use of pharmacological agents, wound 
/ stoma care and surgery. 
Definitive surgery with ECF resection should be deferred until there is re-
epithelisation of the abdominal wall, eradication of sepsis, maturation of adhesions, 
full bowel mapping has been performed and attainment of an adequate nutritional and 
general medical status.  Adequate nutritional status is when the patient is anabolic, 
evidenced by gaining weight, increasing muscle mass and muscle strength.  General 
medical status relates to stability of the underlying conditions as well as correction of 
any electrolyte and metabolic derangements.  This process can take over six months.   
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A period of home leave prior to a planned date for surgery can be both mentally and 
physically beneficial. 
Vacuum assisted pumps are avoided in our unit due to experience of increased ECF 
formation.  The use of non-absorbable meshes is also avoided because ECF surgery is 
often performed in contaminated or grossly infected wounds.  When required a Vicryl 
(Ethicon, Somerville, NJ, USA) mesh or Strattice™ ( Lifecell Corporation, 
Branchburg, NJ , USA)  are used.  Either a stapled and over sewn or hand sewn 
interrupted anastomosis with 4-0 Ethibond (Ethicon, USA) are performed. 
The retrospective audit of our unit revealed the majority of patients underwent 
definitive surgery.  There were improved overall healing rates following both surgery 
and conservative management in the current series compared with the previous series, 
with also improvement in the 30 day post fistula resection mortality  
Multivariate analysis revealed co-morbidity, source of referral and aetiology had 
significant associations with ECF healing.   
Patients from external sources were less likely to heal.  This may be due to a greater 
number of operations being performed at external institutions prior to the decision to 
refer to specialist care.   
This thesis has included the first study and design of a scoring system for predicting 
ECF healing. The scoring systems devised were both validated.   They can now be 
applied on all patients at their first presentation with an ECF.  This is without 
knowing if the patient will require medical treatment alone or progress to requiring 
surgery.   
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It is noted that the course of Crohn's fistula and fistula associated with UC are 
different. The total number of patients with UC related fistula was low in our series 
and it was difficult to independently assess this.    Assessing their individual impact 
on clinical outcome would be useful for any future study as well as the potential 
impact on the scoring system. 
The scoring systems can provide further information to aid clinical management and 
decision making for the multidisciplinary team and predict the possible long term 
outcome for patients at external institutions.  They have the potential to predict ECF 
healing and can be a useful decision making tool.  It would be useful to assess the 
scoring systems at other centres in this regard to see whether they have a role in future 
clinical practice. 
Future work will involve contacting units both nationally and internationally to apply 
the scoring system.  This will allow assessment of its effectiveness and modifications 
to take place. 
Meta-analyses of nine randomised control trials have revealed somatostatin and 
octreotide increase the likelihood of fistula closure.  Both were shown to be beneficial 
in reducing the time to fistula closure. Neither has an effect on mortality.  The risk 
ratio for somatostatin was higher than the risk ratio for analogues.  This may suggest 
that somatostatin could be better than analogues in relation to the number of fistulas 
closed and time to closure.   The best results were following the use of somatostatin or 
long acting somatostatin analogue, lanreotide. 
Our meta-analysis is limited due to several studies having small numbers of patient’s 
recruited, wide variability in study designs and lack of clear definitions relating to 
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recording of study outcomes: fistula closure, time of fistula closure, fistula output 
reduction, complication rate and mortality.  The findings may be compounded by 
limitations such as different treatment protocols, patient selection, population 
characteristics and methodology used to determine the actual time of closure of fistula 
for each trial. Further studies are warranted directly comparing both these agents to 
establish whether there is a significant difference between them and to corroborate 
these apparent findings.   
Recommendation is for a large randomised control trial with adequate patient 
numbers or a multi-centre trial with well-defined criteria and agreed parameters 
between the participating centres.  If a clear option is identified this would benefit an 
already surgically challenging group of patients associated with a high morbidity and 
mortality where it is deemed standard medical treatment has failed. 
The immunological studies reveal encouraging results and a trend has been found in 
the on-going production of cytokine, in particular TNF-α, in non-IBD ECF compared 
with control terminal ileum tissue.  The data is encouraging and may provide evidence 
for the potential use of anti-TNF-α agents in the treatment of non-IBD ECF.   
In section 6.1 a future pilot study has been designed with the aim to identify a 
potential novel therapy for patients with persistent enterocutaneous fistula not 
associated with inflammatory bowel disease.  
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FUTURE DESIGN PROTOCOL FOR A PILOT STUDY 
6.1 INTRODUCTION 
Our pilot study aims to identify a potential novel therapy for patients with persistent 
enterocutaneous fistula not associated with inflammatory bowel disease. This would 
be an alternative option for the treatment of a surgically challenging group of patients 
who have a high morbidity and mortality with operative treatment. 
It has been suggested in a single article that it is possible to treat non-IBD ECF 
patients with Infliximab (175). 
 
6.2 Hypothesis 
Anti-TNF-α antibody (Infliximab) is effective in the treatment of patients with 
persistent enterocutaneous fistula due to non-inflammatory bowel disease who have 
failed to heal following supportive therapy. 
 
6.3 Aim 
 To heal persistent enterocutaneous fistula in non-inflammatory bowel disease 
patients using infliximab. 
 To assess the cytokine milieu in non-inflammatory bowel diseases patients 
with enterocutaneous fistula and their response to infliximab. 
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6.3.1 Primary end points 
 The primary end point is defined as a reduction of 50 per cent or more in the 
number of draining fistula observed at ten weeks as compared to baseline. 
 
6.3.2 Secondary end points 
 Closure of all fistulas. 
 Reduction in fistula volume output. 
 Quality of life scores to assess morbidity pre and post treatment with 
infliximab.   SF-36 (short form health survey with 36 questions), and visual 
analogue scores will be assessed. 
 Serum levels of pro and anti-inflammatory cytokine markers including TNF-α, 
pre and post treatment with infliximab. 
 Levels of pro and anti-inflammatory cytokine markers including TNF-α, in 
enterocutaneous fistula mucosa, fistula output and stool, pre and post 
treatment with infliximab. 
 Magnetic Resonance Imaging (MRI) to assess radiological changes in 
response to treatment with infliximab. 
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6.4 METHODS 
6.4.1 Inclusion criteria 
 Consent 
 18+ years 
 Single or multiple enterocutaneous fistula for at least three months duration as 
a result of non-inflammatory bowel disease, not responding to standard 
treatments. 
 Enterocutaneous fistula confirmed to be due to non-inflammatory bowel 
disease by radiography, endoscopy or pathological examination. 
6.4.2 Exclusion criteria 
 Current sepsis or abscess 
 Previous treatment with infliximab. 
 History of allergy to murine proteins. 
 Treatment with investigational agents or the use of any medication which 
reduces the concentration of TNF-α within three months before enrolment. 
 History of Crohn’s disease or Ulcerative Colitis. 
 Patients will also be excluded if there is evidence of latent or active 
tuberculosis (they will require a clear chest X-ray and evidence of previous 
BCG vaccine) 
 Females who are pregnant or breast feeding. 
 Moderate to severe heart failure. 
 Claustrophobia or other contraindication to MRI. 
 Malignancy. 
 Evidence of distal bowel obstruction from the enterocutaneous fistula. 
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6.4.4 Study design 
This will be a prospective pilot study of patients with enterocutaneous fistula 
secondary to non-inflammatory bowel disease, who undergo this novel treatment with 
infliximab.  We aim to pilot this study in 20 patients. 
Following consultation with a statistician we conclude that 13 patients are required for 
a statistically significant study.  The primary outcome is change in the number of 
draining fistula. The sample size was based on showing a change in the number of 
fistula from pre to post treatment. Patients would have a mean of two fistulas before 
treatment, and it is expected that there will be a 50% reduction to a mean of one 
fistula after treatment.  It is expected that the standard deviation for the change in the 
number of fistula will be 1.25. With a 5% significance level and 80% power, it is 
calculated that 13 patients are required for the study.  
The change in the number of fistula from pre to post treatment will be examined using 
the paired T-test or the Wilcoxon matched pairs test, depending on the distribution of 
the change in number of fistula over time. 
6.4.4 Study Procedure 
An eligible patient will be identified in the outpatient or ward setting and offered 
participation in this study.   
The study will be explained and Infliximab and the alternative options will be 
discussed and patients encouraged to ask questions for discussion.  A trial information 
sheet will be provided. 
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Patients who decide to enter the study will be required to sign a consent form. The 
patients, who decline to enter the study, will be treated with the normal standard of 
clinical care. 
Participants will be given the opportunity for freely informed consent, in accordance 
with the declaration of Helsinki. 
Patients entering the study will require to undergo a full medical history and clinical 
examination. Base characteristics as follows will be noted; age (years), weight (kg), 
BMI, ethnicity, male/female, duration of non-inflammatory bowel disease, area of 
involvement (gastric, duodenum, jejunum, ileum, colon), details of previous operative 
procedures and segmental resections.  A prior history of vaccination with BCG, 
history of Tuberculosis (TB) or exposure to TB will be confirmed. 
A routine physical examination will be performed and the number and location of the 
enterocutaneous fistulae will be noted.  All fistulas will be distinctly identifiable; 
drawings as well as photographs will be used to document the sites of disease. 
A chest X-ray (CXR) and routine bloods including full blood count (FBC), urea and 
electrolytes (U&E’s), liver function tests (LFT’s), C-reactive protein, Erythrocyte 
sedimentation rate (ESR)  will be performed, as part of standard clinical care. 
Patients will be contacted and at an appropriate time and requested to attend the 
Infliximab infusion unit at St. Mark’s Hospital. 
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0 weeks:  (Start of study) 
Patients will be asked to complete a quality of life questionnaire prior to treatment. 
We will use the validated and reliable SF-36.  This is a short-form health survey with 
36 questions. It uses an eight scale profile of functional health and wellbeing scores as 
well as psychometrically based physical and mental health summary measures and a 
preference based health utility index.  It is a generic measure, as opposed to one that 
targets a specific age, disease, or treatment group.  
Visual analogue scores will be used to evaluate quality of life with respect to bowel 
function (e.g. loose stools and abdominal pain), systemic symptoms (fatigue and 
altered sleep pattern), social function (work attendance and the need to cancel social 
events),  emotional status (angry, depressed, or irritable), and their perspective on 
body image. 
A blood test will be taken as part of standard clinical care, for baseline FBC, U&E’s, 
LFT’s including albumin, CRP, ESR. We will also test for pro and anti-inflammatory 
cytokine markers including TNF - α levels.   
Magnetic Resonance Imaging (MRI) will be performed as part of standard clinical 
care to image and assess the anatomy of the enterocutaneous fistula. 
A biopsy of the enterocutaneous fistula tract will be taken to assess for baseline pro 
and anti-inflammatory cytokine markers including TNF – α levels (Biopsy 1).  Biopsy 
forceps will be used to take 1mm tissue samples under direct vision from the fistula 
tract. This procedure requires no anaesthetic and is performed routinely and 
frequently as part of standard clinical care during procedures such as oesophago 
gastric duodenoscopy (OGD), flexible sigmoidoscopy and colonoscopy. 
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Following this, a standard 5mg of Infliximab per kilogram bodyweight will be 
administered intravenously as defined by the manufacturer, and according to 
departmental guidelines (Dose 1). This will be administered in the Infliximab infusion 
unit by a dedicated Inflammatory Bowel Disease Clinical Nurse Specialist.  Routine 
monitoring and surveillance will be performed as is part of normal standard clinical 
care before, during and after administration of infliximab.   
A daily record of fistula output volume will be kept. We will then arrange for the 
patient to return to the Infliximab infusion unit at two weeks from the start date. 
 
At 2 weeks 
A blood test will be taken as part of standard clinical care, for FBC, U&E’s, LFT’s 
including albumin, CRP, ESR. We will also test for pro and anti-inflammatory 
cytokine markers including TNF - α levels.   
The second dose of 5mg of Infliximab per kilogram bodyweight will be administered 
intravenously as defined by the manufacturer, and according to departmental 
guidelines (Dose 2). This will be administered again in the Infliximab infusion unit by 
a dedicated nurse with experience in Infliximab infusion. Routine monitoring and 
surveillance will be performed as is part of normal standard clinical care before, 
during and after administration of Infliximab.   
A daily record of fistula output volume will be kept. We will then arrange for the 
patient to return to the Infliximab infusion unit at six weeks from the start date. 
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At 6 weeks 
A blood test will be taken as part of standard clinical care, for FBC, U&E’s, LFT’s 
including albumin, CRP, ESR. We will also test for pro and anti-inflammatory 
cytokine markers including TNF-α levels.   
The third and final dose of 5mg of Infliximab per kilogram bodyweight will be 
administered intravenously as defined by the manufacturer, and according to 
departmental guidelines (Dose 3). This will be administered in the Infliximab infusion 
unit by a dedicated nurse. Routine monitoring and surveillance will be performed as is 
part of normal standard clinical care before, during and after administration of 
infliximab.   
A daily record of fistula output volume will be kept. We will then arrange for the 
patient to return to the Infliximab infusion unit at eight weeks from the start date 
 
At 8 weeks 
A blood test will be taken for FBC, U&E’s, LFT’s including albumin, CRP, ESR. We 
will also test for pro and anti-inflammatory cytokine markers including TNF-α levels.   
A biopsy of the enterocutaneous fistula tract will be taken (if still present) to assess 
for baseline pro and anti-inflammatory cytokine markers including TNF-α levels 
(Biopsy 2). Biopsy forceps will be used to take 1mm tissue samples under direct 
vision from the fistula tract. This procedure again requires no anaesthetic and is 
performed routinely and frequently as part of standard clinical care during procedures 
such as oesophago gastric duodenoscopy (OGD), flexible sigmoidoscopy and 
colonoscopy. 
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We will then arrange for the patient to return at ten weeks from the start date. 
 
At 10 weeks 
Patients will be asked to complete both the post treatment SF-36 survey and Visual 
analogue score questionnaire, just as they had done prior to commencement of 
treatment. 
A blood test will be taken for FBC, U&E’s, LFT’s including albumin, CRP, ESR. We 
will also test for pro and anti-inflammatory cytokine markers including TNF-α levels. 
A post treatment MRI will be performed as part of standard clinical care to assess the 
anatomy and degree of healing of the enterocutaneous fistula which has taken place.  
We will be able to ascertain information relating to tract length, diameter and volume. 
 
At 14, 18, and 26 weeks 
Patients will be reviewed in outpatient clinic for routine follow up and assessment at 
14, 18 and 26 weeks from the start date. 
If at any point the treatment does not seem to be working or the patient does not want 
to continue, they can leave the trial and be treated exactly as they normally would. 
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Table 6.1: Summary of proposed study protocol 
Weeks 
 Screening 0 2 6 8 10 14 18 26 
Clinical test / Management          
Assess eligibility          
Consent for study          
SF-36 Survey          
Visual analogue scores          
CXR          
Bloods: FBC, U&E’s, 
LFT’s including albumin, 
CRP, ESR 
 
 
 
 
 
 
 
 
 
 
 
 
   
Pro and anti -inflammatory 
cytokine markers including 
TNF-α levels 
  
 
 
 
 
 
 
 
 
 
   
MRI           
Fistulae tract mucosa biopsy          
Infusion of infliximab at 
unit 
         
Outpatient Clinic Follow up          
 
 : Clinical test / Management to take place 
 
6.5 Safety and Monitoring 
There is potential for increased pain and discomfort from the additional blood tests 
and biopsies of the fistula tract.  In both cases the patient will be informed during the 
initial explanation, consent stage, and prior to the procedure, that they may feel a very 
‘small pinch or prick’ sensation as the blood test or biopsy is being performed.  There 
is minimal risk of very light bleeding following either test, and this would be 
controlled as is in normal standard clinical practice with the application of gentle 
pressure until any bleeding subsides. 
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There is a small risk of an infection occurring at the site of blood taking and this will 
be minimised by the use of standard hospital guidelines in relation to use of alcohol 
hand gel and sterile technique as is part of normal standard clinical care. 
There is potential for inconvenience by the attendance for an extra MRI scan (post 
treatment scan) and attendance for extra outpatient clinic appointments. 
There is risk of ionising radiation from the one CXR performed.  If a recent CXR has 
been performed there will be no need for a further CXR. 
The CXR estimated dose constraint is ~ 0.02 mSv (Effective Dose) per individual. 
Risk assessment has been completed by Medical Physicist & Head of Physics 
Department Consultant.  The average annual natural background radiation dose in the 
UK is 2.2 mSv. In this context, therefore, the study "Dose Constraint" of ~ 0.02 mSv 
is equivalent to about three days of exposure to the UK natural background radiation.  
Any associated risk would be considered to be trivial.  
Safety will be assessed in terms of the incidence of adverse events and changes in 
vital signs and routine laboratory measures.  Patients will be monitored for adverse 
events during each infusion and at each study visit. 
Patients are pre medicated with Hydrocortisone 200mg, approximately 30 minutes 
prior to commencement of the Infliximab Infusion.  Infliximab is prepared as per 
manufactures guidelines and given in 250mls of Normal Saline.  Infliximab will be 
given over two hours using a giving set and 1.2-micron filter via an infusion pump as 
per departmental protocol. 
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All patients who are admitted for Infliximab will have a set of observation done 
before commencement of the infusion, as per departmental guidelines.   Observations 
will include:  BP, pulse, temperature, respiratory rate, and oxygen saturation. 
Observations will be performed every 15 minutes for the 1st hour and every 30 
minutes for the 2nd hour.  Hourly observations for two hour post infusion.  Intra 
venous access will remain in-situ for each patient for the appropriate post infusion 
period.  Resuscitation facilities will be available and easily accessible as in normal 
standard of care. 
6.6 Infliximab experience and risks  
Besides infusion reactions and delayed hypersensitivity reactions, other infrequent but 
serious toxicities related to TNF-α neutralizing therapies have emerged. The most 
worrying are infectious complications, such as tuberculosis (TB) and respiratory tract 
infections, and the theoretical risk of cancer and lymphoma (229-231).   In particular, 
an increased risk for TB has been disclosed in post-marketing experience (229, 232), 
but training, screening and monitoring procedures, together with prophylaxis can 
markedly reduce the incidence (229, 233).  We will closely monitor for infections 
including TB before, during and after treatment with infliximab.  
A large-scale post-marketing surveillance study was carried out to determine the 
safety profile of Infliximab in 5000 Japanese patients with rheumatoid arthritis.  
Serious infusion reactions were observed in 0.5% (234). 
Five hundred patients treated with Infliximab at the Mayo Clinic were reviewed. They 
concluded that short and long term Infliximab therapy was generally well tolerated. 
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However, clinicians must be vigilant for the occurrence of infrequent but serious 
events, including opportunistic infection and sepsis, and autoimmune disorders (230). 
The underlying risk of developing malignancies among patients with severe or 
chronically active Crohn’s disease in need of Infliximab treatment is not known but 
the finding of a 1.5% annual incidence of lymphoma emphasises the need for vigilant 
surveillance with respect to this malignant complication (235).  Discussion regarding 
the risk of malignancy versus the length of the course of treatment will take place. 
The TREAT registry has prospectively evaluated patients for pre specified safety 
related outcomes in Crohn’s disease. 6290 patients were enrolled.  Mortality rates 
were similar between Infliximab - and non–Infliximab treated patients. The increased 
risk for serious infection observed with Infliximab likely was owing to disease 
severity and prednisone use (236). 
Details of Infliximab and recommendations are available from the Summary of 
product characteristics (SmPC) (231). 
Infliximab has been associated with acute infusion-related reactions, including 
anaphylactic shock, and delayed hypersensitivity reactions  Acute infusion reactions 
including anaphylactic reactions may develop during (within seconds) or within a few 
hours following infusion. If acute infusion reactions occur, the infusion will be 
immediately stopped. Emergency equipment, such as adrenaline, antihistamines, 
corticosteroids and an artificial airway are available in the Infliximab infusion unit. 
Patients may be pre-treated with an antihistamine, hydrocortisone and/or paracetamol 
to prevent mild and transient effects. In our unit we pre-treat using hydrocortisone as 
standard. 
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Infusion-related reactions: An infusion-related reaction was defined in clinical studies 
as any adverse event occurring during an infusion or within one to two hours after an 
infusion. In clinical studies, approximately 20% of Infliximab-treated patients 
compared with approximately 10% of placebo treated patients experienced an 
infusion-related effect. Approximately 3% of patients discontinued treatment due to 
infusions reactions and all patients recovered with or without medical therapy (231). 
Patients will be monitored closely for infections including tuberculosis before, during 
and after treatment with Infliximab. Because the elimination of infliximab may take 
up to six months, monitoring will be continued throughout this period. Patients would 
be reviewed at outpatient clinic as is the normal clinical practice. 
Suppression of TNF-α may mask symptoms of infection such as fever. Therefore 
early recognition of atypical clinical presentations of serious infections is critical in 
order to minimize delays in diagnosis and treatment. 
Patients taking TNF-blockers are more susceptible to serious infections. Tuberculosis, 
bacterial infections, including sepsis and pneumonia, invasive fungal infections, and 
other opportunistic infections have been observed in patients treated with infliximab. 
Some of these infections have been fatal; the most frequently reported opportunistic 
infections with a mortality rate of > 5% include pneumocystosis, candidiasis, 
listeriosis and aspergillosis (230, 231, 235). 
Patients who develop a new infection while undergoing treatment with Infliximab will 
be monitored closely and managed accordingly. Administration of Infliximab will be 
discontinued if a patient develops a new serious infection or sepsis, and appropriate 
antimicrobial or antifungal therapy will be initiated until the infection is controlled. 
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In clinical studies 36% of infliximab-treated patients were treated for infections 
compared with 25% of placebo-treated patients (236). 
Before starting treatment with Infliximab, all patients will be evaluated for both active 
and inactive (‘latent’) tuberculosis. This evaluation will include a detailed medical 
history with personal history of tuberculosis or possible previous contact with 
tuberculosis and previous and/or current immunosuppressive therapy. A CXR will be 
performed in patients as is the current departmental guideline. 
If active or latent tuberculosis is diagnosed, Infliximab therapy will not be initiated.  
The patient will not be eligible for the trial and a physician with expertise in the 
treatment of tuberculosis will be consulted for further management.  
All patients will be informed to seek medical advice if signs/symptoms suggestive of 
tuberculosis (e.g. persistent cough, wasting/weight loss, low-grade fever) appear 
during or after Infliximab treatment. 
Reactivation of hepatitis B has occurred in patients receiving a TNF-antagonist 
including infliximab, who are chronic carriers of this virus. Patients at risk for HBV 
infection will be evaluated for prior evidence of HBV infection before initiating 
Infliximab therapy. 
Very rare cases of jaundice and non-infectious hepatitis, some with features of 
autoimmune hepatitis, have been observed in the post-marketing experience of 
Infliximab. Isolated cases of liver failure resulting in liver transplantation or death 
have occurred (231). Patients with symptoms or signs of liver dysfunction will be 
evaluated for evidence of liver injury.  If jaundice and/or ALT elevations ≥ 5 times 
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the upper limit of normal develop(s), Infliximab will be discontinued, and a thorough 
investigation of the abnormality will be undertaken. 
The relative deficiency of TNF-α caused by anti-TNF-α therapy may result in the 
initiation of an autoimmune process. If a patient develops symptoms suggestive of a 
lupus-like syndrome following treatment with Infliximab and is positive for 
antibodies against double-stranded DNA, further treatment with Infliximab will not be 
given. 
Infliximab and other agents that inhibit TNF-α have been associated in rare cases with 
optic neuritis, seizure and new onset or exacerbation of clinical symptoms and/or 
radiographic evidence of central nervous system demyelinating disorders, including 
multiple sclerosis, and peripheral demyelinating disorders, including Guillain-Barré 
syndrome. In patients with pre-existing or recent onset of demyelinating disorders, the 
benefits and risks of Infliximab treatment should be carefully considered before 
initiation of Infliximab therapy. 
During clinical studies of Infliximab across all approved indications the incidence of 
lymphoma in Infliximab-treated patients was higher than expected in the general 
population, but the occurrence of lymphoma was rare. Furthermore, there is an 
increased background lymphoma risk in rheumatoid arthritis patients with 
longstanding, highly active, inflammatory disease, which complicates the risk 
estimation. 
With the current knowledge, a risk for the development of lymphomas or other 
malignancies in patients treated with a TNF-blocking agent cannot be excluded. 
Caution should be exercised when considering TNF-blocking therapy for patients 
253 
 
with a history of malignancy or when considering continuing treatment in patients 
who develop a malignancy. 
Rare post-marketing cases of hepatosplenic T-cell lymphoma have been reported in 
patients treated with TNF-blocking agents including infliximab. This rare type of T-
cell lymphoma has a very aggressive disease course and is usually fatal. All cases 
have occurred in patients with Crohn’s disease or Ulcerative Colitis and the majority 
were reported in adolescent or young adult males. All of these patients had received 
treatment with AZA or 6-MP concomitantly with or immediately prior to Infliximab. 
Our patients are non-Crohn's patients and would not have received either of these 
treatments. 
Malignancies and lymph proliferative disorders: In clinical studies with Infliximab in 
which 5,780 patients were treated, representing 5,494 patient years, five cases of 
lymphomas and 26 non-lymphoma malignancies were detected as compared with no 
lymphomas and one non-lymphoma malignancy in 1,600 placebo-treated patients 
representing 941 patient years (234). 
In long-term safety follow-up of clinical studies with infliximab of up to five years, 
representing 6,234 patients-years (3,210 patients), five cases of lymphoma and 38 
cases of non-lymphoma malignancies were reported. 
From August 1998 to August 2005, 1,909 cases of suspected malignancies have been 
reported from post-marketing, clinical studies and registries (321 in Crohn’s disease 
patients, 1,302 in rheumatoid arthritis patients and 286 in patients with other or 
unknown indications). Among those there were 347 lymphoma cases. During this 
period, the estimated exposure is 1,909,941 patient years since first exposure (231). 
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6.7 CONCLUSION 
In this future research pilot study we are replicating work which has been performed 
and published in several prominent peer reviewed journals (including the New 
England Journal of Medicine), but using a different cohort of patients (non-
inflammatory bowel disease patients instead of patient with inflammatory bowel 
disease such as Crohn’s disease).   
Our patient’s safety and monitoring will be as is the normal standard of care when 
Infliximab is administered to patients with inflammatory bowel disease at our 
Infliximab infusion unit.   
We hope to counter the potential increase in pain, distress or inconvenience  caused 
by this trial by preventing the extensive risks, morbidity and mortality  involved in the 
current options of considering further surgery or living with this debilitating condition 
for the remainder of their life. 
We hope that a major positive lifestyle change will result during the Infliximab 
treatment stage.    
This research protocol and study plan has been presented to the pharmaceutical 
research companies: Merck (MSD) and Schering Plough.  Currently we are in this 
process of collaboration to conduct a pilot study with the use of Infliximab on a small 
number of patients with non-inflammatory bowel disease ECF. 
For patients with inflammatory bowel disease, five mg/kg is given as an intravenous 
infusion followed by additional 5 mg/kg doses at two and six weeks after the first 
dose, and then every eight weeks thereafter.   
255 
 
A 100-mg vial of Infliximab costs £419.62p (excluding VAT).  The drug cost differs 
between individuals because the dose is adjusted to each person’s body weight.  For 
example, if it is assumed that vials are not shared between patients, for a person 
weighing 73 kg the cost per infusion would be £1678, corresponding to four 100-mg 
vials needed for a dose of 365 mg.   
As the above has shown, a key component of conducting the pilot study will be in 
obtaining the drug Infliximab or funding for this.   
Any positive or significant findings from the pilot study would equate to a major 
medical advance and a new market for the use of Infliximab and other anti-TNF-α 
agents.  It would provide an alternative option and benefit an already surgically 
challenging group of patient.   
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Future Work 
In addition to the pilot study discussed in 6.1 and future study comparing somatostatin 
and octreotide in a well-designed randomised control trial, there is potential for 
further studies in the management of patients with ECF. 
One avenue is to further the research completed looking into the effect of injected 
Botox on the function of high output stomas and ECF.  The idea is based on studies 
that show blockage of smooth muscle neuromuscular activity and is a method already 
being employed in the treatment of anal fissures.  Current means to manage high 
output stomas or output from ECF can be divided into measures acting to reduce the 
output itself and measures employed to increase functionality of the remaining bowel.  
The aim of future work would be to use Botox to produce an increase in bowel 
function by reducing smooth muscle activity and transit time.  This would be a Phase 
III trial comparing Botox against a placebo. 
Poggioli et al has recommended that local injection of infliximab for the treatment of 
perianal Crohn’s disease in selected cases is safe and feasible. This treatment could 
represent an effective option for those patients with perianal fistulas who cannot 
undergo intravenous infliximab treatment especially if there is associated stenosing 
ileal Crohn’s disease.  However, further randomised studies are needed to evaluate the 
effectiveness and the correct indications for this technique (237). In a similar 
approach, there may be the possibility of injecting anti-TNF-α agents down the ECF 
tract to enhance the local effect, and thus avoiding the degree of systemic side effects 
and complications which can arise from intravenous administration.   
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In summary, this thesis has reviewed several aspects of enterocutaneous fistula 
healing. Through this work, there is now potential for new studies, including 
application of the ECF scoring systems, RCT of somatostatin and its analogues, and 
immunological / clinical therapeutic studies.  Hence, there is a great deal to look 
forward to. 
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APPENDIX II 
 
Patient Information Sheet for Enterocutaneous Fistula Study 
 
Immunological and microbiological factors in inflammatory bowel disease  
 
You are being invited to take part in a research study.  Before you decide it is 
important for you to understand why the research is being done and what it will 
involve.  Please take time to read the following information carefully and discuss it 
with others if you wish.  Ask us if there is anything that is not clear or if you would 
like more information.  Take time to decide whether or not you wish to take part. 
 
What is the purpose of the study? 
The purpose of this study is to understand better how the immune system and bacteria 
play a part in causing gut diseases, in particular inflammatory bowel diseases, such as 
Crohn’s disease and ulcerative colitis. To do this we are collecting samples of 
different tissues of the body so that we can analyse cells called dendritic cells that are 
present within them. We will look at slices of the tissue under a microscope and 
extract cells from the tissues and determine the type of immune reactions that they 
stimulate in test tube experiments. A small part of the tissue will be stored frozen so 
that we can use new tests on it as they become available. 
 
Why have I been chosen? 
You have been invited to take part because you have a fistula track (communication 
between bowel and skin). We would like to take some tissue from the track for our 
research.  
 
Do I have to take part? 
It is up to you to decide whether or not to take part.  If you do decide to take part you 
will be given this information sheet to keep and be asked to sign a consent form. If 
you decide to take part you are still free to withdraw at any time and without giving a 
reason.  A decision to withdraw at any time, or a decision not to take part, will not 
affect the standard of care you receive. 
 
What will happen to me if I take part? 
 
The tissue we need for our research is removed under local anaesthetic in the 
outpatients department or on the ward where you are being seen.  After the local 
anaesthetic is injected, which can be a little uncomfortable, a biopsy will be taken 
using a scalpel or simple punch biopsy.  We will take only five 2mm samples. Any 
bleeding will be stopped and then a dressing will be applied.  If the biopsy is taken in 
the operating theatre local anaesthetic will not be required. 
 
What do I have to do? 
Taking part in the study will not require any additional hospital visits or commitments 
on your part. 
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What are the possible disadvantages and risks of taking part? 
Removal of the tissue may cause some discomfort and the biopsy site may bleed a 
little for a few minutes.  Because the tissue we take is right on the surface, any 
bleeding will be easy to control.  The biopsies will not make your current or future 
care any harder and will not change the timing of your surgery or any medications 
which you are taking. 
 
What are the possible benefits of taking part? 
There is no benefit to you. The information we get from this study may help us to 
treat future patients with inflammatory bowel disease and enterocutaneous fistulae 
better. 
 
What if something goes wrong? 
If you are harmed by taking part in this research project, there are no special 
compensation arrangements.  If you are harmed due to someone’s negligence, then 
you may have grounds for a legal action but you may have to pay for it.  Regardless 
of this, if you wish to complain, or have any concerns about any aspect of the way 
you have been approached or treated during the course of this study, the normal 
National Health Service complaints mechanisms should be available to you. 
 
Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the research will be 
kept strictly confidential.  Any information about you which leaves the 
hospital/surgery will have your name and address removed so that you cannot be 
recognised from it. 
 
What will happen to the results of the research study? 
The results should be published within approximately 1-2 years of the study and you 
can obtain a copy of the results by contacting Dr Ailsa Hart at Imperial College 
London. You will not be identified in any report or publication. 
 
Who is organising and funding the research? 
The research is organised by Imperial College London. It is funded by St Mark’s 
Hospital. 
 
Who has reviewed the study? 
This study has been reviewed in the standard manner by the Research & Ethics 
Committee at North West London Hospitals NHS Trust 
 
Contact for Further Information 
If you have any problems or questions relating to the study please contact Mr Goher 
Rahbour 02082354020 or Dr Ailsa Hart 02088695805 
 
Thank you for taking the time to read this information. If you are happy to take part 
please sign the enclosed consent form. You will be given a copy of the information 
sheet and signed consent form to keep. 
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APPENDIX IV 
 
FACS materials and protocols 
FACS materials 
Product Company / Components 
Complete medium RPMI-1640 Dutch Modification (Sigma 
Aldich, UK) containing 10% Fetal Calf 
Serum, 100µg/ml streptomycin, 100 units 
/ ml penicillin, Gentamycin 
FACS Buffer PBS with 2% FCS, 0.02% sodium azide 
and 1mM EDTA 
Phosphate Buffed Saline (PBS) Sigma, UK 
Fetal calf serum (FCS) Tissue culture systems 
Ficoll-Paque Amersham Pharmacia Biotech AB, 
Uppsala, Sweden 
Flow-countTM Fluorospheres Beckman Coulter, Bucks 
Paraformaldehyde (PFA) 1% BDH chemicals, Poole 
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APPENDIX V 
Antibodies used for labelling surface markers and cytokines 
 
 
 
 
Antibody Definition 
CLA Cutaneous Lymphocyte Antigen 
β7 Purified anti-human/mouse Integrin 
β7 antibody 
Lineage cocktail  
( CD3, CD14, CD16, CD19 and CD34) 
Individual explanations are below 
CD3 Anti-CD3 monoclonal antibody.  
 for T cells   
CD14 Anti-CD14 monoclonal antibody 
for monocytes 
CD16 Anti-CD16 monoclonal antibody 
for macrophages 
CD19 Anti-CD19 monoclonal antibody 
for B cells 
CD34 Anti-CD34 monoclonal antibody 
for stem cells 
HLA-DR React with the human major 
histocompatibility (MHC) class II 
antigen HLA-DR. 
r1ɣm Purified Rat gamma M isotype 
control 
rɣ2A Purified Rat IgG2a  isotype control 
γ1 Gamma 1 antibody 
TNF-α Tumour necrosis factor alpha 
IL12 Interleukin 12  
IL17A Interleukin 17A  
Interferon-  Interferon gamma 
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